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Technological advances in prevention, diagnosis, and treatment of diseases help predict 
disease, prolong life, and promote health. However, with the increase in volume and 
complexity of data and evidence, medical decision making can be a complex process. 
Many decisions involve uncertainties and tradeoffs, and can have serious consequences to 
patients and the clinical practice. For example, to design a radiation therapy treatment 
plan, physicians must determine the locations of over 50 seeds to deliver precise dosage 
to the tumor such that the cancer cells are killed while the functionalities of surrounding 
organs are preserved. To make such complex decisions, providers must balance the 
potential harm and benefit of medical interventions. Computational methods such as 
mathematical programming, simulation, and classification have found broad applications 
in these areas. 
 
In this dissertation, we investigate three topics: predictive models for disease 
diagnosis and patient behavior, optimization for cancer treatment planning, and public 
health decision making for infectious disease prevention.  
 
In the first topic, we propose a multi-stage classification framework that 
incorporates Particle Swarm Optimization (PSO) for feature selection and discriminant 
analysis via mixed integer programming (DAMIP) for classification. By utilizing the 
reserved judgment region, it allows the classifier to delay making decisions on ‘difficult-
to-classify’ observations and develop new classification rules in later stage. We apply the 
framework to four real-life medical problems: 1) Patient readmissions: identifies the 
patients in emergency department who return within 72 hours using patient’s 
demographic information, complaints, diagnosis, tests, and hospital real-time utility. 2) 
Flu vaccine responder: predicts high/low responders of flu vaccine on subjects in 5 years 
using gene signatures. 3) Knee reinjection: predicts whether a patient needs to take a 
second surgery within 3 years of his/her first knee injection and tackles with missing 
 xii
data. 4) Alzheimer’s disease: distinguishes subjects in normal, mild cognitive impairment 
(MCI), and Alzheimer’s disease (AD) groups using neuropsychological tests.  
 
In the second topic, we first investigate multi-objective optimization approaches 
to determine the optimal dose configuration and radiation seed locations in brachytherapy 
treatment planning. Tumor dose escalation and dose-volume constraints on critical organs 
are incorporated to kill the tumor while preserving the functionality of organs. Based on 
the optimization framework, we propose a non-linear optimization model that optimizes 
the tumor control probability (TCP). The model is solved by a solution strategy that 
incorporates piecewise linear approximation and local search. 
 
In the third topic, we study optimal strategies for public health emergencies under 
limited resources. First we investigate the vaccination strategies against a pandemic flu to 
find the optimal strategy when limited vaccines are available by constructing a 
mathematical model for the course of the pandemic flu and the process of the 
vaccination. Second, we analyze the cost-effectiveness of emergency response strategies 








OVERVIEW OF MEDICAL DECISION MAKING 
 
Medical decisions are intrinsically complex. They affect the health and clinical care of 
individuals and they can also influence or facilitate health policy development. Recent 
years have seen numerous technological advances in prevention, diagnosis, and treatment 
of diseases. These innovations assist in preventing illness, prolonging life, and promoting 
health.  However they also add new dimensions and extra complexity to the medical 
decision making process. More parameters, variables, and effects have to be taken into 
account to determine the best course of actions. Since medical decisions have substantial 
consequences and involve uncertainties and trade-offs, decision makers must balance the 
potential harm and benefit of their chosen interventions. Computational methods such as 
mathematical programming, simulation, machine learning and classification have found 
broad applications in this area to assist in determining the best decision(s), understanding 
the alternatives, and estimating the impact of each option. In the following sections, we 
briefly review some emerging challenges and opportunities in applying these 
computational methods. 
 
Disease diagnosis. Historically, diseases were detected when symptoms 
manifested themselves. Screening and surveillance methods including imaging, 
laboratory and blood tests help achieve earlier detection, resulting in improved quality of 
life and/or reduced morbidity. With the advent in human genome sequencing, 
microarrays, omics, and discovery of biomarkers, large-scale biological and clinical data 
are frequently generated.  These big data require powerful and sophisticated classification 
and predictive tools for effective analysis to accelerate the diagnosis process.   
 
Patient behavior. An important and challenging aspect in medical advances 
entails understanding patient behavior and outcome success. Learning patient behavior 
may allow hospitals to improve their care to the patients. One example is to predict the 
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length of stay of arriving patients and the unnecessary return visits in emergency 
department to avoid potential overcrowding.  
 
Treatment decisions. Treatment options are now readily available to many 
diseases that can cure or delay their progression. In some cases treatment decisions are 
one-time decisions, but in other cases treatment decisions recur, often involving the 
coordination of multiple treatment types to achieve control of one or more risk factors. 
An important application area is the design of radiation therapy treatment plans for 
cancer patients.  Here, the decision involves three major pieces 1)  selectingthe radiation 
sources, 2) deciding on the amount of radiation dosage to deliver, and 3) optimizing the 
delivery of the treatment. 
 
Disease prevention. Preventing diseases, especially infectious diseases, requires 
organized efforts of public health and the society. One key challenge is to deliver mass 
vaccine/medications to a population. The design of response logistics must consider the 
impact of epidemic and valuable resource simultaneously. The limited resources should 
be optimally allocated such that the loss from the disease is minimized or mitigated.  
 
In this dissertation, we investigate three topics in medical decision making: 
predictive models for disease diagnosis and patient behavior, optimization for cancer 
treatment planning, and public health decision making for infectious disease prevention.  
 
In the first topic, we propose a multi-stage classification framework that 
incorporates Particle Swarm Optimization (PSO) for feature selection and discriminant 
analysis via mixed integer programming (DAMIP) for classification. By utilizing the 
reserved judgment region, it allows the classifier to delay making decisions on ‘difficult-
to-classify’ observations and develop new classification rules in later stage. We apply the 
framework to four real-life medical problems: 1) Patient readmissions: identifies the 
patients in emergency department who return within 72 hours using patient’s 
demographic information, complaints, diagnosis, tests, and hospital real-time utility. 2) 
Flu vaccine responder: predicts high/low responders of flu vaccine on subjects using gene 
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signatures. 3) Knee reinjection: predicts whether a patient needs to undergo  a second 
surgery within 3 years of his/her first knee injection and tackles with missing data. 4) 
Alzheimer’s disease: discriminates subjects in normal, mild cognitive impairment (MCI), 
and Alzheimer’s disease (AD) groups using neuropsychological tests and biomarkers.  
 
In the second topic, we first investigate multi-objective optimization approaches 
to determine the optimal dose configuration and radiation seed locations in the design of 
high-dose rate brachytherapy treatment plans for cancer patients. Tumor dose escalation 
and dose-volume constraints on critical organs are incorporated to enhance  the dose to 
tumor for better tumor control while minimizing the damage to   healthy organs-at-risks 
and normal tissues. Based on the optimization framework, we propose a non-linear 
optimization model that optimizes the tumor control probability (TCP) directly. The 
model is solved by a solution strategy that incorporates piecewise linear approximation 
and local search. 
 
In the third topic, we study optimal strategies for public health emergencies under 
limited resources. First we investigate vaccine prioritization strategies against a pandemic 
flu to find the optimal strategy when limited vaccines are available by constructing a 
mathematical model for the course of the pandemic flu and the process of the 
vaccination. Second, we analyze the cost-effectiveness of emergency response strategies 









 OPTIMIZATION-BASED PREDICTIVE MODELS  
 
In this chapter we proposed a multi-stage classification framework incorporated with 
Particle Swarm Optimization (PSO) for feature selection and discriminant analysis via 
mixed integer programming (DAMIP) for classification to find the feature subsets that 
can correctly predict the medical outcomes.  
 
2.1 DAMIP 
2.1.1 Mathematical Programming Based Classification Models 
Classification is a fundamental machine learning problem of identifying the group status 
of new observations, on the basis of a set of observations of which the group 
memberships are known. This approach has been applied frequently in disease diagnosis 
where the disease stage of a patient is detected based on symptoms and lab tests. 
Traditional classification methods including linear discriminant analysis for two 
group classification problems (LDA) [49], quadratic discriminant analysis (QDA) [171], 
and other discriminant analyses, such as logit and probit, have been well studied over the 
past several decades. These models are parametric as they incorporate assumptions about 
the distribution of data. Mathematical-programming-based (MP) classification methods 
emerge in the 1960's, gain popularity in the 1980's, and have grown drastically ever since. 
Most MP approaches are nonparametric, and can be considered a valuable alternative to 
the classical models of discriminant analysis (DA) [178].  
 
2.1.1.1 Linear Programming Classification Models 
In a two group classification, the MP formulations define a hyperplane which allows the 
two groups to be separated [14, 52, 71, 123]. Models including minimizing the sum of 
deviations (MSD), minimizing the maximum deviation (MMD), and minimizing the sum 
of interior distances (MSID) were proposed and tested by computational studies by Freed 
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et al [53]. The objective function is L1-norm distance and is zero if the two groups can be 
perfectly separated by a hyperplane. By introducing gap between two regions and 
normalization constraints, Glover et al [65] proposed the Hybrid Model which includes 
different combinations of deviations in the objective function. Stam and Ungar [177] 
introduced a software package RAGNU for solving two-group classification problems 
using LP methods. Comparisons between the linear programming models and the 
traditional methods including LDA and QDA were performed by previous studies [45, 
81, 159]. To solve the issues with unbounded or trivial solutions [126], variant models 
were proposed, including normalization constraints [64], reverse of group designations 
[160], and regularization method [198]. 
 
Bennett and Mangasarian [19] proposed a robust linear programming model 
which minimizes the average of the deviations, and tested it in the diagnosis and 
prognosis of breast cancer [125]. Effect of introducing second-order terms of the feature 
values in the LP models were investigated by Silva [168] and Wanarat [190]. 
Asparoukhov and Stam [10] proposed MSD models to solve the two-group classification 
problem with binary features, which have been frequently found in medical data. 
  
Freed and Glover [54] extended the two-group LP models onto multi-group 
classification problems. An artificial misclassification cost is introduced for each group, 
and the sum of the misclassification cost for all groups is maximized. It uses single 
discriminant function and requires valuation of the misclassification costs. Bennett and 
Mangasarian [18] proposed a LP model that generates a piecewise-linear separation for 
multiple groups. It returns an error-minimizing separation if no feasible separation exists. 
Gochet et al [66] introduced the goodness and badness of fit for an observation with 
respect to a certain group, and solved a multi-group LP model that minimizes the badness 
of fit.  
 
2.1.1.2 Mixed Integer Programming Classification Models 
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Mixed integer programming generates linear discriminant functions by assigning binary 
variables associated to each observation. In two-group classification problems, binary 
variables can be used to represent the exact number of misclassifications. A basic model 
is to minimize the number of total misclassifications (MM). Variant models including 
hybrid models and model of minimizing the expected misclassification cost have been 
proposed in previous studies [1, 14, 15, 161, 167].  Pavur et al. [149] proposed secondary 
goals which maximize the difference between the discriminant scores of the two groups. 
Glen [61, 62] proposed IP techniques for normalization by adding normalization 
constraints into two-group models which maximizes the classification accuracy (MCA). 
From the MCA model, two-stage approaches that aim to identify the observations which 
are difficult to classify and solve a second model with these observations were  proposed 
in Glen [60] and Sueyoshi [181]. Glen [63] proposed piecewise-linear programming 
models to approximate the nonlinearity of discriminant functions of MCA. 
 
To extend the two-group models on multi-group classification problem, Gehrlein 
[59] proposed two MIP models of maximizing the number of proper classifications: a 
single function classification scheme (DSFC) and a multiple function classification 
scheme (DMFC). Stam and Joachimsthaler [175] studied the performance of MIP models 
compared to traditional methods including MSD, LDF, and QDF. MIP models perform 
better when the group overlap is higher, but there are no general conclusions yet [81, 
175]. 
 
2.1.1.3 Non-Linear Programming Classification Models 
Nonlinear discriminant functions can be generated from MP methods by transforming the 
variables [168], by forming dichotomous categorical variables from the original variables 
[60], or based on piecewise linear function [63]. Silva and Stam [169] proposed a second-
order model by introducing external deviations of each observation to the formulation. 
Stam and Joachimsthaler [176] proposed a class of nonlinear programming methods 
using Lp-norm distance as objective. Mangasarian et al. [124] proposed a non-convex 
model that can be solved in polynomial-time and works successfully for diagnosis of 




Support vector machine (SVM) has been widely studied in the field of 
classification. SVM classification problem can be formulated as a convex quadratic 
programming for two-group classification problems. Mangasarian proposed a general 
mathematical programming framework for SVM (GSVM) [122]. Variant SVM based 
methods have been developed for solving large scale classification problems [21, 55, 
113], and problems in healthcare including breast cancer [114] and genome prediction 
[120]. Hsu and Lin [76] compared the SVM methods for multi-group classification that 
are derived from two-group SVMs.  
 
2.1.2 Anderson’s Model and DAMIP 
In this section, we first introduce Anderson’s model [9], a classification rule which 
incorporates misclassification limits, and then discuss the discriminant analysis – mixed 
integer programming (DAMIP) model which provides the optimal classification rule of 
Anderson’s model [57, 58]. 
 
We introduce the notations used in this chapter. Let  be the set of observations, 
 be the set of groups, and ℱ be the set of features. Let n, G, and m denote the number of 
observations, groups, and features, respectively. The ith observation in  is denoted as 
( , ) = 	 ( , , , … , ), where  is group membership and the vector  is the 
feature vector. In a classification problem, the discriminant function : (ℱ × …× ℱ ) 	→
	 	 is determined, it predicts the group membership of new observations based on their 
features.  
 
2.1.2.1 Anderson’s Model 
Assuming that the group density functions and prior probabilities are known, Anderson 
[9] showed that an optimal rule for the problem of maximizing the probability of correct 
classification subject to the constraints on the misclassification probabilities must be of a 
specific form when discriminating among multiple groups with a simplified model. This 
model is parametric – assuming data of each group follow certain distribution. Let  be 
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the prior probability of group  and ( ) be the conditional probability density function 
of group , ∈ 	  for the data point ∈ ℝ . Let ∈ (0, 1), h, ∈ , ℎ ≠  be the 
predetermined limit on the misclassifications where the observations of group  are 
classified to group h. The group assignment decisions of observations that are classified 
into reserved judgment region, denoted by group g = 0 are reserved. The proposed model 
is to seek for a partition { , , … , } of ℝ , where  is the region assigned to group 
g and  is the reserved judgment region in which the group-assignment decisions of 








. .			 	 ( )
	
	≤ 																						∀		ℎ, ∈ , ℎ ≠  (2.1.1) 
 
Anderson showed that there exist nonnegative constants , h, ∈ , ℎ ≠ , 
such that the optimal decision rule, which is referred to the Anderson’s rule, is given by 
= ∈ ℝ : ( ) = 	 max
	∈{ }∪
( ) ,		 	 ∈ {0} ∪ , (2.1.2) 
where 
( ) = 0 
( ) = 	 ( ) −	 ( )
∈ ,
,			 	 ∈  
For G = 2 the optimal solution can be modeled rather straightforward. However, 
finding optimal ′s for the general case, G ≥ 3, is a difficult problem. The complexity 
increases as G increases [23, 24, 57, 58]. 
 
2.1.2.2 Discriminant Analysis via Mixed Integer Program (DAMIP) 
Gallagher et al. [57, 58] first proposed mixed integer programming formulations, named 
DAMIP, for obtaining the optimal ′s in Anderson's rule. Let  denote the set of 
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observations in group g, and  denote the number of observations in group g. Let  
represent the binary variable indicates whether observation i in group g is classified to 
group h, ℎ ∈ {0} ∪ . Thus = 1 denotes a correct classification for observation i in 




  (2.1.3) 
s.t. =	 −	
∈ ,
, ∀	ℎ, ∈ ,			 ∈  (2.1.4) 
 − ≤ 1 − , ∀	ℎ, ∈ ,			 ∈  (2.1.5) 
 ≤ 1 − , ∀	 ∈ ,			 ∈  (2.1.6) 
 − ≥ 1 − , ∀	ℎ, ∈ ,			 ∈  (2.1.7) 
 ≥ 	 , ∀	ℎ, ∈ ,			 ∈  (2.1.8) 
 
∈{ }∪
= 1,		 ∀	 ∈ ,			 ∈  (2.1.9) 
 
∈
≤ ,			 ∀	ℎ, ∈ , ≠ ℎ (2.1.10) 
 ∈ {0,1},				 ∀	ℎ ∈ {0} ∪ , ∈ , ∈   
 	 ,			 ∀		ℎ, ∈ ,			 ∈   
 	≥ 0, ∀		 ∈ ,			 ∈   
 ≥ 0  ∀	ℎ, ∈ , ≠ ℎ  
 
Constraints (2.1.4) define the loss functions ( ) in Anderson’s rule, constraints 
(2.1.5)-(2.1.9) guarantee an observation is uniquely assigned to the group with the 
maximum value of ( ) among all groups, and constraints (2.1.10) set the 
misclassification limits. Brooks [24] and Brooks and Lee [23] showed that DAMIP is 




Lee et al. [110] proposed a linear programming approach, named DALP 





)  (2.1.11) 
s.t. =	 −	
∈ ,
, ∀	ℎ, ∈ , ∈  (2.1.12) 
 − +	 ≥ 0, ∀	ℎ, ∈ , ≠ ℎ, ∈  (2.1.13) 
 +	 ≥ 0, ∀	 ∈ ,			 ∈  (2.1.14) 
 − + ≥ 0, ∀	ℎ, ∈ , ∈  (2.1.15) 
 	 ,			 ∀		ℎ, ∈ ,			 ∈   
 	 ,			 	≥ 0, ∀		 ∈ ,			 ∈   
  ≥ 0  ∀	ℎ, ∈ , ≠ ℎ  
 
where  and  are constants/weights controlling the emphasis on correctly classifying 
observations or placing them in the reserved judgment region. Constraints (2.1.13), 
(2.1.14) and (2.1.15) link the objective-function variables with the  variables in such 
a way that correct classification of observations, and allocation of observations into the 
reserved judgment region, are captured by the objective-function variables. 
 
The DAMIP/DALP approaches have been successfully applied to various multi-
group disease diagnosis and biological/medical prediction problems [46, 47, 102, 108, 





2.2 The PSO/DAMIP Machine Learning Framework 
In this section, we review the feature selection algorithms, discuss a heuristic method 
called particle swarm optimization (PSO), and introduce a machine learning framework 
based on PSO for feature selection and DAMIP for classification. 
 
2.2.1 Feature Selection Algorithms 
Feature selection is the process of selecting a subset of the relevant features for the use of 
model construction in data mining problems, including regression, classification, and 
clustering. The basic assumption of feature selection is that data contains redundant or 
irrelevant features. Using too many features in constructing classification models may 
result in over-fitting. An example of the use of feature selection is analyzing DNA 
microarrays, where there are thousands to millions of features, and a few tens to hundreds 
of subjects. The benefits of adopting feature selection techniques are 1) improving the 
prediction performance, 2) reducing over-fitting, 3) providing faster predictor, and 4) 
improving model interpretability.  
 
There are three main categories of feature selection algorithms: wrappers, filters 
and embedded methods. Wrapper methods use a search algorithm to search through the 
space of features and evaluate the subsets by running the classification models on them. 
Filter methods are similar to wrapper methods, but instead of evaluating by the 
classification models, a simple filter that is independent of the classification models is 
evaluated. Many filter methods provide a feature ranking rather than best subsets, where 
top ranking features can be used in classification models. Embedded feature selection 
algorithms are built in the classifier during the model construction. 
 
Feature subset selection which is to find an optimal subset of features in the space 
of features can be considered as a combinatorial optimization problem. Dash and Liu [33] 
described a feature selection algorithm as in four steps: subset generation, subset 
evaluation, stopping criterion, and result validation. Search strategies including branch 
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and bound [72, 139], greedy procedure and sequential search [153, 172, 179], and 
random search [166] have been widely studied.  
 
Tibshirani [185] proposed the Lasso (least absolute shrinkage and selection 
operator) model that estimates the coefficients  by solving the following quadratic 
program: 









								 	 																																																			∀		 ∈ {0} ∪ ℱ 
 
where t is a tuning parameter, and ’s are standardized. Efron et al. [41] proposed the 
LARS (least-angle regression) model which estimates the coefficients in a regression 
model, one  at each step, based on the equiangular directions. LARS is 
computationally efficient, and can be easily modified to produce solutions for other 
estimators, like the Lasso. Both Lasso and LARS are embedded methods. 
 
Bertolazzi et al. [20] proposed the idea of solving feature selection using 
mathematical programming. The problem for the two group classification problem with 
binary features can be formulated as a set cover problem. Glen [62] incorporated an 
additional constraint into the two group mathematical programming model such that the 
optimal hyperplane contains no more than p features. Iannarilli and Rubin [79] propose a 
nonlinear integer program to find the feature subsets in multi-group classification 
problems.  
 
2.2.2 Particle Swam Optimization 
Particle swarm optimization was originally proposed by Kennedy and Eberhart [88]. It 
solves an optimization problem by iteratively trying to improve a candidate solution in 
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the population of candidate solutions, named particles. A particle is moved around in the 
search space based on its position and a randomly generated velocity. Its movement is 
influenced by its best known position (achieves the best objective value) and the best 
known position of the particles in its neighborhood. Let  denote the position and  
denote the velocity of particle i. Let  be the best position of particle i so far. Initially, 
	and 	for each particle i are randomly generated within some predetermined ranges. 
At each iteration, 	and  are updated by 
	← 	 + ( − ) (	) + ∗( ) − () 
	← 	 +	  
where ∗( ) is the position in the neighborhood of particle i that holds the best objective 
value so far, (	) is a random number between 0 and 1, and 	, , and  are 
parameters. The PSO algorithm can be terminate by criteria including number of 
iterations, target objective value, and the particle movement.  
 
In a feature selection problem, the selection of features can be represented as a 
binary vector, i.e., 1 means that the feature is selected and 0 means that the feature is not 
selected. Kennedy and Eberhart [87] modify the PSO algorithm to work on binary 
variables. Variant PSO based algorithms have been proposed for feature selection [2, 29, 
135, 184, 197].   
 
2.2.3 The PSO-DAMIP Machine Learning Framework 
Wu proposed a modified PSO algorithm to solve the feature selection algorithm where 
the number of selected features is determined [197]. We describe a PSO/DAMIP 
framework which uses the modified PSO algorithm for feature selection and the DAMIP 
model for classification. For particle i, let  denote the velocity and  represent a binary 
vector of length m where m is the number of features.  denotes whether the jth feature 
is selected in particle i. In each iteration of the modified PSO algorithm, a DAMIP model 
is solved using the selected features in each particle. Particle i records the current selected 
features  and the best achieved objective value of DAMIP thus far, denoted by . And 
and  in the next iteration is then determined by a random combination of , , , 
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and ( ) in the current iteration where ( ) is the set of particles in the neighborhood of 
particle i. The algorithm is described as follows. 
 
Initialization: 
For each particle i,  
 is generated by randomly selecting k 1’s and m-k 0’s, 
 is a random number in (− , ) where  is predetermined, 
← , 
← 0 . 
 
Update: 
For each particle i in each iteration,  
Run DAMIP model with the selected features by .  
If the objective value ′ > , update  ← , ← ′. 
	← 	 + ( − ) 	 (	) + ( ) − 	 (). 
 is determined by selecting  features with the largest values in . 
 
Termination: 
The PSO algorithm terminates when 1) the maximum number of iterations is 
achieved, or 2) the percentage of the number of moving particles is less than a 
threshold. 
 
We adopt the von Neumann neighborhood topology, a two dimensional grid with 
neighbors to the top, bottom, left and right, to construct the particles. The number of 
particles can be chosen as 9, 12, 16, 25, 36, or other numbers, depending on the size of 
the feature set. We set the parameters in the PSO algorithm: = 1,  = 0.7298, and 







2.3 Multi-stage Classification Model 
In this section, we introduce a multi-stage DAMIP-based classification model 
incorporated with reserved judgment region. In addition to the multi-stage framework, we 
propose modified DAMIP models to improve the performance at each stage. 
 
2.3.1 Multi-stage Classification Model 
The multi-stage classification model aims to improve the performance of the 
PSO/DAMIP framework by utilizing the reserved judgment region in DAMIP. A DAMIP 
model bisects the data set into ‘easy–to-classify’ subset which it classifies to specific 
groups, and ‘difficult-to-classify’ subset which it classifies to reserved judgment region.  
It delays making group-assignment decision to subjects that are difficult to be classified 
by the DAMIP with selected features. In the multi-stage model we propose, those 
subjects are moved to the next stage where new feature set is selected and new DAMIP 
classifier is developed. In such way the multi-stage framework constructs a chain of 
successive classifiers using different subsets of features. The classifier at the ith stage, 
denoted by , can be represented by a discriminant function ( , ), which is 
determined by the feature subset , and the decision variables  in DAMIP. More stages 
do not necessarily produce a better model. At each stage, the framework selects the better 
of two models: a single-stage model that solves a DAMIP model without reserved 
judgment region, and a multi-stage model that solves a DAMIP model with reserved 
judgment region at this stage. The algorithm naturally terminates when there are no 
observations in the reserved judgment region. As more stages are processed, fewer 
observations remain for DAMIP and the constructed model consists of too many 
successive classifiers. This may result in over-fitting. Hence we propose two additional 
stopping criteria to terminate the process: 1) the number of observations is less than the 
minimum number of remaining observations, denoted by n, and 2) the maximum allowed 
depth, denoted by d is reached. n and d are pre-determined according to the number of 
observations and the number of selected features in the given data. Let S denote the set of 





← , ( , ) is determined by solving the PSO/DAMIP framework with .  
← ( , ) 
 
Update at stage i:  
( , ) is determined by solving the PSO/DAMIP framework with . 
← ( , ) 




The multi-stage model terminates at stage i  when 1) | | ≤ , or 2)  ≥ .  
if 	 ≠ 	∅,  
Solve a PSO/DAMIP model without reserved judgment region using  . 
Let ← ( , ). 
      End if. 
Return the chain of classifiers , , …,	 ,	 ( 	, if one exists). 
 
2.3.2 Modified DAMIP Models 
In the DAMIP model introduced by Gallagher [57, 58] and presented in Section 2.1.2, the 
size of the reserved judgment region is bounded by the misclassification rates specified in 
constraint (2.1.9). DAMIP is able to return good classification results through problem 
fine-tuning of the misclassification rates, especially when the groups are unbalanced. To 
ease this fine-tuning process, we envision that the classifiers in our multi-stage model to 
have the ability of balancing misclassifications and ‘difficult to classify’ observations in 
order to maximize the prediction accuracy through a multi-stage structure. For group g, 
let  be the misclassification rate,  be the proper classification rate, and  be the 
‘difficult to classify’ rate, i.e. the rate of reserved judgment region. These three 














Recall   is the 0/1 variable that denotes whether to classify an observation j in group 
g into group h,  Ng is the set of observations of group g, and ng is the size of Ng (i.e,  ng  = 
| Ng |). The three parameters satisfy that +	 + 	= 1 for each group g. We propose 
three modified DAMIP models to 1) better utilize reserved judgment region and 2) 
handle imbalanced groups more efficiently.  
 
Variant 1: The base model 
				min	
	∈	
	   (2.3.1) 
s.t.   
 = 	 −	∑ ∈ , ,  ∀	ℎ, ∈ ,			 ∈  (2.3.2) 
 − ≤ 1 − , ∀	ℎ, ∈ ,			 ∈  (2.3.3) 
 ≤ 1 − , ∀	 ∈ ,			 ∈  (2.3.4) 
 − ≥ 1 − , ∀	ℎ, ∈ ,			 ∈  (2.3.5) 
 ≥ 	 , ∀	ℎ, ∈ ,			 ∈  (2.3.6) 
 
∈{ }∪
= 1,		 ∀	 ∈ ,			 ∈  (2.3.7) 
 ∈ {0,1},				 ∀	ℎ ∈ {0} ∪ , ∈ , ∈   
 	 ,			 ∀		ℎ, ∈ ,			 ∈   
 	≥ 0, ∀		 ∈ ,			 ∈   
 ≥ 0  ∀	ℎ, ∈ , ≠ ℎ  
 
The base model aims to generate the optimal classification rule without using 
misclassification limits and reserved judgment. The objective is to maximize the 
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minimum value of correct classification rates  among all groups. It ensures that the 
minority groups are treated equally as the majority groups, and hence it can perfectly deal 
with imbalanced groups. Compared to Gallagher’s DAMIP model mentioned in 2.1.2, it 
removes the misclassification rate constraints (2.1.10) and hence drops the reserved 
judgment region. It produces a lower bound of the prediction accuracy of each group, and 






Variant 2: The −  model 
				min	
	∈	
	 − 	   (2.3.8) 
s.t. =	 −	
∈ ,
, ∀	ℎ, ∈ ,			 ∈  (2.3.9) 
 − ≤ 1 − , ∀	ℎ, ∈ ,			 ∈  (2.3.10) 
 ≤ 1 − , ∀	 ∈ ,			 ∈  (2.3.11) 
 − ≥ 1 − , ∀	ℎ, ∈ ,			 ∈  (2.3.12) 
 ≥ 	 , ∀	ℎ, ∈ ,			 ∈  (2.3.13) 
 
∈{ }∪
= 1,		 ∀	 ∈ ,			 ∈  (2.3.14) 
 
∈
≤ ,			 ∀	ℎ, ∈ , ≠ ℎ (2.3.15) 
 ∈ {0,1},				 ∀	ℎ ∈ {0} ∪ , ∈ , ∈   
 	 ,			 ∀		ℎ, ∈ ,			 ∈   
 	≥ 0, ∀		 ∈ ,			 ∈   
 ≥ 0  ∀	ℎ, ∈ , ≠ ℎ  
 
The −  model maximizes the minimum difference between 	and  by 
moving a small proportion of observations into reserved judgment region. Instead of 
using misclassification rate constraints, it incorporates both  and  into the objective 
function to keep the reserved judgment region from getting too large  that weakens the 





Variant 3: The  model  
				 		
	∈	
  (2.3.16) 
s.t. =	 −	
∈ ,
, ∀	ℎ, ∈ ,			 ∈  (2.3.17) 
 − ≤ 1 − , ∀	ℎ, ∈ ,			 ∈  (2.3.18) 
 ≤ 1 − , ∀	 ∈ ,			 ∈  (2.3.19) 
 − ≥ 1 − , ∀	ℎ, ∈ ,			 ∈  (2.3.20) 
 ≥ 	 , ∀	ℎ, ∈ ,			 ∈  (2.3.21) 
 
∈{ }∪
= 1,		 ∀	 ∈ ,			 ∈  (2.3.22) 
 
∈
≤ ,			 ∀ ∈  (2.3.23) 
 ∈ {0,1},				 ∀	ℎ ∈ {0} ∪ , ∈ , ∈   
 	 ,			 ∀		ℎ, ∈ ,			 ∈   
 	≥ 0, ∀		 ∈ ,			 ∈   
 ≥ 0  ∀	ℎ, ∈ , ≠ ℎ  
 
The  model maximizes the prediction accuracy while limiting the size of reserved 
judgment region by adding constraints (2.3.23) on the percentage of reserved judgment  
for each group g. It provides accurate control of the reserved judgment region to avoid too 
many stages in the model. The maximum percentage  for each group g is predetermined 
according to the size of the problem. Thus the   model resembles the original DAMIP 
model (as described in 2.1.2.2) except it constrains the reserved judgment instead of 
constraining the misclassification rate.  
 
In two-group, the modified DAMIP models can be solved in polynomial time. 
The constraints that define ( ) in Anderson’s rule can be written as: 
= ( ) − ( )																																					∀		 ∈ 		 , 
= ( ) − ( )																																					∀		 ∈ 		 ,  
 
21 
where optimal  and  are determined in DAMIP. Wu [197] proved that optimal  
and  in a two group DAMIP model that maximizes the total correct classifications can 
be found by searching on the sorted array  /  where  and  are the density functions 
in constraint (2.1.4) of group 1 and 2 respectively.   
 
When no reserved judgment region is used in the modified DAMIP model, i.e., 
the base model, we define a partition p on the sorted array /  such that observations 
having ( )/ ( ) 	≤ 	  are classified to group 1, and observations having ( )/
( ) >  are classified to group 2. By searching on the sorted array / , p* can be 
found such that the objective function which is the minimum of the correct classifications 
of the two group in the base model is maximized. An optimal solution of ( ,	 ) then 
can be determined by  = ∗.  
 
When reserved judgment region is used in the DAMIP models, we define two 
partitions of the sorted array /   and : observations having ( )/ ( ) 	≤ 	  are 
classified to group 1, observations having < ( )/ ( ) ≤  are classified to 
reserved judgment region, and observations having ( )/ ( ) 	> 	  are classified to 
group 2. By searching on the sorted array  /  , ( ∗,		 ∗) can be found such that the 
objective function is optimized. An optimal solution of ( ,	 ) then can be determined 
by = ∗ and = ∗.  
 
The optimal partition may not be unique: any partition ∈ [ , ) results in the 
same objective value as ∗ ∈ [ , ) where  is the maximum value of  /  of 
observations that is less than or equal to ∗ and   is the minimum value of /  of 
observations that is greater than ∗. A proper way of determining ∗ when searching on 
the sorted array is to choose the mid-point ∗ = 	 	 . The complexity of this algorithm 
is O(nlogn): it takes O(nlogn) to sort the array / , and O(n) to search through the array 






2.4 Medical Predictive Analysis  
We apply the classification framework to real-world medical predictive problems. In this 
section, the results of four applications are presented: readmissions in emergency 





2.4.1 Readmissions in Emergency Department  
This section contains the paper appeared in American Medical Informatics Association 
Proceedings 2012, 495-504. 
 
A Clinical Decision Tool for Predicting Patient Care Characteristics: 
Patients returning within 72 Hours in the Emergency Department 
Eva K. Lee, Ph.D*,1,2,3, Fan Yuan1,2,3, Daniel A. Hirsh, MD4,5, Michael D. Mallory4,6, 
MD, Harold K. Simon, MD, MBA4,5  
1Center for Operations Research in Medicine and HealthCare; 2Industrial & Systems 
Engineering; 3NSF I/UCRC Center for Health Organization Transformation, Georgia 
Institute of Technology; 4Children’s HealthCare of Atlanta, 5Emory University School of 
Medicine, 6Pediatric Emergency Medicine Associates, Georgia.  
 
Abstract 
The primary purpose of this study was to develop a clinical tool capable of 
identifying discriminatory characteristics that can predict patients who will return within 
72 hours to the Pediatric emergency department (PED). We studied 66,861 patients who 
were discharged from the EDs during the period from May 1 2009 to December 31 2009. 
We used a classification model to predict return visits based on factors extracted from 
patient demographic information, chief complaint, diagnosis, treatment, and hospital real-
time ED statistics census. We began with a large pool of potentially important factors, and 
used particle swarm optimization techniques for feature selection coupled with an 
optimization-based discriminant analysis model (DAMIP)  to identify a classification rule 
with relatively small subsets of discriminatory factors that can be used to predict — with 
80% accuracy or greater — return within 72 hours. The analysis involves using a subset of 
the patient cohort for training and establishment of the predictive rule, and blind 
predicting the return of the remaining patients.  
 
Good candidate factors for revisit prediction are obtained where the accuracy of 
cross validation and blind prediction are over 80%. Among the predictive rules, the most 
frequent discriminatory factors identified include diagnosis (> 97%), patient complaint 
(>97%), and provider type (> 57%). There are significant differences in the readmission 
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characteristics among different acuity levels. For Level 1 patients, critical readmission 
factors include patient complaint (>57%), time when the patient arrived until he/she got an 
ED bed (> 64%), and type/number of providers (>50%).  For Level 4/5 patients, physician 
diagnosis (100%), patient complaint (99%), disposition type when patient arrives and 
leaves the ED (>30%), and if patient has lab test (>33%) appear to be significant. The 
model was demonstrated to be consistent and predictive across multiple PED sites.   
 
The resulting tool could enable ED staff and administrators to use patient specific 
values for each of a small number of discriminatory factors, and in return receive a 
prediction as to whether the patient will return to the ED within 72 hours. Our prediction 
accuracy can be as high as over 85%. This provides an opportunity for improving care and 
offering additional care or guidance to reduce ED readmission. 
 
*Corresponding author: eva.lee@gatech.edu 
 
2.4.1.1 Introduction 
Among patients who are discharged from the ED, 3%-4% return within 72 hours. Revisits 
can be related to the nature of the disease, medical errors, and/or care during their initial 
treatment [86, 115, 151].  
 
Early returns to the ED may involve patients who are in a high-risk population, but 
other factors, such as an overcrowded ED, which decreases efficiency, can also contribute 
to the problem [77, 85, 151, 185]. Alessandrini et al analyzed unscheduled revisits and the 
similarity of return visit rates between pediatric ED and general ED [3]. Previous studies 
have identified risk factors for the early return to the ED, including diagnosis, complaints, 
and patient demographic factors [127, 129]. Gordon et al. indicated that initial diagnosis 
may be a useful predictor of early ED return [69]. McCusker et al. developed a screening 
tool called the Identification of Senior at Risk (ISAR) to identify elderly patients at high 
risk of return to the ED [128]. Other efforts have focused on predictors of the return for 
pediatric mental health care [143], Acute Pulmonary Embolism [11], and chronic 




Although these studies have identified factors that appear to be linked to return 
visits, little is known about actually predicting return visits. Studies have applied prediction 
and classification methods to a variety of types of healthcare data [92, 96, 146]. In 1997, 
Gallagher et al. presented a mixed integer programming model (DAMIP) for constrained 
discriminant analysis, an approach to classification with constraints to control the 
likelihood of misclassification [58]. Lee et al. subsequently demonstrated the capability of 
DAMIP on a wide variety of medical problems compared to other classification methods 
[23, 102, 108, 154]. In this study, we leverage DAMIP along with swarm optimization to 
develop a clinical tool capable of identifying discriminatory characteristics that can predict 
patients who will return to the ED within 72 hours.  We contrast the DAMIP results against 
other classification approaches. 
 
2.4.1.2 Methods 
This study was conducted in the EDs of two sites of Children’s Healthcare of Atlanta 
(CHOA): CHOA at Hospital 1 and CHOA at Hospital 2. Included in this study are 66,861 
patients who were discharged from the EDs during the period from May 1, 2009 to 
December 31, 2009. Patients were identified from the ED information system, including 
2519 patients (3.77%) who returned within 72 hours. The patients were classified into two 
groups as the input of the classification model: the patients who revisit within 72 hours, and 
other discharged patients.  
 
The data included 96 factors for each of the patients, including chief and secondary 
complaint, physician diagnosis, 5 factors related to demographic information, 8 factors 
related to patient arrivals, 44 factors related to the treatment and procedures received, and 
35 factors related to the hospital environment.  
 
Factors of patient information, diagnosis, and treatment have been used in previous 
studies to analyze the early return patients [3, 69, 127, 128, 129]. In this study, the 
demographic factors include age, sex, race, and weight; the hospital environment factors 
include day of week, time of arrival, method of arrival, payor status, triage category (acuity 
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level), number of patients in the ED, number of patients waiting for triage, number of 
available physicians, and number of available beds when the patient arrives; and the 
treatment factors include length of service, waiting time before a physician arrives, number 
of orders, number of requested resources, and whether they have taken CT scan, lab tests, 
radiology test, or IV therapy.  
 
The hospital environment data was extracted from the ED electronic medical record 
and tracking system (Picis ED PulseCheck) into the hospitals enterprise Oracle database. 
For ED descriptors and available patient level details, this occurred on an hourly basis. 
During extraction, variables were recorded and calculations for aggregate indicators were 
written to an Oracle datamart. Final patient data determined after the visit (final icd-9 
codes) were written to the datamart when they became available. 
 
Early return of patients is considered a measure of quality of health care [17]. Many 
studies have indicated that the errors in medical care or patient education may increase the 
risk of early return. However, studies have not adequately analyzed the effect of the 
hospital environment on the patient’s decision to revisit.  Previous studies have used 
logistic linear regression models to find patients at increased risk of return. However, these 
models fail to accurately predict a return visit since the association between the Boolean 
value of return and the risk factors is more complicated than linear association. In order to 
predict the revisit patients among the discharged patients, we used a classification model as 
the predictive model. The implemented classifier is discriminant analysis via mixed integer 
program (DAMIP) which realizes the optimal parameters of the Anderson’s classification 
model [9, 58, 108]. DAMIP aims to maximize the overall prediction accuracy using a set of 
factors, subject to an upper bound on the misclassification rate. In the next section, we 
describe the DAMIP-based machine learning framework. 
 
Machine Learning Framework for Establishing Predictive Rules 
The computational design of our machine learning framework focuses on the ‘wrapper 
approach’, where a feature selection algorithm is coupled to the DAMIP 
learning/classification module. The feature selection, classification and cross validation 
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procedures are coupled such that the feature selection algorithm searches through the space 
of attribute subsets using the cross-validation accuracy from the classification module as a 
measure of goodness. The attributes selected can be viewed as critical clinical/hospital 
variables that drive certain diagnosis or early detection. This allows for feedback to clinical 
decision makers for prioritization/intervention of patients and tasks.  
 
Optimization-Based Classifier: Discriminant Analysis via Mixed Integer Program 
Suppose we have  entities from  groups with  features. Let = {1, 2,… , } be the 
group index set, = {1, 2, … , } be the entity index set, and = {1, 2,… , } be the 
feature index set.  Also, let , ∈  and ⊆ , be the entity set which belong to group 
.  Moreover, let , ∈ , be the domain of feature j, which could be the space of real, 
integer, or binary values.  The th entity, ∈ , is represented as 
( , ) = ( , , … , ) ∈ × × ⋯× , where  is the group to which entity  
belongs, and ( , … , ) is the feature vector of entity .  The classification model finds a 
function : ( × ⋯× ) →  to classify entities into groups based on a selected set of 
features. 
  
Let 	be the prior probability of group 	and ( ) be the conditional probability 
density function for the entity  ∈ ℝ  of group , ∈ .  Also let ∈ (0,1), ℎ, ∈
, ℎ ≠ ,	be the upperbound for the misclassification percentage that group h entities are 
misclassified into group .  DAMIP seeks a partition { , , … , } of ℝ , where  , 
∈ , is the region for group , and  is the reserved judgement region with  entities for 
which group assignment are reserved (for potential further exploration).  
 
Let  be the binary variable to denote if entity  is classified to group  or not.  








(Nonlinear DAMIP) [58, 108] 
max 
∈
  (1) 
s.t. = ( ) − ( )
∈ ,




if	 = arg max{0, : ℎ ∈ }
otherwise                             
 ∀	 ∈ , ∈ {0} ∪  (3) 
 
∈{ }∪
= 1 ∀	 ∈  (4) 
 
:	 ∈
≤ ⌊ ⌋ ∀	ℎ, ∈ , ℎ ≠  (5) 
 ∈ {0,1}  ∀	 ∈ , ∈ {0} ∪   
  unrestricted in sign ∀	 ∈ , ∈   
 ≥ 0 ∀	ℎ, ∈ , ℎ ≠   
 
DAMIP has many appealing characteristics including: 1) the resulting classification 
rule is strongly universally consistent, given that the Bayes optimal rule for classification is 
known [97]; 2) the misclassification rates using the DAMIP method are consistently lower 
than other classification approaches in both simulated data and real-world data; 3) the 
classification rules from DAMIP appear to be insensitive to the specification of prior 
probabilities, yet capable of reducing misclassification rates when the number of training 
entities from each group is different; 4) the DAMIP model generates stable classification 
rules regardless of the proportions of training entities from each group [23, 58, 102, 108, 
154]. 
 
In the ED readmission classification experiments and analysis, there are two groups 
of patients: Group 1: non-returning, Group 2: return within 72-hour. Each entity is a 
patient, and each feature is the factor. Patient data from the period May 1, 2009 to 
December 31, 2009 were randomly divided into two sets: a training set and an independent 
set for blind prediction. The DAMIP classifier is first applied to the training set to establish 
the classification rule. The accuracy of the rule is first gauged by performing 10-fold cross 
validation, and can be further gauged by applying the rule to the independent set of patient 
data for blind prediction. Blind prediction is performed only when the 10-fold classification 
for the training set satisfies a pre-set minimum accuracy criteria. To gauge the performance 
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of our classifier, we compare the results with linear discriminate analysis, Naive Bayesian 
classifier, support vector machine, logistic regression, decision tree, random forest and 
nearest shrunken centroid approaches that are implemented in the R© 
language/environment. 
 
By design, the machine learning process strives to identify the smallest set of 
discriminatory features that offers reliable prediction. In our application, a data stream can 
be fed automatically into our machine learning framework. In other applications, e.g., using 
hand-held device for early diagnostics etc., it is desirable that the final prediction rule 
depends on relatively few factors so that it is not a burden on the healthcare staff to enter 
the information.  Regardless of the input of data stream, these discriminatory features 
impact decisions for hospital policy, and thus should contain only the critical factors.  
 
Incorporating the Feature Selection Algorithm  
We developed a heuristic algorithm using particle swarm optimization (PSO) to iteratively 
search among subsets of factors. PSO, originally developed by Kennedy and Eberhart [88, 
152], is an evolutionary computation technique for solving optimization problems.  Below, 
we describe the DAMIP/PSO machine learning framework.  
 
Let n be the desired number of factors to be selected. Let m be the size of the 
particles population.  Let xi and pi be binary vectors representing sets of chosen factors. Let 
vi be a real-value vector representing the velocity of particle i. vi is randomly assigned 
during initialization. 
 
Associated with each particle is a current set of factors, xi, and a record of the best 
classification accuracy with its corresponding factor set, pi, reached thus far by this particle. 
We use a Von Neumann topology with 36 particles (6 × 6 block). Each particle’s 
neighborhood is defined by its top, bottom, left and right.   
 
At each iteration, the factor set for a particle is updated by the following algorithm: 
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o Step 1 Perform DAMIP classifier for cross validation on the training data using the 
selected set of factors xi; 
o Step 2 If the overall accuracy and the accuracy of each group in the 10-fold cross 
validation are over a pre-set value (e.g., > 70%), perform blind prediction using this 
rule on the independent set and output results. Otherwise go to Step 3.  
o Step 3 Update the velocity of the particle: The new velocity vi is obtained from the 
current velocity, the current factor set, and the best accuracy of this particle and its 
neighborhood and their corresponding factor set: 
    ,)(2211 iiNiiii xprcxprcvv 
 
where ω, c1 and c2 are fixed positive coefficients, r1 and r2 are randomly generated 
in the range (0,1), N(i) is the neighborhood of particle i. 
o Step 4 The highest n velocity entries of this new vi form the associated new factor 
set of this particle. 
 
The algorithm updates the m particles sequentially in each iteration, and terminates 
when it reaches a pre-determined maximum number of iterations. 
 
We implemented the DAMIP classifier and PSO feature selection algorithm in C++.  
In this study, the particle population is 36, and the machine learning process consists of 
1000 DAMIP/PSO iterations (= one complete learning cycle). Each cycle requires an 
average of 1,080 CPU seconds. The experiment is repeated 100 times with randomly 
selected starting subsets of factors to strategize our search space and to avoid local 
optimum.  
 
The output of the algorithm is a collection of discriminatory subsets of factors that 
are good candidates for the prediction of return visits within 72 hours. While users can set 
the desired number of discriminatory factors, the size of factors reported herein < 10) is 






Due to the diversity of patients in the two hospital sites, we ran the classification model 
separately for each site. There were 27,534 ED patients at Hospital 1, 996 (3.62%) of 
whom returned within 72 hours; and there were 39,327 at Hospital 2, 1523 (3.87%) of 
whom returned within 72 hours. All patients went home after the first ED visit. In our 
analysis, the training set is 15,000 and 20,000 respectively, and the blind prediction set 
consists of the rest of the patients.  
 
Table 2.4.1. Selected characteristics of patient information 






% of return 






% of return in 
72 hours (%) 
Total 27534 100 3.62 39327 100 3.87 
Day of week       
  Monday 4036 14.66 3.20 5835 14.84 3.75 
  Tuesday 3910 14.20 3.12 5514 14.02 3.46 
 Wednesday 3782 13.74 3.64 5481 13.94 3.45 
  Thursday 3794 13.78 3.61 5334 13.56 3.86 
  Friday 3683 13.38 4.13 5323 13.54 4.30 
  Saturday 4061 14.80 4.14 5660 14.39 4.47 
  Sunday 4268 15.50 3.51 6180 15.71 3.82 
       
Time of arrival         
  20:00-08:00 10681 38.79 3.95 16013 40.72 4.05 
  08:00-12:00 4110 14.93 3.58 5854 14.89 3.79 
  12:00-16:00 5772 20.96 3.50 8139 20.70 3.70 
  16:00-20:00 6971 25.32 3.23 9321 23.70 3.78 
       
Acuity Level       
1 1333 4.84 2.32 637 1.62 2.67 
2 8514 30.92 2.65 8382 21.31 3.30 
3 12060 43.80 3.91 18781 47.76 3.89 
4 5583 20.28 4.76 11372 28.92 4.36 
5 44 0.16 4.55 155 0.39 1.29 
 
The patient factors were acquired from the patient records and the ED information 
system. Table 2.4.1.1 shows the selected patient information for the two sites. We 
categorized free text factors including method of arrival, patient complaint, physician 
diagnosis, race, payor code, financial class, and disposition type via natural language 
 
32 
processing, and then ranked the categories for each factor based on the corresponding 
revisit rate.  
 
Good candidates for revisit prediction are obtained by filtering the good results 
among the 100 complete learning cycles. These results are filtered using the criteria that the 
accuracy of cross validation and blind prediction for both groups are over 70%.  Based on 
the filtered criteria, we found 7 sets of discriminatory factors for Hospital 1 and 70 sets of 
discriminatory factors for Hospital 2 with set size less than 10. The most frequent factors 
appearing among these discriminatory sets are listed in Table 2.4.1.2.  The factors patient 
chief complaint, patient diagnosis, and provider type appear in the list of both sites.
 
Table 2.4.1.2. Factors most frequently occurring among the 7 sets of discriminatory factors 
for predicting <72-hour returns at Hospital 1, and those most frequently occurring among 
the 70 sets of discriminatory factors for predicting <72-hour returns at Hospital 2. 
Hospital 1 Hospital 2 
Factor Name Frequency 
(%) 
Factor Name Frequency 
(%) 
Patient diagnosis 7 (100%) Patient diagnosis 68 (97.14%) 
Patient chief complaint 7 (100%) Patient chief complaint 68 (97.14%) 
Training Physician: Resident or 
Fellow. 
4 (57.14%) Physician Extender (i.e., 
nurse practitioners or others) 
51 (72.86%) 
If IV antibiotics was ordered. 4 (57.14%) If the patient received a 
radiological test 
27 (38.57%) 
Attending Provider Ratio (The 
provider ratio (PR) determines the 
volume of patients that can be 
evaluated and treated by the 
physician providers).  See 
http://www.ncbi.nlm.nih.gov/pubm
ed/11691670 for reference  
3 (42.86%) Expectant Patient: This is a 
patient is on the way to the 
ED who was called in by a 
care provider. 
21 (30%) 
Patient has been in ED in last 72 
hours 
3 (42.86%) Time it took when the first 
medical doctor arrived until 
the attending arrived 
19 (27.14%) 
Primary nurse involved 2 (28.57%) Patients who arrived 
ambulance 
14 (20%) 
Time when the patient got an ED 
bed to time until first medical 
doctor arrived 
2 (28.57%) Number of triaged patients at 
time 
13 (18.57%) 
Number of nursing resources 
requested 




Figure 2.4.1 depicts the highest accuracy values achieved in DAMIP/PSO cross 
validation and blind prediction. The classification accuracy increases as the number of 
factors selected in the classification rule increases, and the highest accuracy was achieved 
when 4 to 10 factors were used.  Figure 2.4.1 also shows that performance levels off as the 
number of factors increases. We include both the cross-validation and the blind prediction 
results to reflect the consistency of predictive power of the developed classification rules.  
 
 
Figure 2.4.1. The highest prediction accuracy obtained via DAMIP/PSO for the two 
hospital sites. The solid lines represent the accuracy of cross validation, and the dashed 
lines represent the blind prediction accuracy. H1: Hospital 1, H2: Hospital 2, CV: 10-fold 
cross validation, BT: blind prediction.  
 
Table 2.4.1.3 contrasts DAMIP/PSO results with other classification methods. 
Uniformly other classification methods suffer from group imbalance and the classifiers 
tend to place all entities into the Non-return group. In particular, linear discriminant 
analysis, support vector machine, logistic regression, classification trees, and random forest 
placed almost all patients (> 99%) into the “Non-return” group, by sacrificing the very 
small percentage of “Return” patients. This table also showcases the importance of 

























Acuity level is a crucial indicator of ED patient treatment resource and service 
needs. To better understand the 72-hour readmission characteristics of patients across 
different acuity levels, we perform DAMIP/PSO classification on patients with acuity level 
1, 2, 3, and 4/5 – level 1 being the highest acuity.  We combine Levels 4 and 5 patients in 
this analysis since there are only 44 and 155 Level 5 patients in each hospital respectively. 
The classification results, reported in Table 2.4.1.4, show higher classification and 
predictive accuracy for Level 1 and Level 4/5 patients. This may be explained by the fact 
that these patients have less diagnosis uncertainty than those in Levels 2 and 3.  
 
Specifically, patients with Level 1 acuity have the lowest re-admission percentage 
(Table 2.4.1.1). These patients have the highest acuity, and thus require the most urgent 
rapid service. The prediction accuracy for these patients can be as high as 88%. Patients at 
Levels 4 and 5 have the highest re-admission percentage (Table 2.4.1.1). These patients 
have less pain severity, and are more concerned with quality of service. The most frequent 
factors shown in the discriminatory sets at the two hospitals are listed in Tables 2.4.1.5a, 
and 2.4.1.5b. We observe similarities between the two hospital sites for Level 1 patients 
(and Level 4/5 patients) critical readmission factors. For Level 1 patients, among the 
acquired discriminatory sets with good predictive results, time when the patient arrived 
until he/she got an ED bed, patient complaint, type/number of providers, and patients 
receive radiologic/CT scans are common and most frequent factors in both sites.  For Level 
4/5 patients, patient diagnosis, patient complaint, disposition type when patient arrives and 
leaves the ED, if the patient has a lab test, and if an IV was ordered are among the most 











Table 2.4.1.3. Comparison of DAMIP/PSO results against other classification methods. 
 
10-fold Cross Validation 
Accuracy 
Blind Prediction Accuracy 
Hospital 1 Training Set: 15,000 Blind Prediction Set: 12,534 









96.3% 99.6% 5.5% 96.1% 99.6% 5.3% 
Naïve Bayesian 51.6% 50.3% 87.0% 51.7% 50.2% 89.2% 
Support Vector 
Machine 
96.5% 100.0% 0.0% 96.2% 100.0% 0.0% 
Logistic Regression 96.5% 99.8% 5.9% 96.3% 99.8% 8.3% 
Classification Tree 96.6% 99.9% 4.4% 96.3% 100.0% 3.0% 
Random Forest 96.6% 100.0% 1.5% 96.3% 100.0% 1.9% 
Nearest Shrunken 
Centroid 
62.7% 62.9% 50.0% 48.7% 48.2% 64.7% 
DAMIP/PSO 83.1% 83.9% 70.1% 82.2% 83.1% 70.5% 








LDA 96.2% 100.0% 0.1% 96.0% 100.0% 0.3% 
Naïve Bayesian 53.4% 52.2% 83.9% 54.4% 53.2% 84.2% 
SVM 96.3% 100.0% 0.0% 96.0% 100.0% 0.0% 
Logistic Regression 96.3% 100.0% 0.0% 96.1% 99.9% 3.3% 
Classification Tree 96.2% 100.0% 0.0% 96.0% 100.0% 0.0% 
Random Forest 96.2% 100.0% 0.5% 96.1% 100.0% 0.5% 
Nearest Shrunken 
Centroid 
60.5% 60.6% 50.1% 45.8% 45.1% 61.2% 











Table 2.4.1.4. DAMIP/PSO classification results for patients in each of the acuity levels.  
 Training set Testing set 
Acuity Size 
10-fold Cross Validation 
Accuracy 
Size Blind Prediction Accuracy 
Hospital 1  Overall Non-return Return  Overall 
Non-
return Return 
1 700 87.9% 82.9% 92.8% 633 85.1% 85.3% 76.4% 
2 5000 76.0% 76.4% 71.4% 3514 73.2% 73.6% 71.6% 
3 6000 80.2% 81.0% 70.2% 6060 80.3% 81.1% 70.3% 
4 and 5 3000 85.2% 81.1% 89.2% 2627 81.0% 81.0% 81.3% 
Hospital 2  Overall Non-return Return  Overall 
Non-
return Return 
1 350 77.2% 75.6% 78.8% 287 76.4% 76.4% 75.0% 




77.5% 78.2% 70.1% 8781 77.5% 78.2% 70.0% 


















Table 2.4.1.5a. Factors most frequently occurring among the 236 sets of discriminatory 
factors for predicting <72-hour returns for acuity-level 1 patients at Hospital 1, and those 
most frequently occurring among the 42 sets of discriminatory factors for predicting <72-
hour returns for acuity-level 1 patients at Hospital 2. 
Hospital 1 Hospital 2 
Factor Name Frequency (%) Factor Name Frequency (%) 
Patient diagnosis 230 (97.46%) Time when the patient 
arrived until he/she got a 
bed 
27 (64.29%) 
Time when the patient 
arrived until he/she got a 
bed 
228 (96.61%) Number of beds 
reserved at time 
24 (57.14%) 
Payor type 180 (76.27%) Patient chief complaint 24 (57.14%) 
Patient chief complaint 178 (75.42%) Physician extender (i.e.. 
Nurse Practitioners or 
others). 
22 (52.38%) 
Number of residents in ED 129 (54.66%) Month 16 (38.1%) 
Number of medical 
students in ED 
106 (44.92%) If the patient received a 
radiologic test 
12 (28.57%) 
If the patient received a CT 
scan for his/her head 
80 (33.9%) Patient’s weight 11 (26.19%) 
If the patient had a rapid 
strep test 
77 (32.63%) If the patient received 
Chest X-Ray 
11 (26.19%) 
Number or waiting patients 
divided by the number of 
available beds29  











Table 2.4.1.5b. Factors most frequently occurring among the 246 sets of discriminatory 
factors for predicting <72-hour returns for acuity-level 4/5 patients at Hospital 1, and those 
most frequently occurring among the 491 sets of discriminatory factors for predicting <72-
hour returns for acuity-level 4/5 patients at Hospital 2. 
Hospital 1 Hospital 2 
Factor Name Frequency (%) Factor Name Frequency (%) 
Patient diagnosis 246 (100%) Patient diagnosis 491 (100%) 
Patient chief complaint 246 (100%) Patient chief 
complaint 
487 (99.19%) 
Disposition type when 
patient first arrives 
206 (83.74%) Disposition type when 
patient leaves 
399 (81.26%) 
if the patient 
comprehensive metabolic 
panel 
122 (49.59%) Called in, patient is on 
way  
210 (42.77%) 
Disposition type when 
patient leaves 
72 (29.27%) If the patient had any 
lab tests done  
166 (33.81%) 
Number of patients in bed 
waiting to be discharged 
69 (28.05%) Disposition type when 
patient first arrives 
163 (33.2%) 
Time when patient arrived 
until a first medical doctor 
arrived on scene 
44 (17.89%) Month 145 (29.53%) 
Arrival method 43 (17.48%) Acuity level when the 
patient leaves 
138 (28.11%) 
If an IV of ondansetron 
was ordered 












2.4.1.4 Discussion and Conclusion 
In this study, we developed a machine-learning framework combining a PSO feature 
selection algorithm and a DAMIP classifier to predict patients who will return to the ED 
within 72 hours. We used this model to select sets of discriminatory factors to establish 
classification rules, and to develop prediction criteria based on these rules that differentiate 
the revisit patients from the rest of the patients with predictive accuracy over 80%.  
 
The input factor pool included patient information, patient complaint, physician 
diagnosis, operations and treatment, and hospital real-time utilization records. For Level 1 
patients, among the acquired discriminatory sets with good predictive results, time when 
the patient arrived until he/she got an ED bed, patient complaint, type/number of providers, 
and patients receive a radiologic/CT scan are common and most frequent factors in both 
sites.  For Level 4/5 patients, physician diagnosis, patient complaint, disposition type when 
patient arrives and leaves, if the patient has a lab test, and if an IV was ordered are among 
the most common factors across the two hospitals. We also note that some key hospital 
environment factors (e.g., time when the patient arrived until he/she got an ED bed, 
type/number of providers) appear among the most frequently chosen factors. Besides the 
common factors, the predictive factors for the two sites are different due to the diversity of 
the patients and the hospital characteristics. This supports the point indicated by Joynt et al. 
that the hospital location may affect readmission of the patients [82].  
 
Our classification model was demonstrated to be consistent when the hospital 
environment varies, and its objective can be extended from short-term revisit to any class 
of revisit. The DAMIP/PSO machine learning framework is generalizable for predictive 
analytics across different hospital sites. It can adapt to different feature input and identify 
the appropriate set of discriminatory features for consistent prediction.  
 
Among the ED patients, about 3-4% are return patients. Their returns may be 
related to their first visit experience. Being able to anticipate and predict return patterns 
may facilitate quality of ED service and quality of patient care and allow ED providers to 
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intervene appropriately.  The DAMIP/PSO classifier is able to blind predict with over 80% 
accuracy, and outperforms other classifiers.  
 
Based on the set of discriminatory factors with high accuracy, we developed a 
decision support tool for predicting patients returning within 72 hours. When implemented 
in clinical settings, the tool can potentially acquire data in real-time from the ED database 
and acquire the current hospital resource status. As the relevant factors for a patient are 
entered by the ED staff or through automated data-streaming, the system will return 
readmission prediction status of the patient.  Since each discriminatory set of factors 
corresponds to a delivery or policy change, and requires action from ED staff, we would 
expect the set of discriminatory factors to be rather small, as discovered in our study.    
 
 
Figure 2.4.2. A sample user interface of a prediction tool for 72-hour return. Key features 
are typed in or selected. 
 
 Figure 2.4.2 shows a simple user interface based on a set of factors that predicted 
return visits with accuracy over 80%. After the required patient data is entered, and the 
employee clicks the “predict” button, the tool will retrieve the hospital related factors from 
the hospital database system, and present the revisit prediction result based on the 
implemented criteria. Such a computerized system allows real-time decision making, and 
ongoing learning and retraining of the predictive rule (and thus the discriminatory factors) 
as the ED data evolves over time.  
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We caution that these are only preliminary results based on a subset of patients in 
predicting readmission cases. Currently, we are conducting more detailed analysis where 
different patient cases will be drawn for training, and consistency among the discriminant 
features will be analyzed. Although we obtain better predictive accuracy (> 85%) when 
more discriminatory factors are selected, it is important to keep in mind that using too 
many factors is impractical. 
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2.4.2 Flu Vaccine Responders 
In this section, we apply the classification model to predict the flu vaccine responders. The 
analysis and results of three data sets are presented. 
 
2.4.2.1 High Responders versus Low Responders 
HAI stands for “hemagglutination inhibition”. Hemagglutination happens when the virus 
envelope protein called hemagglutinin (HA) binds to the sialic acid receptors on cells 
causing the formation of a lattice. When there is no virus or very low amount of virus, the 
hemagglutination will not occur and the red blood cells will sink to the bottom of a well 
and form a visible button. The amount of antibody in a serum by mixing several dilutions 
of the serum (in different wells) with a fixed concentration of virus that normally causes 
hemagglutination can be found through test: If a button (red blood cells that sank to the 
bottom) can be seen, it means that the antibody level on the serum on a given dilution is 
enough to prevent the hemagglutination of red blood cells. The objective of HAI assay is to 
detect the highest dilution of serum (that contains the Influenza-antibodies) that prevents 
hemagglutination. Therefore, this assay is an indirect measure of antibody level for each 
virus strain. 
 
Each shot of vaccine contains 3 flu virus strains and each virus strain has its own 
HAI titer response. We will use the “maximum response” which is the “maximum log2 
fold-change among all 3 strains”. If a vaccinee has a log2 HAI response (day 28/day0) of 1, 
2 and 0 for strain 1, 2 and 3, respectively, the maximum HAI response will be equal to 2, 
which is a 4-fold increase HAI response. 
 
We operationally classified the vaccinees as ‘low HAI responders’ or ‘high HAI 
responders’ based on whether or not a fourfold increase occurred after vaccination. The 
high or low responder is measured by Method 1 (4-fold increase on day 28 versus day 0 




It takes 28 days to identify a patient’s HAI responses after he/she takes the flu shot 
vaccine. In this study, gene signatures are collected by the Emory Vaccine Center for each 
subject before the vaccination and at day 3 and day 7 after the vaccination. We propose a 
machine-learning model that can predict the maximum HAI responders using the gene 
signatures. This scheme can correctly predict ≥ 80% of the patients as being high or low 
responders, and shorten the time of measuring the antibody levels for the flu shot from one 
month to a few days. This could significantly accelerate the process of flu shot 
development. 
 
2.4.3.2 Analysis 1 
This study involves 213 subjects from 5-consecutive-year trials (2007-2011) in Analysis 1, 
among which 141 subjects are with high responses and 72 subjects are with low responses. 
Each subject’s maximum HAI response of all 3 strains and responder (High or Low) on day 
28 are given. For each subject, we selected 54,613 gene signatures that correlated with the 
magnitude of HAI response on day 3 or day 7. 170 subjects are collected in day 3 data set 
and 200 subjects are collected in day 7 data set as shown in Table 2.4.2.1. We aim to use 
minimum number of gene signatures to predict high responders versus low responders. 
 
Table 2.4.2.1. Number of subjects of high/low responders in day 3 / day 7 data sets 
Year Total (Day 3 / Day 7) 
High Responders  
(Day 3 / Day 7) 
Low Responders 
(Day 3 / Day 7) 
2007 9 (9/9) 7 (7/7) 2 (2/2) 
2008 28 (26/26) 21 (19/19) 7 (7/7) 
2009 28 (27/28) 16 (16/16) 12 (11/12) 
2010 75 (74/66) 64 (63/55) 11 (11/11) 
2011 73 (34/71) 33 (17/32) 40 (17/39) 
Total 213 (170/200) 141 (122/129) 72 (48/71) 
 
In the initial analyses, 2/3 of the subjects are randomly selected as training set for 
10-fold cross-validation and the remaining subjects are used as testing set for blind 
prediction. With the PSO/DAMIP framework, we identified 13 and 6 sets of genes 
containing no more than 5 gene signatures which achieve over 80% accuracy in both 10-
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fold cross-validation and blind prediction using day 3 and day 7 data sets respectively as 
shown in Table 2.4.2.2.  
 
Table 2.4.2.2.a. Prediction accuracy using day 3 data (13 sets) 
Gene Signature Set 
10-Fold Cross-Validation (CV) Blind Prediction (BT) 

















































Table 2.4.2.2.a. (continued) 
Gene Signature Set 
10-Fold Cross-Validation (CV) Blind Prediction (BT) 




















0.818 0.783 0.830 0.814 0.909 0.750 
 
Table 2.4.2.2b. Prediction accuracy using day 7 data (6 sets) 
Gene Signature Set 10-Fold CV BT 





























Table 2.4.2.2b. (continued) 
Gene Signature Set 10-Fold CV BT 





0.809 0.800 0.814 0.814 0.818 0.812 
 
Next we used 4 of the trials as the training set and used the remaining one trial as 
the testing set, and hence 5 runs were executed. The sets of gene signatures that correctly 
blind predict the testing set in each run using day 3 and day 7 data sets are presented in 
Table 2.4.2.3 and Table 2.4.2.4, respectively. 
 
Table 2.4.2.3. Prediction accuracy using day 3 data set. 
a. Prediction accuracy when the testing set is the trail in 2007 (4 sets) 






























b. Prediction accuracy when the testing set is the trail in 2008 (5 sets) 





























0.826 0.774 0.844 0.863 0.833 0.875 
 
c. Prediction accuracy when the testing set is the trail in 2009 (9 sets) 




































































d. Prediction accuracy when the testing set is the trail in 2010 (5 sets) 






























0.818 0.75 0.857 0.803 0.777 0.807 
 
e. Prediction accuracy when the testing set is the trail in 2011 (5 sets) 






























0.813 0.72 0.838 0.8 0.75 0.846 
 
Table 2.4.2.4. Prediction accuracy using day 7 data set. 
a. Prediction accuracy when the testing set is the trail in 2007 (33 sets) 



































b. Prediction accuracy when the testing set is the trail in 2008 (39 sets) 


















0.821 0.777 0.845 0.863 0.833 0.875 
… 
 
c. Prediction accuracy when the testing set is the trail in 2009 (4 sets) 




























d. Prediction accuracy when the testing set is the trail in 2010 (4 sets) 




















0.8 0.725 0.859 0.844 0.888 0.836 
 
e. Prediction accuracy when the testing set is the trail in 2011 (3 sets) 















0.783 0.73 0.8 0.758 0.764 0.75 
 
In the next step, we reversed the previous analysis, i.e., used one year trial to predict 
all of the other trials. Due to lack of subjects in 2007, we combined 2007 trial with 2008 
trial. The selected gene signature sets can be different between trials because of two 
reasons. First, the flu virus and vaccine between each year are different. Second, 
PSO/DAMIP framework uses a modified PSO algorithm as the feature selection method to 
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select subsets of gene signatures and cannot identify all good subsets. A gene signature set 
that predicts the high/low responders for all years can be considered as general predictors 
for the high/low responders of the flu vaccine for any given year. And we observed that 
gene signatures that are most frequently shown in the selected sets have significant impacts 
on the prediction accuracy. Therefore, we designed a new feature selection algorithm based 
the original PSO algorithm and incorporated with feature ranking method to find the 
common good sets in all of the 4 trials, i.e., the sets that can correctly predict the subjects in 
all of the 4 trials. Feature ranking methods such as Pearson’s correlation coefficient are 
frequently used when the number of feature candidates is large, but significant features and 
subsets can be excluded due to the different measurement between the feature ranking 
method and DAMIP classifier. In this study, it is critical to find as many good subsets as 
possible for each trial in order to find the common sets. We designed the algorithm as 
follows.  
 
In step 1, the PSO/DAMIP framework is executed for 100 replicates, and all of the 
sets with no more than 10 gene signatures that can correctly predict over 75% of the 
subjects in blind prediction are selected. Then, the gene signatures in the selected sets of 
each trial are ranked by their occurrences, and the gene signatures that are commonly 
shown in top 200 of each of the 4 gene signature rankings are selected as the gene 
candidate set. Next in step 2, DAMIP is executed for all no-more-than-5 gene signature sets 
in the gene candidate set to establish their corresponding classification rules for each trial. 
And we report the sets that can correctly predict on all trials. 
 
We applied the modified PSO/DAMIP framework to discriminate the subjects with 
high/low responders. 46 gene signatures and 66 gene signatures are found from step 1 for 
day 3 data and day 7 data, respectively. Table 2.4.2.5 represents the common sets using day 
3 data or day 7 data. Specifically, 21 sets that can predict all trials with prediction accuracy 
over 70% and 944 sets that can predict 3 trials out of 4 with prediction accuracy over 70% 
are found by the modified feature selection algorithm using day-3 data set. And 175 sets 
that can predict all trials with prediction accuracy over 70% and 10,686 sets that can 
predict 3 trials out of 4 with prediction accuracy over 70% are found using day-7 data set. 
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We highlighted the gene signatures that occur most frequently among the good results as 
shown in Table 2.4.2.6. 
 
Table 2.4.2.5. Common sets that well predict all trials. 
a. Using day 3 data set (21 sets) 
Gene Signature 
Set 
2007-2008 2009 2010 2011 









































b. Using day 7 data set (175 sets) 
Gene Signature 
Set 
2007-2008 2009 2010 2011 






























0.758 0.743 0.75 0.751 0.81 0.747 0.725 0.792 
… 
 
Table 2.4.2.6. Gene signatures with highest occurrence 
Day 3 Day 7 
Gene signature Occurrence (21 set) Gene signature Occurrence (944 set) 
213237_at 16 211430_s_at 121 
211976_at 10 231309_at 105 
1559679_a_at 7 228434_at 43 
224595_at 7 221184_at 32 







2.4.3.3 Analysis 3 
In Analysis 3, 109 subjects with high responses on day 30 from 2007 to 2011 are 
given as shown in Table 2.4.2.7. The subjects are split into two classes, “persistent” 
responders and “temporary” antibody responders. Persistent responders are the subjects are 
with high responses on day 30 and also day 60+, and temporary antibody responders are 
the subjects are with high responses on day 30 but low responses on day 60+. For each 
subject, 6699 gene signatures on day 3 and 5520 gene signatures on day 7 are given. Due to 
lack of subjects in 2007 and 2011 trials, we combined 2007 trial with 2008 trial and 2011 
trial with 2010 trial. And we applied the PSO/DAMIP framework on each of the three trials 
to find the gene signature sets that achieve the best prediction accuracy. The results are 
shown in Table 2.4.2.8. 
Table 2.4.2.7. Subjects of Analysis 3. 
 Total Persistent (P) 
Temporary 
(T) 
2007-2008 23 9 14 
2009 16 6 10 
2010-2011 70 20 50 
Total 109 35 74 
 
Table 2.4.2.8a. Prediction results of 3 trials in Analysis 3 for day 3 data set. 
Year Gene Sign-ature Set 
10-fold Cross-Validation 
(CV) 
Blind Prediction (BT) 

























Table 2.4.2.8a. (continued) 
Year Gene Sign-ature Set 
10-fold Cross-Validation 
(CV) 
Blind Prediction (BT) 






















0.905 0.909 0.904 0.833 0.8 0.857 
 
Table 2.4.2.8b. Prediction results of 3 trials in Analysis 3 for day 7 data set. 
Year Gene Signature Set 
10-fold Cross-Validation 
(CV) 
Blind Prediction (BT) 
































Table 2.4.2.8b. (continued) 
Year Gene Signature Set 
10-fold Cross-Validation 
(CV) 
Blind Prediction (BT) 



























2.4.3 Predicting Response to Intra-articular Injections of Hyaluronic Acid for 
Knee Osteoarthritis 
2.4.3.1 Introduction 
A new CDC study reports that the lifetime risk of knee osteoarthritis (OA) with symptoms 
is nearly one in two, or 46%. The study authors also found that nearly two in three obese 
adults will develop painful knee osteoarthritis over their lifetime. The study provides what 
is likely the first lifetime risk estimate of symptomatic knee osteoarthritis in the United 
States. Knee osteoarthritis—a common form of arthritis that wears away the cartilage 
cushioning the knee joint—is a leading cause of arthritis disability. In 2004, $14.3 billion 
were spent on hospital costs associated with total knee replacements. 
 
At least 18% of out-patient visits to military treatment facilities by active duty 
personnel are attributed to painful knee disorders.  The management of knee pain depends 
on the diagnosis, inciting activity, underlying medical conditions, body mass, and 
chronicity.  In general, non-operative management is the mainstay of initial treatment and 
includes rehabilitation, activity modification, weight loss when indicated, shoe orthoses, 
local modalities, and medication.  The oral medication often prescribed is an analgesic, 
usually with anti-inflammatory properties.  Supplements, such as chondroitin sulfate and 
glucosamine have been shown to have a role.  Since 1997, the regimen has expanded to 
include viscosupplementation.  These agents are preparations of hyaluronic acid or their 
derivatives (HA) which are sterilely injected into the knee.  Research studies have clearly 
demonstrated that HA improves knee function.  
  
The goal of this study is to evaluate two different HA preparations to determine 
which patient population or patient characteristics would benefit most from their use.  The 
study uses a prospective, double blinded clinical trial.  A clinical predictive model is 
developed to uncover discriminatory patterns that can predict outcome.  This predictive 
model can be implemented as part of a clinical practice guideline for evidence-based 
intervention.  The model enables providers to administer HA products more selectively and 
 
60 
effectively to targeted population to maximize cost effectiveness and the percentage of 
patients who experience a successful HA trial.  
 
2.4.3.2 Predictive Analysis 
We apply the method of discriminant analysis via mixed integer programming (DAMIP) on 
the HA data to uncover patient and treatment factors that predict optimal response to intra-
articular injections of hyaluronic acid for knee osteoarthritis. The model determines which 
patient variables lead to the best outcomes of HA. 
 
 Figure 2.4.3 shows the machine learning framework where features are first 
selected via particle swarm optimization. The resulting classification rule is subsequently 
established via the DAMIP classifier. Ten-fold cross validation evaluation is performed. If 
the results satisfy the pre-set conditions, the classification rule is reported. Blind prediction 
using this rule is then performed.  
Figure 2.4.3. Machine learning framework for predictive analytics 
 
In 10-fold cross validation, the training set is partitioned into 10 roughly equal 
parts. In each run, 9-fold are selected to form the rule, and the remaining 1-fold is then 
tested, counting how many of them are classified into which group. Through 10 folds 
procedure (where each fold is being validated exactly once), we obtain an unbiased 




Blind prediction is performed on patients that are independent of the training set to 
gauge the predictive power of the established rule. These patients have never been used in 
the machine learning analysis. We run each patient through the rule, and it returns a status 
of the patient. The status is then checked against the clinical status to confirm the accuracy.  
 
 The above two study aims together will culminate in a clinical decision algorithm 
for the use of viscosupplementation in the treatment of knee OA.  For example, a provider 
determines that HA is indicated for a particular patient.  The provider would then enter 
specific variables into a clinical computer program and a response set would be generated 
for the potential outcome after using hyaluronic acid injections.  The optimal HA agent(s) 
would be ranked.  The provider would then take this information into account as part of the 
clinical decision process to select the HA agent for the individual patient.   
 
For this HA study, we perform computational experiments for the following 
studies:  
o predicting reinjection status using data collected up to i) at first injection, ii) after 
T0, iii) after T5.   
o predicting treatment responder status at T5:  
o WOMACP20, Treatment Responder Status Using 20% Reduction in WOMAC Pain 
Scale (0 = Non-Responder, 1 = Responder),  
o KOOSP20,  Treatment Responder Status Using 20% Reduction in KOOS Pain 
Scale (0 = Non-Responder, 1 = Responder),  
o OARSI,  
o predicting recovery status at T5, recovery on any KOOS Scale 
 
We also perform the prediction over each of the two types of injections to gauge 
their similarities and differences in treatment outcome characteristics.  
 
Table 2.4.3.1 shows the number of patients in the training set and the blind 
prediction set for prediction reinjection status using data up to i) at first injection, ii) after 
T0, iii) after T5.  In this analysis, for every attribute in which there is any missing data, an 
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associated binary attribute is created to capture if data is missing or not for this field. The 
missing data is then be filled with median value of the associated demographic population.  
 
Table 2.4.3.2 shows the training set and blind prediction statistics used for 
predicting treatment responder status and recovery status. We eliminate those patients 
where the predictor variables are missing. 
 
Table 2.4.3.1. Training set and blind prediction set characteristics for predicting reinjection 
status. 




















Using Data Up To 
At First Injection,  27 150 111 39 53 40 13 
Up To After T0 483 150 111 39 53 40 13 
After T5 1215 150 111 39 53 40 13 
 
Table 2.4.3.2. Training set and blind prediction set characteristics for predicting treatment 
responder status and recovery status. 
Predicting Treatment 
Responder /  Recovery 
Status At T5 





























KOOSP20 141 71 70 71 33 38 70 38 32 
KOOSRecovery 141 84 57 71 39 32 70 45 25 
KOOSOARSI 141 80 61 71 37 34 70 43 27 








Table 2.4.3.2. (continued) 
Predicting Treatment 
Responder /  Recovery 
Status At T5 





























KOOSP20 76 36 40 40 17 23 36 19 17 
KOOSRecovery 76 44 32 40 21 19 36 23 13 
KOOSOARSI 76 44 32 40 20 20 36 24 12 
WOMACP20 76 37 39 40 18 22 36 19 17 
Euflexxa 
KOOSP20 65 35 30 35 20 15 30 15 15 
KOOSRecovery 65 40 25 35 22 13 30 18 12 
KOOSOARSI 65 36 29 35 21 14 30 15 15 
WOMACP20 65 38 27 35 21 14 30 17 13 
 
For every attribute in which there is any missing data, an associated binary attribute 
is created to capture if data is missing or not for this field. The missing data is then be filled 
with median value of the associated demographic population. We eliminate those patients 
where the predictor variables are missing.  
 
2.4.3.3 Results for Predictive Analysis 
Analysis Involving Both Injections 
We summarize below the best predictive rules and the associated discriminatory attributes 
for each of the analysis. Tables 2.4.3.3a - 2.4.3.3c show the prediction accuracy for no-
reinjection versus re-injection when using attributes collected up to i) at first injection, ii) 
after T0, iii) after T5 respectively. We can observe the high accuracy in predicting success 
for patients using screening and T0 attributes alone (86% blind predictive accuracy).  This 
is very promising for identifying patients who should be targeted for HA intervention (with 
expected success outcome). Including attributes until T5 increases significantly the 





Table 2.4.3.3a. Best predictive rules for re-injection status when using only screening 
attributes. 
Using attributes 
collected up to first 
injection,  
10-fold cross validation  blind prediction 
Attributes 
Overall  No-reinjection 
Re-





>= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 














Table 2.4.3.3b. Best predictive rule for re-injection status when using screening + T0 
attributes. 
Using attributes 










>= 0.8 >= 0.7 >= 0.7 >= 0.8 >= 0.7 >= 0.7 












Table 2.4.3.3c. Best predictive rule for re-injection status when using screening + T0 to T5 
attributes. 
Using attributes 










>= 0.8 >= 0.8 >= 0.8 >= 0.8 >= 0.8 >= 0.8 










Screening + T0 + T1 + 
T2 + T3 + T4+ T5 with 
category attributes 
modified (highlight in 
yellow) to reflect the 
demographic success 
rate ranking 
10-fold cross validation  blind prediction 
Attributes 
Overall  No-reinjection 
Re-





>= 0.8 >= 0.8 >= 0.8 >= 0.8 >= 0.8 >= 0.8 

















Tables 2.4.3.4a – 2.4.3.4d present the best predictive rules for predicting various treatment 
responder status and the recovery status. 
 
Table 2.4.3.4a. Best predictive rule for predicting treatment responder status KOOSP20 




20 = 0 
KOOSP2
0 = 1 
Overall  
KOOS
P20 = 0 
KOOSP
20 = 1 
>= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 









Table 2.4.3.4b. Best predictive rule for predicting recovery status KOOSRecovery 




overy = 0 
KOOSRec
overy = 1 
Overall  
KOOSRec
overy = 0 
KOOSRec
overy = 1 
>= 0.75 >= 0.7 >= 0.7 >= 0.75 >= 0.7 >= 0.7 

















Table 2.4.3.4c. Best predictive rule for predicting treatment responder status KOOSOARSI 




RSI = 0 
KOOSOA
RSI = 1 
Overall  
KOOSOA
RSI = 0 
KOOSOA
RSI = 1 
>= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 







Table 2.4.3.4d. Best predictive rule for predicting treatment responder status WOMACP20 




P20 = 0 
WOMAC
P20 = 1 
Overall  
WOMAC
P20 = 0 
WOMAC
P20 = 1 
>= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 









Analysis for Synvisc  
We next summarize the results when we consider each injection separately. Tables 
2.4.3.5a-2.4.3.5d show the predictive rules for predicting treatment responder status and 








Table 2.4.3.5a. Best predictive rule for predicting treatment responder status KOOSP20 
with Synvisc. 




20 = 0 
KOOSP
20 = 1 
Overall  
KOOSP
20 = 0 
KOOSP
20 = 1 
>= 0.8 >= 0.75 >= 0.75 >= 0.8 >= 0.75 >= 0.75 







Table 2.4.3.5b. Best predictive rule for predicting treatment responder status 
KOOSOARSI with Synvisc. 




RSI = 0 
KOOSOA
RSI = 1 
Overall  
KOOSOA
RSI = 0 
KOOSOA
RSI = 1 
>= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 >= 0.7 







Table 2.4.3.5c. Best predictive rule for predicting treatment responder status WOMACP20 
with Synvisc. 




P20 = 0 
WOMAC
P20 = 1 
Overall  
WOMAC
P20 = 0 
WOMAC
P20 = 1 
>= 0.8 >= 0.75 >= 0.75 >= 0.8 >= 0.75 >= 0.75 







Table 2.4.3.5d. Best predictive rule for predicting recovery status KOOSRecovery with 
Synvisc. 




overy = 0 
KOOSRec
overy = 1 
Overall  
KOOSRec
overy = 0 
KOOSRec
overy = 1 
>= 0.8 >= 0.8 >= 0.8 >= 0.8 >= 0.8 >= 0.8 












Analysis for Euflexxa  
Tables 2.4.3.6a-2.4.3.6d show the predictive rules for predicting treatment responder status 
and recovery status for patients injected with Euflexxa. 
 
Table 2.4.3.6a. Best predictive rule for predicting treatment responder status KOOSP20 
with Euflexxa. 
10-fold cross validation  blind prediction 
Overall  
KOOSP
20 = 0 
KOOSP2






Attributes >= 0.85 >= 0.8 >= 0.8 >= 0.85 >= 0.8 >= 0.8 












Table 2.4.3.6b. Best predictive rule for predicting treatment responder status 
KOOSOARSI with Euflexxa. 




RSI = 0 
KOOSOA
RSI = 1 
Overall  
KOOSOA
RSI = 0 
KOOSOA
RSI = 1 
>= 0.85 >= 0.85 >= 0.85 >= 0.85 >= 0.85 >= 0.85 































Table 2.4.3.6c. Best predictive rule for predicting treatment responder status WOMACP20 
with Euflexxa. 




P20 = 0 
WOMACP
20 = 1 
Overall  
WOMACP
20 = 0 
WOMACP
20 = 1 
>= 0.8 >= 0.8 >= 0.8 >= 0.8 >= 0.8 >= 0.8 
ScreenEverSm
oked 











Table 2.4.3.6d. Best predictive rule for predicting recovery status KOOSRecovery with 
Euflexxa. 




overy = 0 
KOOSReco
very = 1 
Overall  
KOOSRec
overy = 0 
KOOSReco
very = 1 
>= 0.85 >= 0.8 >= 0.8 >= 0.85 >= 0.8 >= 0.8 
T0AntalgicGa
it 












2.4.4 Alzheimer’s Disease 
2.4.4.1 Introduction 
Alzheimer's disease (AD), the 7th leading cause of death in the United States, is a 
progressive and irreversible brain disease which causes memory loss and other cognitive 
problems severe enough to affect daily life. Dementia is a collection of symptoms of 
cognitive function problems, such as thinking, remembering, or reasoning problems, and 
AD is the most common cause of dementia. Mostly AD occurs in people over 65, although 
familial AD has an earlier onset. Currently, AD is incurable; drugs are used to manage the 
symptoms or to prevent or slow the progress of the disease. 
 
Mild cognitive impairment (MCI) is a condition that there is clear evidence of 
cognitive problems, most often involving short term memory, but normal day to day 
functioning is preserved. In other words, MCI is a situation between normal aging and 
dementia. People with MCI may or may not develop dementia in the future, but people 
with MCI are at higher risk of developing dementia than those without MCI. 
 
The evaluation of AD or MCI is based on patient information including complete 
medical history, Neuropsychological exam, laboratory tests, neuropsychological tests, brain 
scans (CT or MRI), and information from close family members. Neuropsychological 
changes in the expression of cognitive declines are important to the diagnosis of AD and 
MCI. Statistical analyses as predictive analysis tools are applied to neuropsychological data 
to understand MCI patents [119, 182]. Besides statistical analyses, classification models are 
applied to neuropsychological data for predicting brain damage [180] and whether 
nondemented elderly declined to diagnosis of dementia or Alzheimer’s disease [91]. 
 
In addition to the traditional diagnosis, the clinical diagnosis of MCI and AD is 
increasingly aided by biomarkers predictive of underlying pathology. A number of recent 
studies generated additional enthusiasm for a blood-based test to predict non-demented 
control and AD [156, 157]. Identifying MCI and AD remains challenging. Hu [78] 
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measured levels of 190 plasma proteins and identified 17 analytes associated with the 
diagnosis of MCI or AD. 
 
We apply the multi-stage classification model to predict the control, MCI, and AD 
groups using two data sets: The first one was the neuropsychological test data that 
conducted by Emory Alzheimer's Disease Research Center in 2011; the second one was 
plasma biomarkers information collected by 2 independent centers (University of 
Pennsylvania, Philadelphia; Washington University, St. Louis, MO). We present the 
prediction results for both data sets in the following sections. 
 
2.4.4.2 Predictive Analysis Using Neuropsychological Data 
The neuropsychological tests conducted in this data set includes Mini Mental State 
Examination (MMSE), Clock drawing test, Word list memory tasks by the Consortium to 
Establish a Registry for Alzheimer's Disease (CERAD), and Geriatric depression scale 
(GDS). The MMSE is a screening tool for cognitive impairment, which is brief, but covers 
five areas of cognitive function, including orientation, registration, attention and 
calculation, recall, and language. The clock drawing test assesses cognitive functions, 
particularly visuo-spatial abilities and executive control functions. The CERAD word list 
memory tasks assess learning ability for new verbal information. The tasks include word 
list memory with repetition, word list recall, and word list recognition. The GDS is a 
screening tool to assess the depression in older population. 
 
Data of 267 subjects with known groups were collected as shown in Table 2.4.4.1. 
Among the 267 subjects, 2/3 of the subjects in each group are randomly selected as training 
set for 10-fold cross validation, while the remaining subjects are selected as testing set for 
blind prediction. 107 features are included for feature selection and classification. Among 
the 107 features are 3 features representing age, gender, education year, 15 features from 
Clock drawing test, 11 features from GDS, 13 features from MMSE, and 65 features from 




464 feature sets of no more than 10 features that can correctly predict more than 
80% of the subjects in both 10-fold cross validation and blind prediction are found by the 
PSO/DAMIP framework. The feature sets that achieve the best prediction accuracy are 
presented in Table 2.4.4.2. The overall prediction accuracy of 10-fold cross validation and 
blind prediction are over 85%, while the prediction accuracy of each group is over 80%. 
The prediction accuracy no longer improves when more features are used in the 
classification model. In Table 2.4.4.3, we highlight the features that most frequently occur 
in the 464 feature sets.  
 
Table 2.4.4.1. Group information of 267 subjects in neuropsychological data set. 
 Total Control MCI AD MCI or AD 
Training 178 72 51 55 106 
Testing 89 36 26 27 53 
Total 267 108 77 82 159 
 
Table 2.4.4.2. Prediction accuracy of the best feature sets. 
Feature set 10-fold Cross-Validation Blind Prediction Overall Ctrl MCI AD Overall Ctrl MCI AD 
cClockNumbers4 86.0% 87.8% 80.0% 88.3% 86.2% 88.2% 80.6% 90.9% 
cClockCenter 
GDS6 








cClockNumbers4 86.0% 89.2% 80.0% 86.7% 85.1% 85.3% 80.6% 90.9% 
cClockHands4 
cClockCenter 
Score for What is 
the month? 









Table 2.4.4.2. (continued) 




Score for What is 
the month? 














cClockNumbers4 86.6% 89.2% 82.2% 86.7% 86.2% 88.2% 80.6% 90.9% 
cClockCenter 
Score for What is 
the year? 
Score for What is 
the month? 








Table 2.4.4.3. Features with the highest occurrences in the 310 feature sets. 
Feature Test Occurrences 
MMSE Total MMSE 100.0% 
cWLrTotal Word list 94.4% 
cWL1Ticket Word list 94.2% 
cClockCenter Clock 76.1% 
Score for What is the year? MMSE 59.5% 
Score for What is the 
month? MMSE 53.4% 
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2.4.4.3 Predictive Analysis Using Plasma Biomarkers 
Data of 352 subjects with complete information are collected as shown in Table 2.4.4.4. 2/3 
of the subjects in each group are randomly selected as training set for 10-fold cross 
validation, while the remaining subjects are selected as testing set for blind prediction. We 
use 31 features for feature selection including gender, age, education years, MMSE, and 10 
indicators and 17 analytes that identified by Hu [78]. 
 
92 feature sets of no more than 10 features that can correctly predict more than 80% 
of the subjects in both 10-fold cross validation and blind prediction are found by the 
PSO/DAMIP framework. The feature sets that achieve the best prediction accuracy are 
presented in Table 2.4.4.5. The overall prediction accuracy of 10-fold cross validation and 
blind prediction are over 85%, while the prediction accuracy of each group is over 80%. 
The prediction accuracy no longer improves when more features are used in the 
classification model. In Table 2.4.4.6, we highlight the features that most frequently occur 
in the 464 feature sets. 
 
Table 2.4.4.4. Group information of 352 subjects in plasma biomarkers data set. 
 Total Control MCI AD MCI or AD 
Training 250 35 133 82 215 
Testing 102 21 62 19 81 
Total 352 56 195 101 296 
 
Table 2.4.4.5. Prediction accuracy of the best feature sets. 












81.6% 91.4% 72.9% 91.5% 80.4% 81.0% 75.8% 94.7% 
 
77 
























81.6% 91.4% 72.9% 91.5% 80.4% 81.0% 75.8% 94.7% 
 
 
















CHAPTER III  
CANCER TREATMENT PLANNING 
 
This chapter investigates optimization approaches applied to radiation therapy in cancer 
treatment. The key to the effectiveness of radiation therapy for the treatment of cancer lies 
both in the fact that the repair mechanisms for cancerous cells are less efficient than that of 
normal cells, and the ability to deliver higher doses to the target volume. Thus, a dose of 
radiation sufficient to kill cancerous cells may not be lethal for nearby healthy tissue. The 
goal of radiation therapy is to conform the spatial distribution of the prescribed dose to the 
tumor volume while minimizing the dose to the surrounding normal structures. One key 
treatment of radiation therapy is high-dose rate (HDR) brachytherapy which allows 
localized high-dose radiation delivery to the tumor target via short-term implantation of 
radioactive seeds. HDR brachytherapy treatment plans are assessed by tumor control 
probability (TCP) which measures the probability of killing all cancerous cells in the 
affected organ. In the first section, we introduce a TCP-driven HDR treatment planning 
system for cervical cancer. The treatment planning is facilitated by dose escalation on the 
tumor that is guided by the advanced imaging techniques. In the second section, we 
introduce a nonlinear optimization system that maximizes TCP directly in HDR 
brachytherapy treatment planning. It maximizes the nonlinear function TCP while 
preserving the healthy tissues by adopting dose volume constraints. To tackle the nonlinear 
optimization problem, we propose a solution strategy that couples local search with 





3.1 Biological Planning for High-Dose Rate Brachytherapy: Application to 
Cervical Cancer Treatment 
This section contains the paper appeared in Interfaces - The Daniel H. Wagner Prize for 
Excellence in Operations Research Practice 2013; 43(5): 462-47. EK Lee, F Yuan, A 
Templeton, R Yao, K Kiel, JCH Chu. Biological planning for high-dose rate 
brachytherapy: Application to cervical cancer treatment.   
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Cervical cancer has a high mortality rate (approximately 35 percent) in the United States 
and is difficult to treat successfully. One promising treatment is high-dose-rate 
brachytherapy, which entails delivering high-dose radiation to the tumor via the temporary 
implantation of radioactive seeds. This treatment promises to be particularly effective in 
eradicating tumors, while preserving the organs. Yet, major obstacles to successful 
treatment remain, especially (1) determining the best seed type, spatial configuration of 
seeds, and seed dwelling time, and (2) improving the probability that the treatment will 
eliminate all malignant cells. We developed an advanced planning model to simultaneously 
address both of these issues. To permit taking advantage of the best available information, 
our model works with inputs from positron emission tomography. We begin with a 
multiobjective, nonlinear, mixed-integer programming model that is initially intractable. To 
solve the model, we introduce an original branch-and-cut and local-search approach that 
couples new polyhedral cuts with matrix reduction and intelligent geometric heuristics. The 
result has been accurate solutions, which are obtained rapidly. Clinical trials at Rush 
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University Medical Center have demonstrated superior medical outcomes. These analytical 
techniques are applicable not only to cervical cancer, but also to other types of cancer, 
including breast, lung, and prostate cancer. 
 
Key words: cancer therapeutics; cervical cancer; tumor control probability; integer 
programming; biological optimization; high-dose-rate brachytherapy. 
______________________________________________________________________ 
3.1.1 Introduction 
Almost a million cancer patients in the United States receive some form of radiation 
therapy each year [7]. Radiation is delivered using either external beam technology or a 
procedure known as brachytherapy. Brachytherapy uses a radioactive substance sealed in 
needles, seeds, wires, or catheters. which are placed directly (permanently or temporarily) 
into or near the cancer. This allows a full tumoricidal effect to eradicate the tumor from 
within the cancer site, while ensuring that minimal radiation reaches the healthy 
surrounding tissues. For high-dose-rate (HDR) brachytherapy, patients receive treatment 
through catheters during 3 to 10 outpatient sessions over a period of five days to two 
weeks. Brachytherapy preserves organs, usually with no loss of functionality; thus, it is 
rapidly becoming the choice of treatment for prostate, breast, cervix, and uterus cancer. 
 
Operations research (OR) has brought breakthrough advances in treatment-planning 
optimization, as evidenced by the 2007 Franz Edelman award work by Memorial Sloan 
Kettering Cancer Center (MSKCC), which saves half a billion dollars in yearly operations 
and delivery costs via intelligent real-time OR-based treatment-planning approaches, while 
the tumor control probability (TCP) (i.e., the probability of extinction of clonogenic tumor 
cells by the end of treatment) improves from 65 percent to 95 percent [107]. 
 
This work brings two first-of-its-kind advances to HDR brachytherapy treatment 
design. First, TCP, which depends upon a highly complex function that models the 
responses of cancer cells and normal cells to radiation, is incorporated in the planning 
objective. This is distinct from the dose-based planning that is commonly employed in 
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current treatment design. Second, positron emission tomography (PET) information, which 
relates cancer cell proliferation and distribution, is incorporated within the constraints, 
facilitating targeted, escalated dose delivery to improve the overall clinical outcome of 
HDR treatments. 
 
This work is distinct from the MSKCC in three ways: (1) HDR brachytherapy uses 
temporary implants that require multiple sessions; in addition to determining seed 
positions, the dwell time also has to be optimized. (2) This is the first time that TCP, an 
important measure of desired outcome, has been successfully incorporated in a treatment-
planning analytical model; we determine the TCP function from a complex biological 
model, and place it in the objective. (3) This is the first time that PET tumor cell 
proliferation and distribution are incorporated within radiation therapy (external beam or 
brachytherapy) for dose-escalation planning.  
 
The optimization models we develop, which are TCP driven and PET-image guided 
and permit HDR with dose escalation, initially prove to be intractable. The intractability 
arises from three sources. First, our models share the denseness properties of previous 
treatment-planning models [107]. We found that even without the complications that 
nonlinear TCP functions and PET-based dose escalation introduce, we could not solve the 
associated treatment-planning instances using competitive optimization software, even after 
we ran this software for several months of CPU time. Second, the extreme nonlinearity of 
our TCP functions increases the difficulties. Third, the competing PET-based dose 
escalation constraints that seek to go between cancer pockets and critical normal tissues 
offer only a tight solution space. 
 
We focus our discussion on cervical cancer, although the methodologies are 
applicable to most types of cancer. Cervical cancer ranks as the second most common 
cancer in women worldwide, with about 500,000 new cases and 250,000 deaths annually. 
Almost 80 percent of cervical cancer cases are in less-developed countries [194]. The 
majority of cervical cancer cases (75 percent) are caused by the human papilloma virus 
[140]. The cancer grows slowly, and in its early stages may not have any symptoms. Thus, 
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the mortality rate remains high at about 35 percent. In the United States in 2013, an 
estimated 12,340 women will be diagnosed with cervical cancer and about 4,030 women 
will die from it [140]. About 0.68 percent of women born today will be diagnosed with 
cervical cancer at some time during their lifetimes [75].  
 
The five-year survival rate for women diagnosed with cervical cancer is close to 75 
percent [142]. The choice of treatment depends on the stage of the cancer, the size of the 
tumor, the patient's desire to have children, and the patient’s age. Standard treatments 
include surgery, chemotherapy, and radiation therapy. With advances in radiation-therapy 
modalities and their organ-preserving characteristics, it is rapidly becoming the treatment 
of choice for cervical cancer [138].  
 
In this paper, we describe our original treatment-planning models as we applied 
them to cervical cancer, and we describe our computational breakthroughs that permit 
rapid, accurate solutions. Our planning methods were implemented by the Rush University 
Medical Center. To the best of our knowledge, Rush University conducted the first and 
only clinical trial in the United States for HDR brachytherapy with PET-based dose 
escalation applied to cervical cancer. We report on how, with modeling assistance, the 
Medical Center was able to increase its treatment success and improve its quality of care, 
thus reducing both mortality and personal and financial burdens for cervical cancer 
patients. 
 
3.1.2 Challenges and Objectives  
With advances in computed tomography (CT) and magnetic resonance (MR) imaging 
technology, it is possible to produce contours of gross tumor volume, clinical target volume 
(CTV), planning target volume (PTV), and organs at risk (OARs), and to view the radiation 
dose within these contours as radionuclide implant locations and dwell times are adjusted. 
This in turn enables the use of optimization technology to derive custom treatment plans 
that best achieve the clinical goals of delivering a full tumoricidal dose to eliminate the 
cancers, while minimizing the doses to OARs [36, 56, 73, 83, 90, 99, 183]. Inverse 
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planning and multiobjective optimization with penalty costs have become more commonly 
used to address the trade-off between treating the tumor and sparing the OARs, while the 
optimization solution process remains a major challenge [4, 74, 89, 95, 136, 162]. Because 
treatment planning is intrinsically combinatorial in nature, relaxation and heuristic 
algorithms (e.g., linear programming or simulated annealing) have been typically employed 
[4, 16, 74, 84, 89, 136]. 
 
PET imaging is an important advance for cervical cancer brachytherapy treatment 
planning [13, 188]. The ability of PET imaging to accurately define the primary lesion by 
including positive lymph nodes in the PTV facilitates treatment planning. The use of FDG-
PET (i.e., PET with fluorodeoxyglucoseas as a radiopharmaceutical tracer) offers a unique 
method for visualizing tumors, which permits treatment optimization [121]. Integrated PET 
and CT for treatment planning for three-dimensional conformal radiation therapy improves 
the standardization of volume delineation [27]. MR spectroscopy (MRS)-guided dose 
escalation for prostate cancer indicates that the TCP can be dramatically improved if 
biological information can be included within a personalized treatment design [107, 203]. 
This work differs from the dose-escalation work of Zaider et al. [204] in that, in addition to 
incorporating dose-escalation constraints within the treatment constraints, our model 
incorporates, within the objective function, data on the radio resistance and sensitivity of 
both tumor and normal cells to drive the optimization process. 
 
The crux and challenges of HDR brachytherapy dose distributions include the 
following. (1) The seed type, spatial configuration, and dwell time per treatment must be 
determined. (2) Tumor control, a very complex biological relationship, depends on the time 
of the treatment, radioactive decay of the radioisotope, dose received, volume and density 
of tumor cells, and biological radiosensitivity and radioresistancy of the normal and tumor 
cells. (3) Current therapies treat the diseased organ as a homogeneous mass; however, 
advances in PET imaging can now distinguish cell populations based on cell density, and 
the metabolic activities of tumor cells, clearly differentiating them from the normal healthy 
cells. Such capability demands advances in treatment-planning optimization where tumor 
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biological knowledge is incorporated, if true personalized targeted treatment is to be 
realized and result in improvements in local TCPs.  
 
This work tackles complex biological treatment planning via an OR approach, as 
we describe below.  
 
o We derive novel OR-based TCP-driven PET-image-guided dose-escalation 
treatments based on the technology of multiobjective nonlinear mixed-integer 
programming (NMIP). This marks the first time that TCP is incorporated both 
within the treatment optimization and as a plan objective; this is also the first time 
in which PET-image cell-proliferation knowledge is coupled within the treatment-
plan solution space. 
o We derive generalized conflict hypergraphs and uncover new polyhedral theory and 
facial structures for these NMIP instances.  
o We design a rapid branch-and-cut and local-search solution engine that couples 
novel cutting planes, matrix reduction, and intelligent geometric heuristics, along 
with a local hybrid genetic algorithm, to arrive at good solutions to these 
intrinsically NP-hard and intractable treatment-planning instances. 
  
We test the robustness of the resulting plans. The clinicians evaluate the quality of 
the plans based on the TCP, dose distribution, and other clinical metrics that are important 
indicators of treatment outcomes. 
 
3.1.3 Materials and Methods  
High-Dose-Rate Brachytherapy    
HDR brachytherapy treatment is given in 3 to 10 sessions, depending on the type of cancer 
being treated. The HDR system uses a single tiny highly radioactive source of Iridium-192, 
which is laser welded to the end of a thin, flexible stainless steel cable. The source is 
housed in an afterloader (i.e., a remote control device that mechanically places the 
radioactive source at predetermined positions within the applicator and stores the source 
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between treatments). The computer-guided afterloader directs the source into the treatment 
catheters or applicator, which has been placed in the patient. The source travels through 
each catheter in predefined steps, called “dwell” positions. The distribution of radiation and 
dose is determined by the dwell positions at which the source stops and the length of time it 
dwells there. This ability to vary the dwell times is similar to having an unlimited choice of 
source strengths. This level of dose control is possible only with HDR brachytherapy. 
 
A major advantage of HDR is that the final doses are known before any radiation 
treatment is given. Because the patient and implant position is the same as when the 
treatment plan is devised, the doses are accurate. Further, because of the high radioactivity 
of the Iridium-192 source, the treatment time takes only minutes, rendering little 
opportunity for the implant to move and deposit a radiation dose where it is not intended.  
 
The gynecological HDR procedure can be briefly summarized as follows. First, in 
the operating room, catheters are inserted into a patient who is under local, general, or 
spinal anesthesia. Interstitial catheters are inserted through the body tissue to encompass 
the tumor. For cervical treatment, a template is sutured to the skin to hold the treatment 
catheters in position. A CT scan is taken to determine the exact location of the catheters in 
relationship to the diseased organ and normal tissues. The CT images are used for 
treatment-planning optimization. The dosimetrist (i.e., a specialist who has the expertise 
necessary to generate radiation dose distributions and dose calculations, in collaboration 
with a medical physicist and a radiation oncologist) designs the plan on a computer and 
customizes the radiation doses to conform to the target volume, while minimizing the doses 
to the nearby normal tissues. After the physician has approved the treatment plan, the 
computer transfers the treatment-plan instructions to the HDR remote afterloader. On the 
day of the treatment, the patient is moved into the brachytherapy treatment room. The ends 
of the treatment catheters that protrude outside the body are connected to “transfer” tubes, 
which are then connected to the afterloader. The programmed instructions guide the 
afterloader on where to direct the source and how long to leave the source in each dwell 
position. The patient is alone in the treatment room as the treatment is being given, and the 
therapists and nurses continually monitor the treatment through an intercom and closed-
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circuit TV cameras. The entire treatment process takes approximately 30 to 90 minutes, 
depending on the size and complexity of the implant and the activity of the source. Upon 
treatment completion, the sutures holding the catheters in place are clipped and the implant 




Figure 3.1. On the far left, we show the cervix anatomy (top) and the associated HDR 
treatment with the applicator (bottom). The remaining images on the top show the Ir192 
radioactive seeds and the Vienna ring CT-MR applicator. The CT image (bottom middle) 
shows the catheters and seed positions with respect to the diseased cervix. The image is 
used for treatment-planning optimization. The bottom right shows a transverse view with 
isodose curves overlaid. 
 
PET Image  
For our study of a group of cervical cancer patients, we obtained both PET images and CT 
scans. The biological PET image is first fused onto the treatment CT image (see Figure 
3.2). PTVs, critical structures, and OARs are delineated from CT images. The enhanced 
PET signal allows the identification of dense pockets of cancer cells, which define the 
boost target volume (BTV). HDR plans are optimized to deliver a prescribed dose of 35 Gy 
Ir192 to the PTV and 37 to 40 Gy to the BTV, following 45 Gy of external beam 




Figure 3.2. This figure shows the CT treatment image for the cervix (left), and the 
resulting image with an overlay of the PET image for plan design and optimization (right). 
We can clearly observe the PET tumor pockets (bright spots) inside the cervix. 
 
Novel OR-Based Treatment-Planning Model  
The OR challenges we faced are: 
1. Effectively modeling the TCP within the treatment-planning objective; 
2. Incorporating the PET-image information for biological targeted dose escalation; 
and 
3. Advancing computational strategies to solve the associated intractable nonlinear 
combinatorial instances. 
 
Dose calculation is based on guidelines from the American Association of Physicists in 
Medicine (AAPM) task groups for brachytherapy [158], which we describe in detail in the 
appendix. 
 
To the extent that PET can indicate the presence of faster-proliferating and (or) a 
higher density of tumor cells, recognizing such regions in the organ could be consequential 
in terms of tumor control. Therefore, we incorporate the TCP in our treatment-planning 
process. Specifically, we are interested in: (1) the maximal TCP gain obtainable by 
incorporating PET information in treatment planning, and (2) the largest fractional tumor-
pocket volume for which PET-guided planning remains useful. Clearly, if tumor cells are 
uniformly spread throughout most of the cervix volume, the gain would be insignificant. 
 
We generalize the TCP based on a reliable biological model [203], which is derived 
by using birth and death processes. The parameters include the number of tumor cells, their 
 
88 
survival probability, and the birth and death rates. The survival probability depends on the 
dose delivered, its timing and duration, and the repair of sublethal damage. We describe the 
full TCP model in the appendix. 
 
In our treatment-planning model, we represent each anatomical structure by a 
collection of discretized voxels (three-dimensional volumetric pixels), and choose sizes 
such that they are conducive for modeling. Each dwell location is modeled via two 
variables: a binary decision variable to indicate whether a radioactive seed will be 
deposited and a continuous variable to denote the associated dwell time. We impose 
constraints to ensure 95 percent PTV coverage, while restricting the underdose to the PTV, 
and upper- and lower-dose bounds for OARs and PTVs. We then strategically choose dose 
levels and parameters so that the overall PTV dose remains relatively homogeneous, as the 
clinicians desire, while protecting the OARs by using the maximum dose that the organs 
can tolerate to avoid inflicting severe and permanent harm. In the escalated-dose case, the 
PET-identified region receives an escalated dose over the prescribed dose. Not all the dose 
bounds can be satisfied simultaneously because of the close proximity and conflicting dose 
targets of cancerous and normal cells; therefore, our first objective is to find a treatment 
plan that satisfies as many dose bound constraints as possible. This helps to achieve a rapid 
dose fall-off from the PTV-prescribed dose, ensuring that the prescribed dose conforms to 
the tumor shape, while minimizing damage to healthy normal tissues. The second objective 
incorporates the TCP function, which depends on the time of the treatment, radioactive 
decay of the radioisotope, dose received, volume and density of the tumor cells, and 
biological radiosensitivity and radioresistancy of the normal and tumor cells. This results in 
a multiobjective NMIP problem, which is intractable by existing computational techniques. 
We present the full model in the appendix. 
 
Computational Challenges and Solution Strategies 
The treatment model has three objectives: (1) the temporal delivery objective that governs 
the dwell times; (2) the dose volume-based objective that, along with the temporal 
objective, guides the optimization engine to a solution that best satisfies the imposed 
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dosimetric and volumetric constraints for conformal treatment; and (3) the biological and 
clinical TCP objective.   
   
To apply our multiple-objective mixed-integer programming (MIP) solution 
strategies, we begin by first solving the MIP instance that requires the minimum PTV 
coverage, while minimizing the maximum dwell time across all the possible seed locations.  
 
For the dose volume-based objective, these MIP instances inherit the dense dose 
matrix properties as in the MSKCC brachytherapy instances [107]. Using a competitive 
commercial solver, the solver does not return a feasible solution, even after running for a 
month of CPU time on an Intel Xeon E5430 Quad Core Xeon Processors at 2.66 GHz, 
1333 MHz FSB, and 12 MB Cache per processor.  
 
We employ hypergraphic polyhedral cuts to accelerate the solution process. In 
particular, Easton et al. [38] introduce the notion of uniform hypergraph and derived facial 
structures of uniform hypercliques. In their work, they show that these hyperclique 
inequalities can help to successfully solve the small, yet 100 percent dense, previously 
intractable market-share instances. Lee and Zaider [107] show that hypercliques, along 
with novel matrix-reduction approaches and clever geometric-based heuristics, can help 
solve these intractable MIP instances to optimality. Furthermore, the solution process can 
be achieved within seconds; thus, the real-time treatment-planning process, which has since 
become standard across the United States, for prostate permanent implants, was realized. 
 
In our work, the challenges are more complex; these challenges include the 
multiobjective nature of our problem, the highly nonlinear TCP objective, and the 
competing dose escalation and OAR dose distribution within the solution space. 
 
We advance the polyhedral theory work of Easton et al. [38] and introduce the 
concept of generalized conflict hypergraphs. Within this high-dimension construct, we 
derive new polyhedral theories, including generalized hyper-clique, hyper-oddholes, hyper-
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antioddholes, hyper-webs, hyper-antiwebs, and hyper-star facial structures, and their 
associated Chvátal-Gomory (CG) ranks [100, 101]. 
 
Computationally, we tackle the dose volume-based and the biological tumor control 
objectives simultaneously using a branch-and-cut and local-search approach. We caution 
that because TCP is highly nonlinear, it is difficult to convexify or linearize it for actual 
branch-and-cut solution exploration. Specifically, we solve the MIP instance with the dose 
volume-based objective via a branch-and-cut algorithm that couples new polyhedral cuts, 
along with matrix reduction and intelligent geometric heuristics algorithms. When we 
obtain an integer solution, or when a heuristic within the branch-and-cut setting returns a 
feasible solution, we perform a local search to examine the TCP values across the entire 
neighborhood. Given a seed configuration with dwell times, we calculate the associated 
TCP based on the resulting PTV and PET-pocket dose volume histograms. We then keep 
the best solution (i.e., the solution with the maximum TCP value) as the incumbent 
solution. The local search involves swapping and a hybrid genetic algorithm, where one 
can rapidly examine the neighborhood space to identify the best TCP-value solutions. 
 
Such an approach guarantees the return of a feasible solution, while exploiting the 
best possible TCP values within the neighborhood feasible space. In addition to deriving 
novel general hypergraphic structures and encapsulating them within a rapid computational 
engine for solving these instances, we also investigate polyhedral approaches in MIP 
convexification of posynomial and signomial functions [164, 165]. We expect further 
advances in directly addressing the TCP objective using these novel cutting planes and 
polyhedral results, which we have obtained from special classes of nonlinear MIPs. 
 
We examine multiple variations to determine the one with the best performance in 
terms of dose distribution to various organs and the associated TCP. The variations include 
minimizing the overdose and underdose to the PTV, and (or) a combination of these. The 
overdose and underdose can be obtained by transforming the binary variables LPv  and 
U
Pv in 
Constraints (6) and (7) (see the appendix) into continuous variables to capture the dose 
differences. The weights in the objective function can be nonlinear to the overdose or 
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underdose amount (e.g., it can be piecewise linear or quadratic penalties). Other variations 
include maximizing the dose fall-off from the prescribed PTV dose.  
 
3.1.4 Validation and Results  
To gauge the feasibility, characteristics, and potential benefit of PET-image-guided dose 
escalation, our initial validation consists of 15 cases in which the patient has cervical 
cancer. Each patient had previously received a 45 Gy dose of external radiation. The PTV 
ranges from 82.8 to 137.47 cm3 and the BTV ranges from 10 percent to 41 percent. For 
each case, we contrast three alternative strategies: (1) a standard HDR plan with no dose 
escalation, (2) a BTV escalation with the same PTV prescription dose, and (3) a BTV 
escalation with a reduced PTV prescription dose. For both escalation strategies, we 
consider two variations (a 37 Gy increase and a 40 Gy increase to the BTV), and observe 
the effects on PTV and OAR dose profiles and TCP quality.  
 
Figure 3.3a illustrates the dose volume histogram and dose profiles for a patient 
with a BTV that is 19.39% of the cervix. The y-axis is the cumulative volume, and the x-
axis is the radiation dose received. In this figure, the standard plan is labeled by a square, 
escalated PET > 37 Gy with 35 Gy PTV prescribed dose is labeled by circles, escalated 
PET > 37 Gy with 33 Gy reduced PTV is labeled by an x, escalated PET > 40 Gy with 35 
Gy PTV prescribed dose is labeled by triangles, and escalated PET > 40 Gy and 33 Gy 
reduced PTV dose is labeled by rhombuses. We can observe the escalated dose of the BTV 
versus the PTV. Further, compared to the standard plan, dose reduction occurs in the 
rectum and bladder in the escalated plans with a BTV > 37 Gy. We observe a larger 
reduction when we increase the BTV to > 40 Gy. This translates to a reduction in normal 
tissue toxicity and complications. Figure 3.3b illustrates similar trends for a small BTV 





Figure 3.3a. This figure shows the dose volume histogram for a cervical cancer patient 
with a BTV that is 19.39% of the PTV.  
 : Standard HDR plan (PTV prescribed dose = 35 Gy); there is no separate curve for 
the PET.  
o :Escalated PET (PTV prescribed dose = 35 Gy, PET > 37 Gy). 
*    :Escalated PET and reduced PTV dose (PTV prescribed dose = 33 Gy, PET > 37 
Gy). 
Δ   :Escalated PET (PTV prescribed dose = 35 Gy, PET > 40 Gy).  







Figure 3.3b. This figure illustrates the dose volume histogram for a cervical cancer patient 
with a BTV that is 6.3% of the PTV.  
 
To contrast the dose distributions of the standard versus escalated plans, Figure 3.4 
illustrates clear hot spots (i.e., high dose, 150 percent isodose curves) around the PET-






Figure 3.4. This figure contrasts the isodose curves of a standard plan (top left), an 
escalated plan with 35 Gy of PTV prescribed dose (top right), and an escalated plan with 33 
Gy of PTV prescribed dose (bottom left). We can observe the very conformed 100 percent 
isodose curves to the PTV contour. The 150 percent isodose curves in both escalated plans 
around the PET-identified pockets are clearly absent from the standard plan. The 120 
percent isodose curve is tighter in the bottom escalated plan, reflecting the lower dose to 
PTV because of the lower prescribed value (33 Gy versus 35 Gy). 
 
For the 15 cases, the TCPs for standard plans range from 52 percent to 64 percent. 
For dose escalation, when an escalated dose of > 37 Gy is placed in the PET-identified 
tumor pockets, all escalated plans show a slight reduction of 0.5 percent to 12.4 percent in 
the rectum and bladder dose, while 99 percent of the BTV receives over 40 Gy. The 
resulting TCP values range from 87 percent to 99 percent. When the BTV is less than 15 
percent of the PTV, dose escalation can be delivered with a virtually identical PTV dose, as 




When the BTV is over 20 percent of the PTV, dose escalation to PET-identified 
voxels intrinsically increases the PTV dose by 1 percent. Boosting the BTV to 40 Gy 
results in no dose increase to the PTV in all plans. When the PTV is prescribed as a 
reduced dose of 33 Gy, independent of the size of the BTV, escalation can be achieved, 
while the dose to the PTV, bladder, and rectum are reduced simultaneously All plans can 
be generated within a CPU minute. This allows for real-time OR-based treatment planning 
and on-the-fly dynamic reconfiguration. 
 
Table 3.1 highlights the TCP for three representative patients: BTV < 10 percent of 
PTV (small), 10 to 25 percent (medium), and > 25 percent (large). On all patients, the TCP 
of all escalated plans is over 70 percent. Specifically, when the BTV is boosted to over 40 
Gy, the resulting TCP is uniformly high (> 87 percent). We list the plans A to E according 
to improvements to the TCP. The best TCP (Plan E) is achieved when we boost the PET-
identified pockets to over 40 Gy, while maintaining the PTV dose at 35 Gy. This can be 
partially explained by the fact that there remain cancer cells loosely populated outside the 
PET-identified pockets. Hence, a prescribed dose of 35 Gy is able to eliminate these cancer 
cells, but a prescribed dose of 33 Gy may not be as effective. Table 3.2 contrasts the dose 
received by the OARs. For brevity, we focus on the plans where the PTV all receives 35 





Table 3.1. This table contrasts the TCPs in various plans. The boldface values represent the 
TCP associated with escalated plans. 
BTV/PTV ratio category Small Medium Large 
PTV (in cc) 82.5 131.5 89.7 
PET-identified volume (BTV in cc) 5.2 25.5 26.0 
Ratio: BTV/PTV 6.3% 19.39% 28.99% 
Treatment-planning model Tumor control probability (TCP) 
A: Standard HDR plan (PTV dose = 35 Gy) 0.6052 0.6358 0.5942 
B: PET-guided escalated plan (BTV > 37 Gy, PTV = 35 Gy) 0.8741 0.9383 0.9663 
C: PET-guided escalated plan (BTV > 37 Gy, PTV = 33 Gy) 0.8401 0.7382 0.7849 
D: PET-guided escalated plan (BTV > 40 Gy, PTV = 33 Gy) 0.9777 0.9465 0.9638 
E. PET-guided escalated plan (BTV > 40 Gy, PTV = 35 Gy) 0.9861 0.9639 0.9730 
 
Table 3.2. This table displays the dose distribution in standard plans versus escalated plans 
(using the same prescribed PTV dose). D90 (cGy) represents the dose received by 90 
percent of the organ and D 2cc is the minimum dose to the most exposed two cm3 of 
OARs. 
Patient 
  D90 (cGy) D2cc (cGy) Mean dose (cGy) 
 Plans PTV PET pockets Bladder Rectum Bladder Rectum 
Small 
STANDARD  3,735.8 4,091.3 2,650.37 2,400.57 2,272.5 2,006.5 
B: BTV > 37 Gy, PTV 
= 35 Gy -0.7% +3.2% -6.5% -0.2% -0.5% -0.9% 
E: BTV > 40 Gy, PTV 
= 35 Gy -0.6% +4.6% -6.1% -0.2% -0.5% -0.8% 
Mediu
m 
STANDARD 3,675.4 4,135 2,602.77 2,654.15 1,782.2 2,006.1 
B: BTV > 37 Gy, PTV 
= 35 Gy +0.8% +3.8% +3.1% -3.2% -1.0% -0.9% 
E: BTV > 40 Gy, PTV 
= 35 Gy +0.4% +6.5% +2.3% -2.0% -1.8% -2.6% 
Large  
STANDARD 3,666.2 4,046 2,791.26 2,881.11 1,189.3 3,042.2 
B: BTV > 37 Gy, PTV 
= 35 Gy -0.7% +3.1% -8.5% -7.5% -6.4% -6.9% 
E: BTV > 40 Gy, PTV 
= 35 Gy +0.1% +7.1% -5.0% -8.5% -1.7% -12.4% 
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3.1.5 Findings, Implementation, and Challenges  
With the precision of the HDR brachytherapy delivery, a TCP improvement in treatment 
plans can be readily realized in the outcomes of actual treatments. TCP offers biological 
information about tumor and normal cells and their radiosensitivity and radioresistancy to 
radiation doses; thus, incorporating such information in optimized personalized treatment 
plans is invaluable. Coupled with TCP knowledge, advances in biological and functional 
imaging offer new opportunities to incorporate radiobiological parameters within the 
planning process. The OR-based treatment-planning algorithm we describe herein allows 
for TCP-driven PET-enhanced personalized treatment, which facilitates the targeted 
delivery of escalated doses and improvements in overall clinical outcomes. 
 
Our study reveals improvements both in local tumor control and OAR toxicity, two 
competing and desirable goals that were previously thought to be unachievable 
simultaneously. The work herein showcases the importance of novel modeling and 
breakthrough optimization solution strategies in personalized treatment-planning advances. 
The dose escalation is sensitive to the size of the PET BTV. In addition, we have 
demonstrated that it is possible to reduce the PTV dose, while escalating doses to the BTV, 
as plans C and D, in which the PTV receives only 33 Gy.  
This work addresses three unique challenges.  
o The TCP function is complex and highly parametric, and is sensitive to the density 
of cancer cells and the radiobiological characteristics of normal and tumor cells.    
o The biological-driven MIP treatment models are intractable using existing 
methodologies and competitive solvers, because they would require breakthroughs 
in polyhedral theory and computational advances. This is the first time that TCP is 
being incorporated within a treatment-planning optimization modeling and solution 
process. This is also the first time that PET-image-guided dose escalation is being 
performed. 
o The actual gain in local tumor control must be validated through clinical trials to 
quantify the associated treatment outcome improvements that are realized through 
PET-guided dose escalation.  
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In practice, the sophisticated modeling and novel and fast optimization algorithm 
ensures that there is no increase in solution time for escalated dose planning. The radiation 
oncologists must guide us regarding the proper escalated dose values.  
 
Rush University Medical Center began a clinical trial for PET hot HDR dose 
resteering in July 2011. All patients enrolled were diagnosed as having International 
Federation of Gynecology and Obstetrics (FIGO) IIB or IIIB cervical cancer. In a FIGO 
IIB cancer, the tumor has spread to the parametrial area (i.e., tissue surrounding the uterus); 
in a FIGO IIIB cancer, the tumor has grown into the pelvic wall and (or) causes 
hydronephrosis or nonfunctioning kidneys [8]. The patient’s treatment included whole 
pelvic radiation therapy with concurrent chemotherapy. The radiation therapy treatment 
schemes included external beam treatments for the cervix and parametrium, along with 
HDR to the cervix with boosted PET-positive doses. The HDR CTVs were delineated 
based on CT and MR imaging positive volumes. The PET-positive volumes were boosted 
to 50 percent higher doses than those delivered to CTVs. Some cases were treated with the 
Syed applicator; others were treated with the tandom-ring applicator, in conjunction with 
three or four parametrial interstitial needles. 
 
All patients who entered the study received two treatment plans: one using the in-
house treatment-planning algorithm for dose escalation and another using a commercial 
algorithm with options for manual fine-tuning. The attending physician was responsible for 
selecting the final plan. Acceptable boost plans were achieved for all patients. These 
boosted plans were then successfully delivered to all patients. For the boosted plans, the 
PET pockets received elevated doses compared to the standard plans, while doses to the 
bladder and rectum were reduced. The clinician was pleased with the performance of the 
PET-image-guided targeted-dose escalation and the successful completion of the clinical 
study. The hospital is planning to continue the study by enrolling additional patients. The 
results thus far indicate that such dose escalation is feasible to deliver and is beneficial to 
the cancer patients. The techniques are applicable to the treatment of other types of cancer, 




3.1.6 Impact and Significance 
As we state above, cervical cancer is the second most common cancer in women 
worldwide; approximately 500,000 new cases are diagnosed each year [194]. In developing 
nations, it is often the most common cause of cancer-related death among women and a 
leading cause of death overall [141]. In this section, we discuss the significance of our 
work.  
 
Quality of Care and Quality of Life for Patients   
o Compared to standard HDR plans, PET-guided dose-escalation plans improve 
tumor control consistently across all patients. This translates to improvements in 
cure rates and reductions in mortality.   
o Clinical evidence shows a reduction of the radiation dose to the bowel, bladder, and 
rectum. Thus, our system reduces side effects and complications. This has a 
profound impact on both health-care costs and the patient's quality of life.  
o The planning process requires only seconds to return good treatment plans. This 
offers quality assurance in treatment delivery (image-guided or not), independent of 
the training and experience of the operators. It helps to ensure a uniform quality of 
care among patients and across all hospital sites.   
 
Advancing the Cancer Treatment Frontier  
o The work marks the first time that complex TCP is incorporated within treatment 
planning, and as an objective in driving high-quality treatment plans. 
o This work also marks the first time that PET images are incorporated within the 
treatment-planning environment for targeted dose-escalation planning optimization. 
o The fast solution engine and the seamless incorporation of functional imaging 
information allows treatment-plan optimization and reoptimization in real time 
based on new images. as the patients receive daily treatments. This opens up the 
potential for next-generation adaptive real-time image-guided HDR brachytherapy.  
o With advances in biological imaging, such as PET and MRS, incorporation of such 
knowledge within treatment modalities will soon become standard for personalized 
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treatment planning. To the best of our knowledge, Rush University’s radiation 
therapy clinical trial is the first and only one in the country that delivers PET-based 
dose- escalation HDR brachytherapy for patients with cervical cancer. Our work 
has the potential to set the national standard and guidelines for biological image-
guided brachytherapy treatment. 
o Observing the clinical trend, brachytherapy is rapidly becoming the treatment of 
choice, because its side effects are generally less severe when compared to external 
beam radiation therapy and surgery, and because of its effectiveness for early-stage 
treatment. Further, brachytherapy preserves the organ and its functionality. The 
latter is of special concern to younger early-stage cancer patients who still look 
forward to bearing children.  
o The methodologies are applicable to brachytherapy (both high-dose rate and low-
dose rate) for other types of cancer, including prostate, breast, bileduct, lung, and 
sarcoma. 
 
Advances in Operations Research Methodologies 
o This study marks the first use of sophisticated combinatorial optimization 
approaches to tackle the complexities inherent in incorporating TCP as a clinical 
objective within HDR brachytherapy. The resulting treatment plans offer superior 
TCPs with simultaneous toxicity reduction to OARs. This can be a precursor to 
subsequent clinical trials. 
o This study is the first in which PET images are incorporated within the planning 
optimization model, giving rise to the competing goals of escalating the dose to the 
tumor, while simultaneously not increasing the dose to the OARs. 
o The highly nonlinear multiobjective MIP environment offers a powerful modeling 
paradigm. However, the resulting intractable instances demand theoretical and 
computational breakthroughs to solve these instances for actual clinical delivery.  
o We introduce a new concept of generalized conflict hypergraphs and derive 
polyhedral results, including hypercliques, hyper-oddholes, hyper-antioddholes, 




o The branch-and-cut and local-search approach described herein couples new 
polyhedral cuts, along with matrix reduction and intelligent geometric heuristics. 
This approach can successfully address the highly complex and nonlinear TCP 
function and the dose-based objective. It can rapidly return good, feasible solutions.  
o Independently, this work motivates our polyhedral investigation on MIP 
convexification of posynomial and signomial functions [141, 142], an area that 
deserves advances in its own right, because many real-world problems can be 
modeled as complex NMIPs that demand theoretical and computational advances. 
 
Within the medical community, there is an urgent push to incorporate the 
radiobiological characteristics of normal and tumor cells, and biological and functional 
imaging advances, within treatment delivery to realize and improve clinical outcomes and 
tumor control. Our work provides proof of concept of the feasibility and potential clinical 
benefits of such personalized, targeted treatment-planning design and delivery. Moreover, 
the resulting plans offer improvements in tumor control and reduce the radiation to the 
OARs, two competing and desirable characteristics that were previously thought to be 
unachievable simultaneously. 
 
Our rapid operator-independent biological treatment-planning system provides the 
groundwork for advancing the technological frontier of image-guided brachytherapy. It 
opens up opportunities to conduct complex clinical investigations that may otherwise be 
impossible, as evidenced in MRS-guided dose-escalation studies [147, 126, 127, 128, 129, 
130, 131]. The sophisticated OR modeling paradigm provides great flexibility in 
realistically modeling the clinical problem, and the novel rapid solution engine objectively 






Dose Calculation  
Let )r(D  denote the dose contribution per minute of a seed to a voxel that is r units away. 
The two-dimensional dose-rate calculation can be represented as ),r(D  , which is 










where Sk is the air kerma strength (U, 1U = 1 cGy cm2/hour), kS/),r(D 00   represents 
the dose-rate constant (cGy/hr-U), )(rg  is a radial dose function, ),( rG  represents a 
geometry function, with ),( 00 rG  as the geometry function at the reference point ),( 00 r , 
where 10 r cm and 
900  , and ),( rF  is a two-dimensional anisotropy function. The 
values for the geometry function ),( rG  are obtained from tabulated data.  
 
Incorporating the TCP within the Treatment-Planning Objective 
To the extent that PET can be taken to indicate the presence of faster-proliferating and (or) 
a higher density of tumor cells, recognizing such regions in the organ could be 
consequential in terms of tumor control. We incorporate the TCP within our treatment-
planning process. Specifically, we are interested in (1) the maximal TCP gain obtainable by 
incorporating PET information in treatment planning, and (2) the largest fractional tumor-
pocket volume for which PET-guided planning remains useful. Clearly, if tumor cells are 
uniformly spread throughout most of the cervix volume, the gain would be insignificant.  
 
We generalize the TCP based on a reliable biological model developed by Zaider 
and Minerbo [204]. The formulas are derived using the birth and death processes. For 
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where n  is the initial number (at time 0t ) of tumor cells, )(tS  is the survival probability 
of tumor cells at time t, and b  and d  are the birth and death rates of these cells, 
respectively. 
 
The birth rate b  and the death rate d  relate to two parameters: potential doubling 
time potT  and tumor cell loss factor  , where potTb /693.0  and bd / . In the TCP 
calculation, the time t  in Equation (2) is typically taken to be the duration of the treatment 
period or the expected remaining life span of the patient.  
 
For simplicity and convenience in Equation (2), we use the linear quadratic 
expression for the survival function: 
2)()( DtqDeDS   , where D  is the dose delivered 
over the time interval t , and )(tq  makes explicit the repair of sublethal damage. In the case 
in which the dose rate decreases exponentially, 
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where   is the radioactive decay constant of the radioisotope ( 0.0094  d-1 for 192Ir) and 
0/1 t , where 0t  is the average time for the sublethal damage repair, typically in the 
order of one hour.  
 
To complete the TCP calculation, we give numerical values to the parameters n , 
potT ,  ,  ,  , and 0t  to represent the response of the rapidly proliferating and (or) 




 The TCP value is sensitive to the volume and density of cells. We take the volume 
and density of cells in the cervical tumor ranges from 810  to 1010 cells/cm3. The 
potential doubling time is taken as 15potT  or 20potT  days, and the cell loss factor is 
taken as 5.0  or 75.0 . In addition, 487.0  Gy-1, 055.0  Gy-2 for 
radiosensitive cells, and 155.0  Gy-1, 052.0  Gy-2 for radioresistant cells, whose 
values are determined from in vitro cell-survival measurements. For the sublethal damage 
repair constant. we take 10 t  hour.  
 
Novel TCP-Driven PET-Image-Guided Treatment-Planning Model 
We employ a multiobjective MIP model for HDR brachytherapy treatment planning. The 
model incorporates the TCP as the objective function, in addition to the rapid dose fall-off 
function to ensure dose conformity to the tumor region. 
Briefly, let jx  be a 0/1 indicator variable for recording placement or nonplacement 
of a seed in grid position j and jt  be the continuous variable for the dwell time of a seed in 
grid position j . The total radiation dose at voxel P  is given by  
 ,t||)XP(||D
j
jj    (3) 
where jX  is a vector corresponding to the coordinates of grid point j , |||| 
 
denotes the 
Euclidean norm, and )r(D  denotes the dose contribution per minute of a seed to a voxel 
that is r units away.  
 
The target lower and upper bounds, PL  and PU , for the radiation dose at voxel P 




jj Lt||)XP(||D                        (4a) 
 .Ut||)XP(||D P
j
jj                        (4b) 
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For each voxel P  in each anatomical structure, a binary variable is used to capture 
whether or not the desired dose level is achieved. For simplicity, we use the BTV to 
represent the set of tumor voxels identified by the PET images.  
 
The TCP-driven PET-image-guided dose-escalated multiobjective treatment model 










 subject to                           
  PrDose
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jj  1  P in PTV-BTV, 













j     (10) 
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U
Pv , },1,0{jx 0jt    
           
PrDose represents the clinical prescribed dose to the tumor, and   (  > 1) 
represents the dose-escalation factor. This factor is guided by clinicians as well as its effect 
on normal tissue complication. Constraint (5) ensures that the PET-identified tumor voxels 
receive escalated doses. In Constraints (6), and (7), LPv  and 
U
Pv  are 0/1 variables. If a 
solution is found such that LPv  = 1, then the lower bound for the dose level at point P  is 
satisfied. Similarly, if UPv  = 1, the upper bound at point P  is satisfied (see Constraint 7).  
 
The constants PM  and PN  are chosen appropriately for the PTV and for various 
OARS. For PTV, PM  corresponds to the underdose limit, whereas PN  corresponds to 
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overdose limit, and PL  = PrDose corresponds to the prescription dose. PM  and PN  are 
strategically chosen so that the overall PTV dose remains relatively homogeneous (e.g., 
PN  / PM  < 1.2), as the clinicians desire. For the OARs, PN represents the maximum dose 
tolerance that the organs can sustain, without inflicting severe and permanent harm. These 
values are determined from clinical findings and are part of the planning procedures and 
guidelines. For cervical cancer treatment, Constraint (6) does not apply to any OAR. 
 
In Constraint (8),  corresponds to the minimum percentage of tumor coverage 
required (e.g.,   = 0.95). Because all the PET-identified tumor voxels satisfy the 
prescribed dose bound (and beyond), we count those in PTV-BTV and these BTV-voxels 
to ensure that overall it satisfies   percent of the tumor volume. Here, PTV  represents the 
total number of voxels used to represent the PTV of the cervix. Constraint (8) thus 
corresponds to the coverage level that the clinician desires. In Constraint (9), the duration tj 
in grid position j is positive only when this position is selected. Its value is bounded by the 
maximum time limit Tj. The time usually is bounded by the length of the treatment session, 
which is usually between 20 and 30 minutes, depending on the tumor stage and prognosis 
condition. Constraint (10) limits the number of seeds used to MaxSeeds. The constant can 
be omitted; however, in some cases, clinicians know their desired numbers, which they tell 
the planner. 
 
Note that BTV voxels are excluded in Constraint (7) because there is no reason to 
place an upper bound on the dose to these tumor voxels. Constraint (5) ensures that no 
underdose for PET-identified voxels exists; thus, Constraint (6) is unnecessary for these 
voxels. 
 
 The first objective is to find a treatment plan that satisfies as many bound 
constraints as possible; this is surrogate to rapid dose fall-off, ensuring conformity of the 
prescribed dose to the tumor. The parameters P and P  allow us to prioritize the 
importance of various anatomical structures. Using a weighted sum is important for the 
cervical cancer cases to balance the volume of the cervix versus the nearby OARs (e.g., 
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bladder, rectum, and bowel). The second objective function incorporates the TCP function, 
which depends on the time of the treatment, radioactive decay of the radioisotope, dose 
received, volume and density of tumor cells, and the biological radiosensitivity and 
radioresistancy of the normal and tumor cells.  
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3.2 TCP Optimization in Cancer Treatment Planning 
In this section, it includes a paper that is prepared for submission to the International 
Journal of Radiation Oncology, Biology and Physics. 
3.2.1 Introduction 
In radiation therapy, radiation is delivered using either external beam technology or using 
internal seed implantation which is known as brachytherapy. For high-dose rate (HDR) 
brachytherapy, the radioactive substance that sealed in the seeds or catheters are placed 
temporarily into or near the cancer to eradicate the tumor while minimal radiation is 
delivered to the healthy tissues. Recent advances in functional imaging, such as magnetic 
resonance spectroscopy (MRS) and positron emission tomography (PET), facilitate 
identification of the tumor cells based on their molecular characteristics, which allows the 
treatment planning to deliver escalated dose to the tumor inside the target organ [50, 107]. 
The improvement on the overall clinical outcome in HDR treatment using dose escalation 
guided by PET imaging has been shown in our previous studies [93]. 
 
Operations research approaches such as linear optimization, mixed integer 
programming, and multi-objective optimization, have been wildly applied to construct the 
treatment planning optimization models [30, 32, 34, 43, 48, 93, 94, 162]. The goal of 
treatment optimization is to deliver the prescriptive dose to the tumor while limiting or 
minimizing radiation to healthy cells and critical organs in the neighborhood of the tumor. 
The radiation dose to the healthy cells and critical organs in treatment optimization can be 
controlled by dose volume constraint and generalized equivalent uniform dose (gEUD). 
Dose volume constraint on an organ limits the portion of the organ that receives more than 
a given prescriptive dose [34, 43, 48]. Generalized EUD for an organ is given by gEUD =
(1/ ∑ ) / , where n is the number of voxels in the structure, di is the dose to voxel i, 
and a is a parameter. Craft et al incorporated the gEUD as an objective into the multi-
objective optimization model for IMRT treatment planning [32]. The function f(d) = da in 
gEUD is fitted with a three-segment piecewise linear convex function. Thus the multi-
objective optimization can be constructed as a two-step linear programming problem: 
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minimizes the excess of the piecewise linear gEUD function over the maximum desired 
level in the first step, and uses the solution from the step 1 model as constraints to find the 
Pareto optimal treatment plan in the second step. 
 
Tumor control probability (TCP) is an estimated function of the probability of 
killing all malignant cells in the affected organ given a dose of radiation in radiation 
therapy. In treatment planning of radiation therapy, TCP has been wildly used for assessing 
the biological response of the treatment plans [43, 50, 80, 147, 191, 205]. Mohan et al 
investigated the balance between TCP and normal tissue complication probability (NTCP) 
[134]. Potential improvement on TCP from a treatment plan has been investigated [174]. 
When an integral total dose volume or energy deposition is given, the maximum TCP value 
can be obtained by solving the TCP equation with Lagrange multipliers [40, 173, 200], and 
the obtained dose distribution can be served as the prescription dose in the following 
inverse planning [201]. Levin-Plotnik et al. discussed about finding the dose distribution 
that maximizes the TCP function while the mean dose is fixed and given [116]. Zaider et al 
derived an analytical expression of TCP taking into account the length of the treatment and 
the stochastic process of eradiating tumor cells [204]. To find the dose distribution with 
optimal TCP while constraining on the dose requirement on the health tissues remains 
challenging. 
 
We incorporated the TCP into the objective of the multi-objective optimization 
model in previous study [43]. The optimal TCP is found within the neighborhood of the 
solution obtained from various optimization models. In this study, we build an optimization 
model that maximizes the TCP directly and satisfies the dose requirements on the targeted 
organ, and healthy tissues in order to preserve their functionalities while delivering an 
escalated dose to the tumor. We focus on the optimal treatment planning of HDR 
brachytherapy on cervical cancer using dose escalation guided by PET imaging. We design 
a solution strategy that first fits the piecewise linear approximation of the TCP function, 
then solves the piecewise-linear optimization problem that maximizes the piecewise linear 
approximation of TCP, and finally performs a local search to improve the TCP value within 




TCP is a function computing the probability that no malignant cells are left in the affected 
organ. It can be estimated in the treatment planning by using spatial dose configuration and 
the dwell time per treatment. Let  be a 0/1 indicator variable for recording placement or 
non-placement of a seed in grid position j and  be a continuous variable for the dwell time 
of a seed in grid position j. The total radiation dose received by voxel P  in a treatment can 
be calculated as: 
 
j
jjjP Tt,t|XP|DTd )()( , 
where  denotes the duration of the treatment,  denotes a vector corresponding to the 
coordinates of grid point , | ∙ | denotes the absolute distance, and (| ∙ |) denotes the dose 
contribution per minute of a seed to a voxel. Let  represent the number of tumor cells in 
the representing area of voxel . Therefore, the TCP equation at the end of the treatment 











































where the survive probability ))(( td,tS P can be calculated by 
)()()( 2))(( tdtqtdP PPetd,tS
  . 
 
Our optimization model maximizes the TCP that also  satisfies the dose requirement 
given by the physician. We employ PET-image to facilitate our treatment planning by 
identifying the dense pockets of cancer cells. The volume delineated by PET-image defines 
the boost target volume (BTV). Thus escalated dose can be delivered to BTV while the 
prescriptive dose is delivered to the rest of the volume in the planning target volumes 
(PTV), which is the cervix in this study. In addition to killing the cancer cells and 
preserving the functionality of the cervix, a treatment plan should preserve the 
functionalities of the surrounding critical organs including rectum, bladder, and bowel. For 
convenience of reading, we denote PTV-BTV as the set of voxels in the region of PTV and 
outside the region of BTV, and BTV as the set of voxels in the region of BTV. Let PrDose 
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denote the prescriptive dose for PTV-BTV, and BTV_PrDose denote the escalated 
prescriptive dose for BTV.  Let OAR denote the set of voxels in critical organs. In our 
study, OAR can be split into three subsets surrounding the cervix: RECTUM, BLADDER, 
and BOWEL.  
 
We incorporate partial dose volume constraints on the maximum/minimum dose to 
PTV-BTV and BTV and maximum dose constraints to RECTUM, BLADDER, and BOWEL. 
For example, a constraint of a maximum dose to RECTUM can be that 95% of the voxels 
must receive no more than 90% of the prescriptive dose and 100% of the voxels must 
receive no more than 120% of the prescriptive dose. Let  denote the voxel coverage 
percentage,  denote the percentage of the prescriptive dose, and ,  denote a 0/1 
indicator to denote whether the dose to voxel ∈  satisfies the dose requirement 	  for 
set s in 	{ , - , , , }. The prescriptive dose of tumor 
that can kill the tumor cells is instructed by physicians. Recall BTV_PrDose and PrDose 
denote the prescriptive dose for BTV and PTV-BTV respectively where BTV_PrDose is 
PrDose plus the escalated dose on BTV. The multiple sets of dose constraints can be used 
with different combinations of ( , ) as shown in Table 3.3. Specifically, a hard 
constraint is set for the minimum dose to BTV that the escalated prescriptive dose of BTV 
must be satisfied. For the minimum dose to PTV-BTV, two constraints are set: 100% level 
at 93% of the prescriptive dose, 95% level at 100% of the prescriptive dose. For the 
maximum dose to PTV-BTV and BTV, three levels of coverage are predetermined: 90% 
level at 150% of the prescriptive dose, 95% level at 160% of the prescriptive dose, and 
100% level at 200% of the prescriptive dose. For organs in OAR, four levels for the 
maximum dose are pre-determined: 100% level at 120% of the prescriptive dose, 95% level 
at 90% of the prescriptive dose, 90% level at 80% of the prescriptive dose, and 80% at 60% 





Table 3.3a. Partial dose volume constraints for minimum dose requirements. 
Set s % of covered voxels ( ) 
% of prescriptive 
dose ( ) 
Prescriptive 
dose 
BTV 100% 100% BTV_PrDose 
PTV-BTV 100% 93% PrDose 95% 100% PrDose 
 
Table 3.3b. Partial dose volume constraints for maximum dose requirements. 
Set s % of covered voxels ( ) 
% of prescriptive 




100% 200% BTV_PrDose 
90% 150% BTV_PrDose 
95% 160% BTV_PrDose 
PTV-BTV 
100% 200% PrDose 
95% 160% PrDose 
90% 150% PrDose 
OAR 
100% 120% PrDose 
95% 90% PrDose 
90% 80% PrDose 
80% 60% PrDose 
 
Let TCP(D) denote the TCP value given a dose configuration = { }, 	 ∈  
for simplicity and the fixed treatment duration T = 20 min. The optimization model then 
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jj dt|XP|D   (3.2.1) 
 Maximum dose constraints on PTV-BTV and OAR   
 







 ∈  , 
s = PTV- BTV, OAR (3.2.3) 
 Minimum dose constraints on PTV-BTV   
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    ∈ -  (3.2.5) 
 Minimum dose constraints on BTV   
 .PrDose_BTVdP   	 ∈  (3.2.6) 
 Maximum seeds constraint   
 Seedsmaxx
j
j    (3.2.7) 
    10100 ,L,,x,xTt Psjjj   	 ∈   (3.2.8) 
 
( ) denotes  value corresponding to a given , and  represents the number 
of voxels in set s.  Constraints (1) derive the dose at voxels from the duration of seeds and 
the dose rate function. Constraints (3.2.2) - (3.2.3) ensure that the maximum dose coverage 
constraints are met for all voxels in PTV-BTV and OAR. Constraints (3.2.4) - (3.2.5) ensure 
that the minimum dose coverage constraints are met for all voxels in PTV-BTV and OAR. 
Constraints (3.2.6) ensure that the minimum dose requirements for voxels in BTV are 
satisfied. Constraint (3.2.7) limits the number of seeds to maxSeeds. This constraint can be 
omitted, or in some cases, clinicians have their desired numbers in which they can inform 
the planner. The duration tj in grid position j is positive only when this position is selected, 




It is difficult to solve the optimization problem with the nonlinear objective TCP 
function, this is true also for the convexified and linearized version of the TCP function due 
to its sensitivity and highly nonlinear characteristics. We design a solution algorithm 
described as follows. 
 
The optimization problem is equivalent to a convex optimization problem that 
maximizes the logarithmic function of the TCP function log(TCP(T, dP)) since the TCP 
function is a non-decreasing function with: 










P dTCPlogdTCPlogDTCPlog )()( . 
Furthermore, the logarithm function log TCP(dP) is a concave function that values in (-∞, 
0] as TCP(dP) is a non-decreasing function on [0,1]. By fitting log TCP(dP) with a concave 
piecewise linear function where the numbers and the length of segments are pre-determined 
by the minimum and maximum dose requirements, the optimization problem can be 
converted into a piecewise linear optimization problem, and ultimately a linear 
optimization problem that maximizes the concave piecewise linear approximation of the 
TCP function.  
 
In the final step, we perform local search within the neighborhood of the obtained 
optimal solution that maximizes TCP(D) rather than the piecewise approximation of it. A 
simulated annealing algorithm is executed for 1,000 iterations in which subgradients of the 
dwell time vector t are found by swapping 0.01 minute of seed duration from one seed 
location to another to search for an improvement direction.  
 
3.2.3 Results 
To gauge the feasibility, characteristics, and potential benefit of PET-image guided dose 
escalation, initial validation consists of fifteen cervical cancer patient cases. These patients 
have all received prior 45 Gy of external radiation dose. The PTV ranges from 82.8 to 
137.47 cm3 and the BTV ranges from 10% to 41%. For each patient case, 3 alternative 
strategies are contrasted: a) standard HDR plan with no escalation, b) BTV escalation with 
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the same PTV prescription dose, and c) BTV escalation with reduced PTV prescription 
dose.  For both escalated strategies, we consider two variations (37 Gy boost to BTV vs. 40 
Gy boost) and observe the effect on PTV and OAR dose profiles and TCP quality.  
 
For the fifteen patients, the tumor control probabilities for standard plans range 
from 48% to 63%. For dose escalation, when an escalated dose of > 37 Gy is placed on the 
PET-identified tumor pockets, in all escalated plans, there is slight reduction (2-5%) in 
rectum and bladder dose, while 99% of BTV receives over 40Gy. The resulting TCP values 
range from 82% to 99%. When the BTV is less than 15% of the PTV, dose escalation can 
be delivered with virtually identical PTV dose as in the standard plan. When BTV occupies 
over 20% of the PTV, dose escalation to PET-identified voxels intrinsically increases PTV 
dose by 1%.  Boosting BTV to 40Gy results in no dose increase to PTV in all plans.  When 
PTV is prescribed a reduced dose of 33Gy, independent of the size of the BTV, escalation 
can be achieved while dose to PTV, bladder and rectum are simultaneously reduced.  All 
plans can be generated within a CPU minute. This allows for real-time OR-based treatment 
planning and on-the-fly dynamic re-configuration. 
 
Table 3.4 highlights the tumor control probability for three representative patients: 
BTV 10% of PTV (small), 20-30% (medium), and 41% (large). On all patients, TCP of all 
escalated plans is over 80%. Specifically, when BTV is boosted to over 40Gy, the resulting 
TCP is uniformly high (> 89%). We list the plans A –E according to improvement in TCP. 
The best TCP (E) is achieved when we boost the PET-identified pockets to over 40Gy 
while maintaining the PTV dose at 35 Gy. This can be partially explained by the fact that 
there remain cancer cells loosely populated outside the PET-identified pockets. Hence a 
prescribed dose of 35 Gy is able to eliminate these cancer cells, but a prescribed dose of 33 
Gy may not be as effective. Figure 3.5 illustrates the dose volume histogram and dose 








Table 3.4. Comparison of TCPs in treatment plans. Plan B - E: Minimizing total overdose 
in cervix incorporated with TCP. Plan B1 and C1: Solving the linear relaxation problem of 
maximizing TCP. 
BTV/PTV Ratio Category Small Medium Large 
Planning Target Volume (PTV in cc) 82.5 131.5 89.7 
PET-identified volume (BTV in cc) 5.2 25.5 26.0 
Ratio: BTV/PTV 6.3% 19.39% 28.99% 
Treatment Planning Model  Tumor Control Probability 
A. Standard HDR Plan (PTV dose = 35 Gy) 60.5% 63.6% 59.4% 
B. PET-guided Escalated Plan (BTV > 37 Gy, PTV = 35Gy) 87.4% 93.8% 76.6% 
C. PET-guided Escalated Plan (BTV > 37 Gy, PTV = 33Gy) 84.0% 63.8% 68.5% 
D. PET-guided Escalated Plan (BTV > 40 Gy, PTV = 33Gy) 97.8% 94.7% 96.4% 
E. PET-guided Escalated Plan (BTV > 40 Gy, PTV = 35Gy) 98.6% 96.4% 97.3% 
B1. TCP Optimization Plan (BTV > 37 Gy, PTV = 35Gy) 99.0% 97.8% 99.1% 





Figure 3.5. Comparison of Dose volume histogram between dose escalated plan (B) and 









CHAPTER IV  
PUBLIC HEALTH DECISION MAKING 
Public health emergencies such as pandemic flu and bioterrorism attack require public 
health administrators to assess the upcoming event and determined the needed resources to 
mitigate the impact of the emergencies. When the resources are limited, it is critical to 
allocate the resources optimally and strategically such that the loss from the emergency is 
minimized. For example, the number of infections in a flu pandemic can be minimized by 
vaccination that prioritizing the high-risk groups. On the other hand, when the resources are 
adequate to prevent the emergency, it is beneficial for the public health department to adopt 
the most efficient strategy such that the effort and budget can be saved for other incidents. 
  
In this chapter we discuss two topics: In the first section, we investigate  
vaccination strategies against a pandemic flu to find the optimal strategy when limited 
vaccines are available by constructing a mathematical model for the course of the flu 
development and the process of the vaccination; in the second section we analyze the cost-
effectiveness of emergency response strategies against a large-scale anthrax attack where 





4.1 Strategies for Vaccine Prioritization  
This section contains the paper to be appeared in Interfaces - The Daniel H. Wagner Prize 
for Excellence in Operations Research Practice 2015; EK Lee, F Yuan, F Pietz, BA 
Benecke. Vaccine Prioritization for Effective Pandemic Response. 
 
Vaccine Prioritization for Effective Pandemic Response 
Eva K Lee *, Fan Yuan *, Ferdinand Pietz †, Bernard Benecke ‡ 
*School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA, †  




When vaccine availability is limited, prioritized vaccination is considered the best 
strategy to contain a (flu) pandemic. We derive a mathematical decision framework to 
track the effectiveness of prioritized vaccination through the course of a pandemic. Our 
approach couples a disease propagation model with both a vaccine queuing model and 
optimization engine to determine the optimal prioritized coverage in a mixed vaccination 
strategy. This approach demonstrably minimizes infection and mortality.  
 
The study reveals there is an optimal coverage for the high-risk group that results 
in the lowest overall attack and mortality rates, given known outbreak characteristics, 
vaccine inventory levels, and individual risk factors,  Such information is critical to 
public health policy makers as they determine the best strategies for population 
protection. This is particularly important in determining when to switch from a prioritized 
strategy focusing on high risk groups to a non-prioritized strategy where the vaccine 
becomes publicly available. This analysis highlights the importance of non-interrupted 
vaccine supply. Although the 2009-H1N1 supply eventually covered over 30% of the 
population, the resulting attack and mortality rates are inferior to a scenario in which only 
20% of the population is covered by a non-interrupted supply. Early vaccination is also 
important: a 3-week delay diminishes a 9.9% infection reduction to a mere 0.9%.  
 
The optimal trigger for switching from prioritized to non-prioritized vaccination is 
sensitive to infectivity and vulnerability of the high-risk groups. Our study underscores 
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the importance of throughput efficiency in dispensing and its effects on the overall attack 
and mortality rates. The more transmissible the virus is, the lower the threshold for 
switching to non-prioritized vaccination. Our model is generalizable, and allows 
incorporation of seasonality and virus mutation of the biological agents. The system 
empowers policy makers to make the right decisions at the appropriate time to save more 
lives, better utilize limited resources, and reduce the health service burden during a 
pandemic event.   
   
*The findings and conclusions in this paper are those of the authors and do not 




When limited vaccines are available, prioritized vaccination is considered the best 
strategy to mitigate the impact of a (flu) pandemic [132, 187]. Traditionally, healthcare 
workers and volunteers involved in vaccinations [150], children, elderly, and others 
with underlying medical conditions receive priority for receiving vaccine. The 
effectiveness of prioritizing elderly, however, has been under debate [170]. Previous 
prioritized vaccination strategies focused largely on spatial distribution of the population 
and age, with the goal of minimizing the severity of the pandemic measured by 
infections, deaths, years of life lost, and cost [130, 133, 163, 196]. Prioritizing children 
from ages 5 to 17 years old and an early start of the vaccination campaign are stressed for 
reducing morbidity and mortality [28]. Tuite et al investigated the optimal ranking for age 
stratified groups and risk stratified groups under unlimited vaccine availability [186]. 
Willinga et al reported an importance leveling strategy to decide the vaccination coverage 
for risk groups under limited vaccine availability [189]. Mylius et al compared 
complications ranking and infection ranking strategies [137]. Yang et al. report that 
vaccinating children before adults may mitigate a severe epidemic if vaccine coverage of 




Previous work has proposed strategies for optimal vaccine distribution by an 
iterative guessing routine [118], by linear approximation [130,131], and via a stochastic 
simulation framework [148]. Most United States public health departments use a mixed 
vaccination strategy that starts as prioritized then switches to a non-prioritized strategy 
after a certain time interval [26]. Determining when that switch should occur is critical 
and vital.  
 
Past studies assumed that vaccination takes no time and all vaccinees receive 
vaccine simultaneously once vaccines arrive [130, 131, 186]. Others assumed that 
vaccination occurs before the pandemic [117]. A proper disease spread model must 
consider the distribution of vaccinations over time, including such important factors as 
supply interruptions and varying patient arrival rates. 
 
This project was initiated ahead of the H1N1 flu when the lead author was invited 
to a White House public health event. The White House Director for Medical 
Preparedness Policy sought technical advice and recommendations for better optimizing 
population protection initiatives. The computational system and the paper emerged from 
that effort. 
 
The goal is to design a system that empowers policy makers with strategies for 
mass infection and casualty mitigation during pandemic under strained time and limited 
vaccine supplies. Our work takes all the critical factors into account by coupling a 
vaccine dispensing queuing model with a vaccination optimization module. These are 
driven by a disease propagation model that aims to determine the optimal trigger for 
switching from prioritized to non-prioritized vaccination so as to minimize infection and 
mortality severity throughout the pandemic’s course when vaccine supplies are limited.  
We contrast two propagation models: systems of ordinary differential equations (ODE) 
versus an individualized agent-based model. In both cases, a 6-stage disease transmission 
model is used, and the vaccination process is characterized by operations and service 
distribution data collected via time-motion studies in seasonal and H1N1vaccination 




We analyze the sensitivity of the optimal switch trigger (i.e., trigger for switching 
from a prioritized to a non-prioritized dispensing strategy) over these parameters: vaccine 
availability, start of vaccination, dispensing throughput efficiency, triage accuracy, 
outbreak characteristics, infectivity rate, and risk factors.  
 
We believe this work is the first mathematical-computational model to combine 
disease propagation, dispensing operations, and optimization capability; and the first that 
allows rapid determination of optimal switch triggers. Moreover, it includes innovative 
computational strategies to derive good near-optimal solutions. To the best of our 
knowledge, previous studies on vaccine prioritization did not include all the critical 
details considered herein in their models, nor were they used by the CDC, or used 
otherwise, to influence public-health policy making.  
 
CDC confirms that this is the first time an actionable and operational switch 
trigger has been defined, an advance that is critical and vital to better mitigation of 
infections and mass casualties. The study confirmed the importance in the establishment 
of the National Institute of Translational Medicine for rapid medical countermeasures and 
drug design. The system, RealOpt-VacOpt, has been in use since 2011 for advising on 
vaccine distribution, prioritization, and triage strategies. In particular, the CDC Strategic 
National Stockpile escalated their dispensing training with a team of dedicated CDC 
public health experts who are providing hands-on training with RealOpt-POD to improve 
operational performance. 
 
4.1.2 Materials and Methods 
Models and Parameters 
To study the infectious status of the population, we develop mathematical computational 
models that capture a 6-stage SEPAIR disease propagation process (susceptible (S), 
exposed (E, infected but not infectious), infectious (P, infectious but not yet 
symptomatic), asymptomatic (A, infectious and asymptomatic), symptomatic (I, 
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infectious and symptomatic), and recovered and immune (R)) along with the stochastic 
vaccination process inside point-of-dispensing sites (PODs) (Figure 4.1). For comparison, 
we take two approaches. The first integrates a system of ordinary differential equations 
for disease progression with a queueing model for vaccine dispensing (ODE-queueing), 
and an optimization module for finding the optimal switch trigger while tracking the 
vaccination and disease propagation process. The second replaces the ODE-queueing 
model by agent-based simulation [97]. The disease spread here is tracked in great detail 
as individuals go through the vaccination process. Optimization is performed over the 
ODE system or within the simulation environment to determine the optimal mixed 
strategy.   







We stratify the population into five risk groups: normal adults, children 10 years-
old and younger, healthcare workers, pregnant women, and patients with underlying 
disease conditions. The latter four are considered high-risk groups for influenza related 
complications; i.e., they have higher probability of being infected, and have higher 
mortality rate once they are infected [37].  
 
The novel 6-stage SEPAIR transmission model is used to track the disease 
progression of each individual [97,195]. The measure of transmission is the basic 
reproduction number R0 [35, 51, 70]. We create three more stages: special care (SC), 
vaccinated and immune (V), and deceased (D). SC tracks the individuals with influenza-
like symptoms who choose to self-quarantine at home, or are treated by the doctors for 
the illness. Consequently, these symptomatic individuals do not infect others. V tracks the 
Figure 4.1. This figure shows the 
patient flow inside a typical point-
of-dispensing (POD) site for flu 
vaccination. Based on collected 
H1N1 mass vaccination data, 
triage service time is fitted with a 
triangular distribution of (0.25, 
2.642, 3.75) (minute), whereas 
dispensing is estimated with a 
triangular distribution of (0.2, 
0.684, 1.633) (minute) 
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individuals who have received vaccines, developed immunity, and are protected by the 
vaccines.   
 
PODs are set up for dispensing the flu vaccine; and each individual receives only 
one shot of the vaccine [26]. Due to heterogeneous system behaviors inside and outside 
the POD, the vaccination model is divided into three components: outer-POD, intra-POD, 
and post-POD. All individuals stay in outer-POD at the beginning. Once a prioritized 
vaccination strategy begins, high-risk individuals will arrive at the POD and receive 
vaccine. 
 
The computational model characterizes the services inside the POD, including 
paperwork, triage, vaccination, and special care as shown in Figure 1. Other stations, 
such as orientation and medical and mental evaluation can also be incorporated. 
Individuals in any of the SEPAIR stages will arrive at the POD to be vaccinated.  
Everyone except symptomatic individuals receive vaccines. Inside the POD, health care 
workers triage individuals with influenza-like symptoms and assign them to consultation, 
treatment, or hospitalization as necessary. Vaccines only work on individuals in 
susceptible stage. However efficacy is not inherently100% [26]. Therefore, some 
vaccinated individuals (about 10%) return to the community with their immune status 
unchanged. With only one vaccine per individual allowed, they do not come back to the 
POD. (The model itself can accommodate the use of 2 or more vaccine doses per 
individual.) Appendix A presents the ordinary differential equations and queueing model 
for disease propagation and POD operations  
 
Past studies assumed that vaccination takes no time and all vaccinees receive 
vaccine simultaneously once the vaccines arrive [130,186]. Others assumed that 
vaccination occurs before the pandemic [118]. Neither assumption reflects realistic or 
typical on-the-ground situations. For more practical views, we integrate vaccination 
operations from actual events within our transmission models to study the overall disease 




During CDC time-motion studies for flu and H1N1 mass dispensing, we collected 
arrival rates and service times. These observed data are incorporated into our model.  
Specifically, we consider the case where the arrival rate decreases as the number of non-
vaccinated individuals in the population decreases. During the prioritized vaccination 
stage, only high-risk, not-yet-vaccinated people will come.  
 
We assume that the initial arrival rates for prioritized strategy and non-prioritized 
strategy are similar. Since the high-risk population is significantly smaller than the non-
high-risk one with this assumption, we infer that high-risk individuals are more willing to 
receive vaccine under the prioritized strategy than the overall population. This 
appropriately aligns with the assumption that the high-risk individuals are more willing to 
receive vaccine compared to the general population [39, 145]. Motivated public health 
campaigning helps facilitate this process. 
 
Let J be the total number of risk groups, j=1, 2, …, J, where “1” represents the 
low-risk group (normal adults). The arrival rate λ(t) at time t can be expressed as a linear 
function of the current non-vaccinated live population. Let N denote the total population, 







   
where πj is the percentage of population in group j. Specifically, λ(t) can be expressed as 




























strategy is being used, 
if prioritized strategy 
is being used.
Here, λ0 is the initial arrival rate, N0(t) is the non-vaccinated non-special care live 
population outside the POD at time t, and N0, j(t) denotes the number of individuals of 
group j in N0(t). Figure 4.2 illustrates an example of the variation of arrival rates under 




We use the symbol g to denote the switch trigger. The prioritized strategy is halted 
when the percentage of vaccine covering the high-risk individuals reaches an optimal 
value for g.  
 
Let AR represent the overall attack rate, and ARj represent the overall attack rate 
in group j. The attack rate is a form of incidence that measures the proportion of persons 
in a population who experience an acute health event during a limited period (e.g., during 
an outbreak), calculated as the number of new cases of a health problem during an 
outbreak divided by the size of the population at the beginning of the period. The optimal 
switch trigger g* that minimizes the total number of infections and mortality can be 
obtained by solving the following nonlinear optimization problem: 
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where VEj(t) represents the number of vaccinees in group j, N’ represents the high-risk 
population, VS(t) represents the total vaccine supply by time t, VS represents the overall 
vaccine supply level, and u is an upper bound of the prioritized coverage. (1) ensures that 
the number of high-risk individuals who receive vaccine is no greater than g fraction of 
total available vaccine supply under the prioritized strategy. (2) ensures that the total 
number of vaccinees will not exceed the total vaccine supply at any time. Both VEj and 
ARj are output from the ODE system. The system collects the value of VEj continuously 
to maintain feasibility of the constraints. Thus, once the total number of vaccinees 
Figure 4.2. Arrival rate for 2009 H1N1 
supply when mixed strategy was used: 4 
batches of vaccine supply were available at 
day 1, day 45, day 60, and day 75, 
respectively. The mixed strategy switched 
from prioritized to non-prioritized on Day 




reaches the current vaccine supply, prioritized vaccination stops. At that point, the PODs 
are shut down until the next batch of vaccines arrives. This reflects the actual practice 
where POD planners keep track of their total vaccine inventory, and maintain headcounts 
of arrival to ensure proper closing of the entrance door.  
 
In our model, the optimal switch trigger is obtained by a line search algorithm for 
a given scenario where the objective function value is calculated through the ODE-
queueing or the simulation system. We perform multiple iterations with random initial 
switch trigger values. It is computationally intensive to solve the ODE-queueing-
optimization system, with each instance requiring about 4000 CPU minutes to solve. 
 
Optimization within a simulation environment is also difficult and remains a 
challenge. We employ our large-scale computational system developed at CDC, 
RealOpt©, to achieve the results [98].  
 
Design of Experiments 
The model allows us to stratify the risk groups and their vulnerabilities. We use ηj to 
denote the risk-factor of the infection rate for group j, ηj ≥ 1, where 1 represents the 
standard risk factor for normal adults. Then, η2 =2 implies that the infection rate for 
children 10 and younger is two times that of normal adults. In our study, we also contrast 
the optimal switch trigger with high-risk group including children (0-10 years-old) versus 
the scenario that excludes school children (6-10 years-old).   
 
We perform our analysis based on the 2009 H1N1 vaccine supply, which arrived 
in four batches: the first batch covered 10.0% of the population; the subsequent three 
batches covered 6.67%, 4.0%, and 10.0% of the population, and were available 45 days, 
60 days, and 75 days respectively after the first batch [26].  
 
Early vaccination has been shown to be crucial to contain the pandemic [67]. We 
consider early vaccination from two factors: i) vaccine supply without interruption and ii) 





We contrast the 2009 H1N1 vaccine supply schedule to two other levels: 20% and 
40% continuous supply. In the mathematical model, the time horizon is set to 90 to 120 
days, and the time unit is in minutes. The reproduction number R0 ranges from 1.0 to 2.0. 
We analyze vaccination effectiveness under different start times (no delay to 3-week wait 
until arrival of vaccines) as well as different initial numbers of infection, 0.5% to 2.0% of 
the population.  
 
To illustrate the importance of integrating vaccination operations into the disease 
propagation study, we contrast the attack rates and mortality rates when vaccination 
throughput varies. Our default triage accuracy is set to 95%. We also experiment with 
triage false positive and false negative rates ranging from 50% to 100% to gauge their 
importance. To validate the performance of our models, we contrast the results from the 
agent-based stochastic simulation-optimization model to the ODE-queueing-optimization 
model. We also compare our results against the actual infection estimates of the H1N1 
pandemic as reported by the CDC [26, 144].  
 
4.1.3 Results 
We report optimal switch triggers for the mixed vaccination strategy for three scenarios 
of vaccine supply: 1) The 2009 H1N1 vaccine supply schedule; 2) 20% vaccine supply; 
and 3) 40%. The analysis is performed for the state of Georgia with a population of 
9,687,663 [25]. Forty-three point-of-dispensing sites are setup strategically for mass 
vaccination to protect the region [98].  
 
The high-risk groups consist of 14.8% children 10 years-old and younger, 3.0% 
healthcare workers and volunteers, 1.2% pregnant women, and 0.3% patients with 





The switch trigger is expressed in terms of the percentage of vaccine used for the 
high-risk population before vaccination is opened up to the general population. The term 
full non-prioritized strategy refers to the case when the switch trigger is 0%, meaning a 
non-prioritized strategy is employed from the outset, where no distinction is made of the 
risk factors among the population. The term full prioritized strategy means that vaccine 
will be given first to all high-risk individuals before it will be distributed to the general 
population. Thus, the switch trigger for a full prioritized strategy is 100% if the number 
of available vaccine doses is less than the number of individuals in the high risk 
population, and is equal to the ratio of the high risk population to available doses 
otherwise. Note that when the vaccine supply is less than that of the high-risk population, 
a full prioritized strategy means all vaccine will be used for the high-risk group and 
nothing is left for the general population. The term mixed strategy refers to a situation 
where a specified percentage of vaccine is used first to vaccinate the high risk group, 





Figure 4.3 shows plots of the overall attack rate and mortality rate as a function of 
the high-risk group coverage when the reproduction value R0 = 1.2, and the initial 
infection of the population is 1%. We indicate the global minimum of each curve and 
Figure 4.3. Plot of the overall 
(day 0 to day 90) attack rate 
and mortality rate as a 
function of percentage of 
high-risk coverage when R0 = 
1.2 (blue = 2009 H1N1 
supply level, red = 20% level, 
green = 40% level). Solid 
lines denote attack rates, and 
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mark on it the associated optimal switch trigger, g, with respect to the three vaccine 
supply levels. We note that an increase of attack rate of 1% in our study amounts to 
96,876 sick individuals. 
 
Table 4.1 shows the optimal mixed strategies under the three vaccine supply 
scenarios as R0 varies, and compares the associated attack rate for the optimal mixed 
strategy to those resulting from the full prioritized strategy, and the full non-prioritized 
strategy. When R0 = 1.2, under the 2009 H1N1 vaccine supply schedule, the optimal 
mixed strategy occurs with switch trigger of 46.9%. The attack rate increases by 1.54% 
and 36.78%, respectively, for the full prioritized coverage and the full non-prioritized 
strategies. Across all R0, these strategies produce an average attack rate increase of 0.84% 
and 16/96% respectively, when compared to the optimal mixed strategy for H1N1 
vaccine supply. Note that for the 40% vaccine supply level, the full prioritized strategy is 
strikingly inferior to the optimal mixed strategy. (Attack rates increase by 77% or more 
for all R0.) 
 
Independent of the vaccine supply level, the optimal switch trigger decreases as 
R0 increases. This indicates that the start time for non-prioritized vaccination should 
begin earlier when the pandemic is more severe. Likewise, when the level of vaccine 
supply is relatively high, the start time for non-prioritized vaccination should also begin 
earlier. In general, the percentage of high-risk population receiving vaccine decreases as 
the vaccine supply level increases and as the pandemic is more severe. There is a slight 
abnormality for 2009 H1N1 vaccine supply (74.5% high-risk coverage versus 71.7% for 
20% vaccine level). This is partly due to the supply interruption. For the same reason, for 
a given R0, the 2009 H1N1 vaccine supply schedule contributes to the highest attack rate 








Table 4.1. Optimal mixed strategy and associated attack rate, and comparison 
with attack rates for the full prioritized strategy, and the full non-prioritized strategy, as 




Optimal mixed strategy % increase in attack rate w.r.t. optimal attack rate, AR* 
Optimal switch 
trigger g = % of 
vaccine used 
for high-risk 








20% 69.19% 71.7%   9.37% +6.30%* +37.14% 
2009 H1N1 46.90% 74.5% 14.98% +1.54% +36.78% 
40% 26.12% 54.1%   5.48% +81.75% +9.12% 
1.6 
20% 69.00% 71.5% 33.72% +8.16% +15.90% 
2009 H1N1 32.73% 52.0% 46.48% +0.88% +10.20% 
40% 20.27% 42.0% 16.20% +125.12% +12.59% 
2.0 
20% 59.25% 61.4% 52.76% +8.23% +5.14% 
2009 H1N1 32.67% 51.9% 64.75% +0.11% +3.89% 
40% 16.45% 34.1% 32.25% +77.05% +5.89% 
* The % increase in attack rate is computed as (AR – AR*)/AR*, where AR is the attack 
rate of the indicated strategy, and AR* is the rate for the optimal mixed strategy. 
 
Figure 4.3 and Table 4.1 highlight one very important result: although the 2009 
H1N1 vaccine supply eventually covered 30.67% of the population, the resulting attack 
and mortality rates are inferior to the scenario when vaccine supply level is only 20% but 
available for continuous use with no supply disruptions.   
 
Figure 4.4a contrasts results obtained from the ODE-queueing model with those 
obtained from the individual-based stochastic simulation model for the optimal mixed 
strategy (46.9%), the full prioritized strategy, and the full non-prioritized strategy under 
the 2009 H1N1 vaccine schedule when R0 = 1.2. From simulation, the attack rates are 
14.32%, 14.51%, and 19.53% respectively for the optimal mixed strategy, the full 
prioritized strategy, and the full non-prioritized strategy. Note that 0.19% infection 
amounts to 18,406 infections. We observe similar trends: by day 94, optimal mixed 
strategy results in 1.54% and 36.78% infection reduction with respect to the other two 
strategies in the ODE-queueing model, and 1.36% and 36.38% reduction in the 
individual-based stochastic simulation model. Figure 4.4b zooms in to show the 








In Table 4.2, we contrast optimal mixed strategies for various risk-factor 
combinations for pre-school children and school children in two scenarios: i) all children 
10 years and younger are included in the high-risk group (14.8%); ii) exclude school 
children (age 6-10, 6.6%) from the high-risk group. In the first scenario the optimal 
switch trigger increases when the risk factor of preschool children and/or of school 
children increases.  
 
If school children (age 6-10) are excluded from the high-risk group, the optimal 
switch trigger increases when the risk factor of pre-school children increases or the risk 
factor of school children decreases. 
 
  
Figure 4.4b. A closer look at the 
difference between the optimal mixed 
strategy versus full prioritized strategy 
 
Figure 4.4a. Attack rate curves for the ODE-
queueing model (dotted) versus the individual-based 
stochastic simulation model (solid) when R0 = 1.2 
for 3 vaccination strategies under the 2009 H1N1 
vaccine supply scenario.   
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Table 4.2. The table contrasts the optimal switch trigger (%) against risk factor 
combinations for pre-school and school children. Risk factor 1 represents no added 
risk, 2 means twice as likely to get infected if exposed, and 4 means four times as 
likely to get infected.  
 
Vaccine supply level: 20% 







Preschool children risk factors 
1 2 4 1 2 4 1 2 4 
Include all ≤ 
10 years old  
1 32.04 62.63 75.46 32.98 38.97 50.42 15.97 16.07 20.99 
2 56.26 69.19 77.30 34.06 46.90 50.48 16.07 16.12 23.40 
4 72.09 76.04 77.88 50.42 50.48 50.75 20.27 23.40 25.81 
Exclude 6-10 
years-old 
1 28.85 60.99 72.28 47.40 47.59 47.65 13.94 14.14 24.70 
2 28.18 60.78 72.18 47.34 47.53 47.65 13.90 14.09 24.70 
4 10.42 60.69 70.25 3.15 47.40 47.53 5.45 14.09 24.66 
 
To quantify the importance of early vaccine availability, Figure 5a compares the 
daily prevalence of infection for optimal mixed strategies given a single-batch 10% 
supply versus the 2009 H1N1 vaccine supply schedule for different scenarios related to 
when initial vaccination begins. For the case of no delay, with vaccination beginning on 
day 0, the H1N1 supply schedule begins to show reduction in daily prevalence starting at 
day 45 and eventually achieves over two-fold reduction (at day 90, 0.08% vs. 0.27%). 
There is no difference prior to day 45 since the H1N1 schedule starts out at only 10%, but 
eventually covers 30% of the population. However, in the cases for which there is a delay 





Figure 5b compares the overall attack rates (left figure) for optimal mixed 
strategies given four supply levels and different scenarios as to when initial vaccination 
begins. It shows that when vaccination starts on time, the 2009 H1N1 supply results in 
9.9% reduction in overall infections compared to a single-batch 10% supply (14.98% 
versus 16.63%). However, when vaccination is delayed for 3 weeks, the associated 
reduction is only 0.9%. A similar trend is observed for the mortality rates (right figure). 







Figure 4.6 (left) shows the optimal switch triggers for several combinations of 
reproduction number and initial number of infected individuals with respect to the initial 
Figure 4.5b. This figure contrasts the overall (day 0 to day 90) attack rates (left) and 
mortality rate (right) associated with four different supply scenarios in the face of an initial 
delay in availability ranging from zero to three weeks. The optimal switch triggers are 
100%, 69.19% and 31.20%, respectively, for 10%, 20%, and 30% vaccine supply levels. 
The differences in both attack and mortality rates are less profound as the delay increases.  
Figure 4.5a. This figure shows the 
percentage of population that are infectious 
at the end of each day resulting from the 
2009 H1N1 supply (dashed curves) versus 
10% vaccine supply (solid curves) when 
vaccination begins on time,1 week delay, 2 
weeks delay, and 3 weeks delay and is 
dispensed according to the associated 
optimal mixed strategy. Here, R0 = 1.2, 
initial infected population is 1.0%. The x-
axis represents the number of days since the 




vaccine supply level. The optimal switch triggers appear to converge as the vaccine 
supply level reaches around 50%. Recall that the percentage of high risk population in 
our study is 19.3%. Figure 4.6 (right) shows that when the vaccine supply is less than 
13.8% of the population, independent of the pandemic severity and the initial population 
infection, all vaccines will be given to the high-risk individuals. Table 3 shows the 
maximum vaccine supply level under which all will be dispensed to the high-risk 
population. This table reinforces that to achieve optimal infection and mortality reduction 










Table 4.3. From Figure 4.6 (right), the maximum vaccine supply level under which all 
will be dispensed to high-risk individuals.  
(R0, α) R0 = 1.2 R0 = 1.6 R0 = 2.0 
α = 0.5 17.9% 17.5% 16.0% 
α = 1.0 17.7% 17.2% 15.1% 
α = 2.0 17.2% 16.0% 13.8% 
 
Figure 4.7 shows the resulting attack rates and mortality rates for the three 
vaccine supply levels and varying dispensing throughput efficiency rates. Observe that 
Figure 4.6. This figure (left) shows optimal switch triggers (percentage of vaccine 
dispensed to the high-risk group) against the vaccine supply levels in the optimal mixed 
strategy for nine different scenarios (R0, α) of initial reproduction rates, R0, and percentage 
of initial infection, α. The high-risk population is at 19.3%. The graph shows that, even 
when there is quite limited supply of vaccine, it is advantageous to begin vaccination of the 
general population before vaccinating all those in the high risk group. A magnified view 




the attack rate increases as the dispensing throughput decreases, with the increase more 
significant when the dispensing throughput is low. A similar trend is observed across all 
three vaccine supply levels. A similar trend is also observed for the mortality rates. This 
underscores the importance of dispensing efficiency, even within an optimal mixed 
strategy with no vaccination delay. Accepting that server variability in dispensing is 
unavoidable, dispensing throughput efficiency is highly influenced by optimal resource 




When triage fails to identify individuals with flu perhaps due to lack of symptoms 
(false-negative), the resulting attack and mortality rates increase slightly. However, the 
optimal switch trigger remains rather constant. This trend is observed on all vaccine 
supply levels and we briefly illustrate the results for vaccine level 20%. Figure 4.8a 
shows the attack rate decreases from 9.46% for 50% triage accuracy to 9.27% at 100% 
triage accuracy. The optimal switch trigger remains at 69.19% throughout. However, 
when healthy people are being triaged as infected (false positive), the optimal switch 





Figure 4.7. Contrast of the overall 
(day 0 to day 90) attack rates and 
mortality rates associated with 
three supply scenarios with 
respect to dispensing throughput 
efficiency. Solid lines denote 
attack rates, and dotted lines 








Figure 4.9 contrasts the CDC reported attack rates for the 2009 H1N1 pandemic 
versus our simulation results. The curves are obtained by varying the values for three 
parameters: the initial infection rate, the reproduction number, and the switch trigger.  
 
 
4.1.4 Impact and Significance 
In this study, we propose a ‘mixed model’ approach to quickly determine the optimal 
‘switch trigger’ in a mixed vaccination strategy to minimize both infection and mortality 
over the course of a pandemic. We do this by interoperably coordinating a disease 
Figure 4.8a. Effect of triage accuracy (results 
from false negative) on overall attack rate and 
mortality rate. Attack rate increases slightly 
from 9.27% to 9.46%.  A triage error of 10% 
results in 9.31% attack rate 
Figure 4.8b. The optimal switch trigger drops 
from 69.19% to 56.16% when triage accuracy 
for healthy individuals is reduced by 10% (false 
positive, red line). It remains at 69.19% 
independent of any Type II errors committed. 
Figure 4.9. Contrast of attack 
rates for the 2009 H1N1 pandemic 
from our study versus actual CDC 
reported data. The solid curves are 
our results. The dashed curves 
represent the CDC reported attack 
rates from the 2009 pandemic. 
Each line of our results represents 
a combination of two parameters: 
the reproduction number, and the 
switching time. Example: (1.1, 60) 
refers to R0 = 1.1, with optimal 
switch trigger (g=52.1%) happens 





propagation model with a vaccine queueing model and an optimization engine. For 
realism and pragmatic purposes, we integrate vaccination operations from actual events 
within our models to study overall disease propagation process. We perform our study 
using census data and hospital information from Georgia and the 2009 H1N1 vaccine 
supply. This work advances both the scientific and public health policy frontiers.  
 
Mathematical OR Advances  
This study offers unique features that have not been previously investigated / 
incorporated: 
o This is the first mathematical-computational model marrying disease propagation 
with optimization capability that allows rapid determination of the optimal switch 
triggers – that is, the timing for switching from the prioritized vaccination strategy 
to the non-prioritized strategy during the course of the pandemic. It is also the 
first model that mathematically defines “optimal switch trigger” that minimizes 
the overall attack and mortality rates. Using the computational decision 
framework, optimal switch triggers can be obtained based on the parameters of 
the high-risk individuals, the characterization of the pandemic, the vaccine supply 
availability, and the vaccination rate. The implicit relationship between the 
optimal switch trigger and the parameters is made explicit and appropriately 
modeled. 
o This is also the first model which incorporates actual vaccination operations and 
dispensing processes. Mathematical models have been developed to evaluate 
various vaccination strategies, including early vaccination [67], sequencing the 
order of the vaccination for the risk groups, and aiming on various objectives to 
mitigate the influenza [186]. Our study determines the optimal switch trigger, 
accounting for supply levels and actual dispensing operations. The findings 
highlight the importance of these factors within the policy making process. 
o The ODE+queueing+optimization model are computationally intensive. We 
derive rapid solution techniques to obtain good near-optimal solutions. Similarly, 
when replacing the ODE disease propagation and POD queueing model with an 
individualized agent-based simulation model (ABM), the resulting 
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ABM+optimization model remains computationally challenging. We derive 
efficient computational strategies in solving these instances, as well. [98].  
o The model is generalizable for other types of infectious diseases. It can also 
handle seasonality and virus mutation of the biological agents. This information is 
critical to public health policy makers and decision makers as they determine the 
best strategies for population protection during pandemics when vaccine supplies 
are limited and time is critical. 
 
 To the best of our knowledge, previous studies on vaccine prioritization did not 
include all the critical details considered herein in their models, nor were they used by 
the CDC, or used otherwise, to influence public-health policy making.  
 
Implementation, Public Policy, and Health Impacts 
The system, RealOpt-VacOpt, was designed and implemented in Java for portability. It 
has been in use since 2011 for advising on vaccine distribution, prioritization, and triage 
strategies. The public health implications are that policy makers can evaluate better trade-
offs faster to save more lives and better utilize limited resources during a pandemic 
event. We outline briefly some of these decisions (obtained from our system) adopted by 
policy makers and their implications below. 
o Optimal switch time to minimize overall attack and mortality rates CDC confirms 
that this is the first model to define and determine an actionable and operational 
switch trigger, an advance that is critical and vital to better mitigation of 
infections and mass casualties.  Given outbreak characteristics, vaccine inventory 
level, and individual risk factors, there is an optimal switch trigger for prioritizing 
vaccines that results in lowest overall attack  and mortality rates.  This optimal 
strategy is a significant improvement over full prioitized and full non-prioritized 
strategies. Such information is critical to public health policy makers as they 
determine the best strategies for population protection, and in particular when to 
switch from a prioritized strategy focusing on high risk groups to a non-prioritized 
strategy in which vaccine is made available to the general public. Our model is 
the first that incorporates virus characteristics, disease spread, and dispensing 
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operations to optimize vaccine strategies.  
 The optimal switch trigger is sensitive to the infectivity and vulnerability of the 
high-risk groups. Specifically, we illustrate the effect to the optimal switch trigger 
when the vulnerability of the pre-school and school children vary. A full non-
prioritized strategy may be preferred if some high-risk individuals are excluded 
from the prioritized groups (i.e., school children or elderly). Furthermore, we 
present the optimal switch trigger under different levels of pandemic severity as a 
function of the early vaccine availability, where the importance of early vaccine 
availability is emphasized. (Figures 4.5a, 4.5b) 
 The results reflect that a full prioritized strategy to cover all of the high-risk 
individuals is not an optimal strategy (Figure 4.3, Table 4.1). When early vaccine 
supply is limited at a low level, the doses should all be given to the high-risk 
individuals (Figure 4.6, Table 4.3). But the optimal switch trigger decreases as 
more vaccine becomes available. And this value converges as the vaccine supply 
is above 50% (Figure 4.6). Uniformly under various reproductive values, 
population infection levels, and vaccine supply levels, vaccinating a fraction of 
the high-risk individuals in the mixed strategy offers the best disease mitigation 
results compared to a full prioritized or full non-prioritized strategy.  
 The analysis indicates that timely vaccination and a mixed strategy are critical. 
Further, delayed vaccination and batched vaccine supply reduce effectiveness and 
raise overall attack and mortality rates. The more transmissible the virus is, the 
lower the optimal switch trigger. For very transmissible viruses, the non-
prioritized strategy should begin promptly. 
o Improved understanding of vaccine supply and importance of timeliness of 
vaccination: The analysis highlights the importance of non-interrupted vaccine 
supply: although the 2009 H1N1 vaccine supply eventually covered over 30% of 
the population, the resulting attack and mortality rates are inferior to the scenario 
when a supply covering only 20% of the population is available without supply 
interruption. This finding challenges the traditional rolling-out policy where 
supplies are acquired and shipped in batches. It also highlights the importance of 
early vaccination: the 2009 H1N1 supply results in 9.9% reduction in overall 
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infections when compared to a single-batch 10% supply, but the reduction is only 
marginal (0.9 %) when vaccination is delayed for 3 weeks. These findings are 
critical to the important policy decisions that public health leaders must make: the 
acquisition and the timing for vaccination. The system and the results confirmed 
the decision in the establishment of the National Institute of Translational 
Medicine for rapid medical countermeasures and drug design. 
o Importance of efficient dispensing operations: Our study underscores the 
importance of dispensing throughput efficiency and its effects on the overall 
attack rates and mortality rates (Figure 4.7). As a result, the CDC Strategic 
National Stockpile escalated their dispensing training with a team of dedicated 
CDC public health experts. The CDC team provides regular hands-on RealOpt-
POD mass dispensing training to state/local/tribal public health emergency 
response coordinators to improve operational performance. 
o Understand the effect of triage: Triage operations have proven to be expensive for 
mass dispensing. CDC has been undecided regarding triage since their own 
analysis indicated that addition of triage within a POD can slow down dispensing 
throughput by over 20%. Our analysis herein informed CDC decision makers that 
errors made by false negatives pose negligible effect on the overall attack and 
mortality rates (Figure 4.8a). Removing triage saves resources and improves 
dispensing throughput, which is critical to improving the overall attack and 
mortality rates. 
o An objective tool for policy analysis and decision making: The computational 
decision framework is generalizable and flexible and can be used for analysis of 
any type of infectious disease. Such an objective decision framework empowers 
policy makers to better understand the health implications of their decisions. The 
resulting policy directly impacts the overall ability to protect population health of 
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Appendix: The ODE-queuing disease propagation model  
We define the disease progression stage space as Φ = {S(susceptible), E(exposed), 
P(infectious), A(asymptomatic), I(symptomatic), RC(recovered and immune)}, along 
with SC = special care, V = vaccinated and immune individuals, and D = deceased. The 
individual flow between these stages is illustrated in Figure 4.S1. The risk group space 	 
= {1, 2, 3, 4, 5} represents the five risk groups: normal adults, children 10 years-old and 
younger, healthcare workers, pregnant women, and patients with underlying disease 
conditions. We assume POD has K service stations. To track individuals from each risk 
group and where these individuals are, we use double indices, i, j, where i runs from Ω = 
{0, 1, …, K, K+1} and j ∈ 	 to indicate live individuals a) outside the POD (outer-POD, 
i = 0), b) inside the POD (inside-POD, in one of the K service stations, i = 1, …, K), and 
c) exiting the POD when the vaccine fails (post-POD, i= K+1). Individuals who are 
vaccinated and are immune will move to stage V. Let ϑi,j be the number of individuals of 
group j at station i with disease stage ϑ, where i ∈{0,1,…,K, K + 1}, j ∈ 	, and ϑ ∈ Φ. 
Finally, let Ni , i ∈{0,1,…,K, K+1} denote the number of live individuals (under 
different disease stages) at each station: outside the POD, inside the POD, and post-POD.   
 
The transmission model is shown in Figure 10. We apply our model to a 
population of 9,687,653 with specific percentages for each risk group. Table S1 
summarizes the input model parameters.  
 
For discussion brevity, we let K = 2, so that station 0 is outer-POD, station 1 is 
triage station, station 2 is vaccination station, and station 3 is post-POD. The allocation of 
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nurses and their service times at triage and vaccination listed in Table 4.S1 are the real 
numbers obtained from time motion study in H1N1 flu campaigns. The outer-POD 
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and represent the real service rate for the individuals staying at transmission stage ϑ from 
group j at POD station i. Equations (5-1) to (5-7) represent the rates of change in the 
population who go back to the community (outside of the POD) without immunity (that 
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d   (5-6) 
jSCjHHj SCIpSCdt
d
,3,3,3    
(5-7) 
Equations (6) and (7) represent respectively two outcomes for the transmission flow: 




















jVj   
(7) 
Equation (8) represents the infection flow, which relates to the objective function of the 
optimization problem. Equation (9) cumulates the vaccine consumption, which is used to 































Thus, everyone who goes to the POD gets vaccinated (if they are in the proper risk 
group) except those being triaged as infected, who will be sent for treatment in the 
hospitals or for special care. 
 
 
Figure 4.S1. This figure shows the diseases progression stages. Each stage is further 
stratified by the risk groups.  
 
Table 4.S1. Model parameter description. 
Parameter Description Base case value (at time t=0) 
Ω Station space 
Ω = {0, 1, …, K, K+1}, where 0 is outer-POD, 1, …, K 
are service stations inside the POD. Station K is the 
vaccination station, station K+1 represents post-POD. 
Φ 
Disease progression stage 
space 
Φ = {S(susceptible), E(exposed), P(infectious), 
A(asymptomatic), I(symptomatic), RC(recovered and 
immune)}.  
Γ Risk group space 
{1, 2, 3, 4, 5} ({normal, children 10 or younger, 
healthcare workers, pregnant women, patients with 
underlying disease conditions}) 
Π Risk group population 
distribution 
{0.807, 0.148, 0.03, 0.013, 0.002}. [26]  
N 
Total population of the 
region   
N’ High-risk population  N’ = (1 – π1) N, where π1 = 0.807. 
Vj 
Number of vaccinated and 
immune individuals in 
group j. 
At time t = 0, Vj = 0.  
V 
Total number of vaccinated 







SC Special care At time t = 0, SCj = 0.  
Dj 
Number of deaths in group 
j. 
At time t = 0, Dj = 0.  
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Table 4.S1. (continued) 
Ni 
Number of non-special care 
live individuals at station i  
}1,...,,1,0{,  KKiRCIAPESN iiiiiii  
At time t = 0, N0 = N, N1 = … = NK = NK+1 = 0. 
Ni,j 
Number of non-special care 
live individuals of group j at 
station i  





   
α Initial infection percentage 1.0%, range 0.5% - 2.0%    
AR Attack rate At time t = 0, AR = αN.   






At time t = 0, AR j = πj ·AR. 
η  
Relative risk factor for each 
risk group {1, 2, 1, 3, 3}. 




1 day  
1/μA 
Mean asymptomatic 
duration 3 days  
1/ μI Mean symptomatic duration 3 days  
1/ μH 
Mean duration before 
special care from showing 
symptom 
2 days 
1/ μSC Mean special care duration 5 days 
pS  Symptomatic probability  2/3  
βj 









   
pV Vaccine effectiveness 90% 
pH 
Percentage of symptomatic 
patients being hospitalized 
20% 
mj Mortality rate for group j 0.12%   
m_scj 
Mortality rate for group j 
after special care (or 
hospitalization) 
mj / 2 
ϑi   
Number of individuals at 
station i with disease  stage 
ϑ 
At time t = 0,  
S0 = (1- α)N,  
E0 = αN · Δ · 1/ μE,  
P0 = αN · Δ · 1/ μP,  
A0 = αN · Δ · (1- pS) · 1/ μA,  
I0 = αN · Δ · pS · 1/μI,  
V0 = 0, SC0 = 0, D0 = 0, RC0 = 0,  
where Δ = (1/ μE + 1/ μP + (1- pS) ·1/ μA + pS ·1/μI) -1 , 
ϑi = 0, for i ≠ 0. 
   
   
   
 
147 
Table 4.S1. (continued) 
ϑi,j   
Number of individuals of 
group j at station i with 
disease  stage ϑ 








At time t = 0, ϑi,j = πj ·ϑi, for i ∈{0, 1, …, K, K+1}, j ∈ Γ. 
VEj 
Number of vaccinees in 
group j. At time t = 0, VEj = 0. 
VS(t) Cumulative vaccine supply 



















































if non-prioritized strategy is used 
if prioritized strategy is used,
where N0 is the number of non-vaccinated live 
individuals outside the POD, N is the total population, 
and N0,j denotes the number of non-vaccinated live 
individuals of group j outside the POD. λ0 is the initial 
arrival rate, λ0 = 12.018 / min at time 0.  
 
ρj (t) 
Arrival allocation for high-





















































λj (t)   Arrival rate for group j = λ(t) ρj (t) 
ni 
Number of nurses at station 
i   
STi Service time at station i   
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4.2 Dispensing Medical Countermeasures in Response to an Anthrax Attack  
4.2.1 Introduction 
Once a large-scale anthrax attack happens, people may die by the end of 48 hours if they 
do not receive medical countermeasures against anthrax. It is crucial that all individuals 
living  in the metropolitan area where the attack occurs receive medications within the 48 
hour timeframe. An individual needs to take 2 pills of ciprofloxacin or doxycycline per 
day for 60 days until the epidemic has terminated to be kept from infection. In addition to 
the medications, individuals must be registered with the government and be instructed by 
physicians in a face-to-face meeting in order to ensure the he/she is fully protected.  
 
Strategies for dispensing medical countermeasures against a large-scale anthrax 
attack, including postal delivery [6] and mass dispensing by Point-of-Dispensing (POD) 
[5, 12, 22, 31, 112, 192, 193] have been examined by numerous researchers. Postal 
delivery is to deliver the medical countermeasures by USPS postal carriers to each 
household in the city. Mass dispensing at POD is to let the population pick up the 
medical countermeasures at PODs, which are set up at public places in the city. However, 
these two strategies are not flawless: Postal carriers can only deliver a fixed amount of 
pills to each household rather than providing the enture prescriptive dose to each 
individual; to dispense the medical countermeasures in PODs within 48 hours may 
increase the risk of infection due to the congestion in the PODs. We herein consider a 
postal delivery and POD refill strategy, named Postal+Refill, to protect the entire 
population by delivering initial medications by postal carriers within the first 24 hours 
and refilling medications at PODs in the following days. People who finish their initial 
medications need to pick up sufficient medications at PODs such that they are kept from 
infection till the end of the epidemic. This strategy takes the advantage of both postal 
delivery and mass dispensing at POD: postal delivery provides fast temporary prevention 
to the entire population; and mass dispensing ensures people are instructed by the 





4.2.2 Model Description 
In a Postal+Refill strategy, the initial medical countermeasures must be dispensed by 
postal delivery to the entire affected population in the first 24 hours after the attack. The 
medications are prepared by the public health departments within the first 12 hours, and 
then postal carriers deliver medication to each household in the following 12 hours. A 
bottle of 20 pills is delivered to each household, which provides temporary protection 
from anthrax. The length of the protection depends on the size of a household, i.e., 20 
pills provide 6-day prevention to a family of 3, or 5-day prevention to a family of 4.  
 
Households are required to refill their medications before they finish their 
temporary medications. Every individual must be registered with the government and be 
instructed by physicians face-to-face in order to make sure he/she receives enough 
medications and understand its full usage. During the postal delivery of the initial 
therapy, mass dispensing events in PODs are set up and organized in the city. POD 
locations are selected from a candidate list that consists of schools, gyms, clinics, and 
other public common areas. The employees in these candidate locations are pre-trained 
by CDC such that the locations are well prepared. Starting from the second day which is 
24 hours after the attack, the PODs are open to public and dispense the sufficient 
medications (≥ 60 pills per person per instruction of physicians) to the population.  
 
To plan a Postal+Refill strategy in the city, public health emergency planners 
must determine within the first 12 hours: 
1. Number of postal carriers and police force required, 
2. The POD locations and the covered population of each location, and 
3. The staff resource required at each POD and their responsibilities.  
 
In our analysis, four metropolitan areas are considered in evaluating the cost and 
the staff resource requirement of the Postal+Refill strategy: Washington DC, New York 





Figure 4.10. Metropolitan area of the four metropolitan areas 
 
In postal delivery, USPS postal carriers follow the postal carrier routes to deliver 
one bottle of pills (20 pills) to every household in the city regardless of the household 
size. Postal delivery routes are the regular mailing routes that go through the city and 
serve each of the households along the route. To estimate the required staff and budget 
for postal delivery, we make the following assumptions. First, each of the carriers covers 
two regular postal carrier routes in a zip-code area within 12 hours. Extra carriers are 
required at a higher cost (150% of the regular cost) if the current workforce cannot cover 
all of the postal carrier routes in the city. Second, additional routes are used to deliver the 
pills to the population who do not reside at a permanent address in the city. Third, one 
police officer is assigned to each carrier for security, and 20% additional security officers 
for consolidating the delivery units in the city. The estimation of the required work forces 















City of Los 
Angeles 
Population 599,657 8,363,710 2,853,114 3,833,995 
Number of households 233,330 3,254,362 1,110,161 1,491,827 
Number of USPS carriers in the 
city 
531 3067 1755 1108 
Ratio of postal carriers to 
households (10-3) 
1.51 0.85 1.14 1.02 
Number of postal carriers required 352 2,762 1,268 1,936 
 
Number of postal carriers 
on regular routes 
320 2200 1018 1428 
 
Number of postal carriers 
on additional routes 
30 562 250 94 
 
Number of additional 
postal carriers required 
0 0 0 414 
Number of security officers 
required 
422 3,314 1,522 1,826 
Unit cost per postal carrier (per 
12-hour shift, Estimated by hourly 
salary + rough estimate of  fuel 
cost 
320.2 330 326.1 335.15 
Unit cost per security officer 372 408 418.8 494.4 
Total labor cost  243,654  2,038,356  944,533  1,606,009  
 
Starting from Day 2 (the second day after the anthrax attack), PODs are open to 
the public so that households can register and pick up the remaining pills that will 
provide protection from anthrax. To determine the locations of PODs and the covered 
population for each POD, we build a mixed integer programming model in RealOpt-
Regional© [98] that minimizes the number of PODs in the city and subjects to the travel 
distance to the POD less than or equal to 15 miles. Households are required to pick up the 
refilled pills in the POD on any day no later than the refill due day. Given the initial 
medications of 20 pills, the refill due day of a household depends on the household size 
(Table 4.5). PODs are designed to open 12 hours a day until Day 10 (20 pills prevent a 
family of 1 person for 10 days).  For simplicity, we assume that a household will arrive 
on any day between Day 2 and the refill due day with equal probability. Thus, the 
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designed throughput at PODs on any open day must satisfy the expected arrivals 
(percentage of population) on this day as shown in Table 4.5.  
 
In a general dispensing process, households go through the following steps: 
arrive, register and file forms, get triaged by healthcare workers, pick up pills from 
physicians, and leave. The process at each city can be slightly different (Figure 4.11) 
according to the feedbacks from the previous POD operational drills. The distribution of 
the processing time at each step is estimated using CDC time motion studies in full-scale 
drills or actual dispensing operations. Six types of staff are recruited to operate a POD: 
volunteer, nurse/MD, health technician, security, traffic controller, and interpreter. Their 
responsibilities are different as shown in Table 4.6. For some major ethic groups, e.g., 
Hispanic population or Chinese population, interpreters are required at each step when 
over 5% of the arrivals speak Spanish/Chinese rather than English.  
 
To avoid the increased risk of infection, a household is designed to stay in the 
POD with no more than 30 minutes including all waiting times and processing times. The 
minimum number of worker-shift of each type of staff at a POD that can serve the 
expected arrivals and the maximum duration of each household is determined by a 
simulation optimization model in RealOpt-POD© [44,42,98] using the POD layout used 





Figure 4.11. Layout of the PODs in the four cities.  
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Table 4.5. The required throughput at PODs (% of population). 
Household 
size Refill due 
Day  
2 3 4 5 6 7 8 9 10 Total 
4+ (10%) Day 2 100% 0% 0% 0% 0% 0% 0% 0% 0% 100% 
3 (55%) Day 3 50% 50% 0% 0% 0% 0% 0% 0% 0% 100% 
2 (30%) Day 5 25% 25% 25% 25% 0% 0% 0% 0% 0% 100% 
1 (5%) Day 10 11% 11% 11% 11% 11% 11% 11% 11% 11% 100% 
Required throughput:  45.6% 35.6% 8.1% 8.1% 0.5% 0.5% 0.5% 0.5% 0.5% 100% 
 
Table 4.6. Staff responsibilities 
 
Greeting and 





Volunteer* Y     
Nurse/MD Y Y Y   
Health 
technician Y     
Security Y   Y  
Traffic 
controller Y    Y 
Interpreters Y Y Y Y Y 
*: no volunteer recruited in New York City 
 









City of Los 
Angeles 
Number of PODs 9 99 39 61 
Work force 
required 
Volunteer 432 0 2,188 3,838 
Nurse/MD 621 5,188 2,456 3,390 
Health 
Technician 472 3,148 2,432 2,664 
Security 532 5,898 2,000 2,612 
Traffic Control 540 5,346 3,861 3,843 
Interpreters 344 4,295 750 995 
Total 2,941 23,875 13,687 17,342 
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4.2.3 Cost-effective Analysis 
We compare the Postal+Refill strategy to another strategy -- the 36-hour mass dispensing 
strategy which has been adopted by many cities. 36-hour mass dispensing strategy 
prepares PODs and medical countermeasures in the first 12 hours and dispenses the 
medications in the PODs in the following 36 hours so that the population is protected 
within 48 hours after the anthrax attack. The two strategies are evaluated by the estimated 
required work force and the total cost including labor cost and operation cost. 
 
The Postal+Refill strategy operates 9 days (from Day 2 to Day 10), while the 36-
hour mass dispensing strategy operates three consecutive 12-hour shifts and the 
healthcare workers cannot cover two consecutive shifts.  Postal+Refill requires more 
worker shifts compared to the 36-hour POD mass dispensing in the scenarios of three 
cities with the exception of the City of Chicago as shown in Table 4.8a. However, in 36-
hour mass dispensing strategy, the healthcare workers cannot cover two consecutive 
shifts, the number of workers required to participate in training is more than those in 
Postal+Refill strategy in the scenarios of three cities except Washington DC as shown in 
Table 4.8b.  
 
The cost of each strategy consists of two parts: training cost and operation cost. 
Training cost is the cost for setting up drills and training healthcare workers for learning 
and practicing their responsibilities during the real event, while operation cost is the cost 
that occurs during the real event. We assume each POD must complete 3 days training. 
The labor cost during an event can be estimated by the average hourly salary in the city 
for a particular position (including vehicle cost for postal carriers) as shown in Table 4.9. 
The site cost spent in an event, such as power, water, and rent, is difficult to measure, and 
can range from $0 to $10,000 depending on the location and the size of the event. When a 
default daily operation cost per POD is assumed to be $5,000, the total cost of 
Postal+Refill strategy are lower than that of the 36-hour mass dispensing strategy in the 
three cities with the exception of  Washington DC as shown in Figure 4.12, Figure 4.13, 
and Table 4.10. The 36-hour mass dispensing strategy costs more in training because it 
uses more PODs and requires more workers. When the daily POD operation cost ranges 
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from $0 to $10,000, the Postal+Refill strategy always costs more than the 36-hour mass 
dispensing strategy in Washington DC, while it always costs more in City of Chicago and 
City of Los Angeles (Figure 4.14). In New York City, the Postal+Refill strategy is the 
cost-effective strategy when the daily POD operation cost is less than $8,751.  
 








City of Los 
Angeles 
Postal+Refill 3,293 26,636 14,954 19,277 
  postal carriers 352 2,762 1,268 1,936 
  healthcare workers  2,941 23,874 13,686 17,341 
36-hour mass dispensing 1,929 23,763 13,389 19,530 
 








City of Los 
Angeles 
Postal+Refill 1,692 13,638 7,503 9,836 
  postal carriers 352 2,762 1,268 1,936 
  healthcare workers  1,340  10,876  6,235  7,900 
36-hour mass dispensing 1,286 15,842 8,926 13,020 
 








City of Los 
Angeles 
Postal carrier 320.2 330 326.1 335.15 
Police officer 372 408 418.8 494.4 
Volunteer 0 0 0 0 
Nurse/MD 363.6 427.2 256.8 405.6 
Health Technician 232.92 279.6 249.6 247.2 
Security 372 408 418.8 494.4 
Traffic Control 218.4 168 145.2 157.2 
















City of Los 
Angeles 
Postal+Refill 2,945,205 26,700,041  9,931,429  15,321,289  
    Postal delivery         243,654  2,038,356  944,533  1,606,009  
    POD refill cost      2,701,551  24,661,685  8,986,896  13,715,280  
        training cost      1,324,217     12,295,557   4,423,150    6,721,271  
        operation cost      1,377,334  12,366,128  4,563,745  6,994,009  
        number of PODs 12 99 39 61 
36-hour mass 
dispensing      2,253,130  28,928,318  11,182,939  19,827,174  
        training cost  1,442,087   18,790,546   7,260,293   12,913,116  
        operation cost         811,043  10,137,773  3,922,646  6,914,058  
        number of PODs 12 115 47 73 
 
 
Figure 4.12. Worker allocation in 4 metropolitan areas under Postal+Refill strategy and 





Figure 4.13. Cost comparison of the Postal+Refill and the 36-hour mass dispensing. 
 
 
Figure 4.14. The cost-effective strategy when the POD operation cost varies. Blue: 36-






In summary, the Postal+Refill strategy delivers the initial medications to the population 
by postal carriers within 24 hours and dispenses the remaining pills at PODs in the 
following days. It allows extra time to set up the PODs for pill refill by providing 
temporary protection to the entire population by postal delivery, and reduces the infection 
risk of congestions in the PODs by extending the dispensing process from less than 2 
days to 9 days. As shown in our analysis, this strategy is more effective in the cities with 
high population density in terms of the required work forces and the cost. Compared to 
the mass dispensing strategy, it benefits from the reduced work load for training the 
PODs and workers for dealing with the potential congestions in the first two days. 
However, security concerns may be an issue since postal workers could become target of 
hoax or opportunistic criminals. Citizens may not take the pills if there is rumored or 
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